<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus - Hemmingsen, B - 2017 | Cochrane Library</title> <meta content="Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus - Hemmingsen, B - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012204.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus - Hemmingsen, B - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012204.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012204.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus" name="citation_title"/> <meta content="Bianca Hemmingsen" name="citation_author"/> <meta content="Herlev University Hospital" name="citation_author_institution"/> <meta content="biancahemmingsen@hotmail.com" name="citation_author_email"/> <meta content="David P Sonne" name="citation_author"/> <meta content="Gentofte Hospital, University of Copenhagen" name="citation_author_institution"/> <meta content="Maria‐Inti Metzendorf" name="citation_author"/> <meta content="Institute of General Practice, Medical Faculty of the Heinrich‐Heine‐University Düsseldorf" name="citation_author_institution"/> <meta content="Bernd Richter" name="citation_author"/> <meta content="Institute of General Practice, Medical Faculty of the Heinrich‐Heine‐University Düsseldorf" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD012204.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/05/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012204.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012204.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012204.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adamantane [analogs &amp; derivatives, therapeutic use]; Blood Glucose [metabolism]; Diabetes Mellitus, Type 2 [complications, *prevention &amp; control]; Dipeptidyl-Peptidase IV Inhibitors [*therapeutic use]; Exenatide; Fasting; Glucagon-Like Peptide 1 [*analogs &amp; derivatives]; Glucose Intolerance; Glycated Hemoglobin [metabolism]; Hypoglycemic Agents [therapeutic use]; Incretins [*therapeutic use]; Liraglutide [therapeutic use]; Metformin [therapeutic use]; Nitriles [therapeutic use]; Peptides [therapeutic use]; Pyrrolidines [therapeutic use]; Randomized Controlled Trials as Topic; Risk Factors; Venoms [therapeutic use]; Vildagliptin" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012204.pub2&amp;doi=10.1002/14651858.CD012204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="9mpoajSI";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012204\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012204\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012204.pub2",title:"Dipeptidyl\\u2010peptidase (DPP)\\u20104 inhibitors and glucagon\\u2010like peptide (GLP)\\u20101 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus",firstPublishedDate:"May 10, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Metabolic and Endocrine Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012204.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012204.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012204.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012204.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012204.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012204.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012204.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012204.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012204.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012204.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8202 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012204.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-sec-0173"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-sec-0029"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-sec-0030"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-sec-0073"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-sec-0167"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/appendices#CD012204-sec-0178"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/table_n/CD012204StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/table_n/CD012204StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/information#CD012204-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Bianca Hemmingsen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/information#CD012204-cr-0003">David P Sonne</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/information#CD012204-cr-0004">Maria‐Inti Metzendorf</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/information#CD012204-cr-0005">Bernd Richter</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/information/en#CD012204-sec-0198">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 May 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012204.pub2">https://doi.org/10.1002/14651858.CD012204.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012204-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012204-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012204-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012204-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012204-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012204-abs-0001" lang="en"> <section id="CD012204-sec-0001"> <h3 class="title" id="CD012204-sec-0001">Background</h3> <p>The projected rise in the incidence of type 2 diabetes mellitus (T2DM) could develop into a substantial health problem worldwide. Whether dipeptidyl‐peptidase (DPP)‐4 inhibitors or glucagon‐like peptide (GLP)‐1 analogues are able to prevent or delay T2DM and its associated complications in people at risk for the development of T2DM is unknown. </p> </section> <section id="CD012204-sec-0002"> <h3 class="title" id="CD012204-sec-0002">Objectives</h3> <p>To assess the effects of DPP‐4 inhibitors and GLP‐1 analogues on the prevention or delay of T2DM and its associated complications in people with impaired glucose tolerance, impaired fasting blood glucose, moderately elevated glycosylated haemoglobin A1c (HbA1c) or any combination of these. </p> </section> <section id="CD012204-sec-0003"> <h3 class="title" id="CD012204-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials; MEDLINE; PubMed; Embase; ClinicalTrials.gov; the World Health Organization (WHO) International Clinical Trials Registry Platform; and the reference lists of systematic reviews, articles and health technology assessment reports. We asked investigators of the included trials for information about additional trials. The date of the last search of all databases was January 2017. </p> </section> <section id="CD012204-sec-0004"> <h3 class="title" id="CD012204-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) with a duration of 12 weeks or more comparing DPP‐4 inhibitors and GLP‐1 analogues with any pharmacological glucose‐lowering intervention, behaviour‐changing intervention, placebo or no intervention in people with impaired fasting glucose, impaired glucose tolerance, moderately elevated HbA1c or combinations of these. </p> </section> <section id="CD012204-sec-0005"> <h3 class="title" id="CD012204-sec-0005">Data collection and analysis</h3> <p>Two review authors read all abstracts and full‐text articles and records, assessed quality and extracted outcome data independently. One review author extracted data which were checked by a second review author. We resolved discrepancies by consensus or the involvement of a third review author. For meta‐analyses, we planned to use a random‐effects model with investigation of risk ratios (RRs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes, using 95% confidence intervals (CIs) for effect estimates. We assessed the overall quality of the evidence using the GRADE instrument. </p> </section> <section id="CD012204-sec-0006"> <h3 class="title" id="CD012204-sec-0006">Main results</h3> <p>We included seven completed RCTs; about 98 participants were randomised to a DPP‐4 inhibitor as monotherapy and 1620 participants were randomised to a GLP‐1 analogue as monotherapy. Two trials investigated a DPP‐4 inhibitor and five trials investigated a GLP‐1 analogue. A total of 924 participants with data on allocation to control groups were randomised to a comparator group; 889 participants were randomised to placebo and 33 participants to metformin monotherapy. One RCT of liraglutide contributed 85% of all participants. The duration of the intervention varied from 12 weeks to 160 weeks. We judged none of the included trials at low risk of bias for all 'Risk of bias' domains and did not perform meta‐analyses because there were not enough trials. </p> <p>One trial comparing the DPP‐4 inhibitor vildagliptin with placebo reported no deaths (very low‐quality evidence). The incidence of T2DM by means of WHO diagnostic criteria in this trial was 3/90 participants randomised to vildagliptin versus 1/89 participants randomised to placebo (very low‐quality evidence). Also, 1/90 participants on vildagliptin versus 2/89 participants on placebo experienced a serious adverse event (very low‐quality evidence). One out of 90 participants experienced congestive heart failure in the vildagliptin group versus none in the placebo group (very low‐quality evidence). There were no data on non‐fatal myocardial infarction, stroke, health‐related quality of life or socioeconomic effects reported. </p> <p>All‐cause and cardiovascular mortality following treatment with GLP‐1 analogues were rarely reported; one trial of exenatide reported that no participant died. Another trial of liraglutide 3.0 mg showed that 2/1501 in the liraglutide group versus 2/747 in the placebo group died after 160 weeks of treatment (very low‐quality evidence). </p> <p>The incidence of T2DM following treatment with liraglutide 3.0 mg compared to placebo after 160 weeks was 26/1472 (1.8%) participants randomised to liraglutide versus 46/738 (6.2%) participants randomised to placebo (very low‐quality evidence). The trial established the risk for (diagnosis of) T2DM as HbA1c 5.7% to 6.4% (6.5% or greater), fasting plasma glucose 5.6 mmol/L or greater to 6.9 mmol/L or less (7.0 mmol/L or greater) or two‐hour post‐load plasma glucose 7.8 mmol/L or greater to 11.0 mmol/L (11.1 mmol/L). Altogether, 70/1472 (66%) participants regressed from intermediate hyperglycaemia to normoglycaemia compared with 268/738 (36%) participants in the placebo group. The incidence of T2DM after the 12‐week off‐treatment extension period (i.e. after 172 weeks) showed that five additional participants were diagnosed T2DM in the liraglutide group, compared with one participant in the placebo group. After 12‐week treatment cessation, 740/1472 (50%) participants in the liraglutide group compared with 263/738 (36%) participants in the placebo group had normoglycaemia. </p> <p>One trial used exenatide and 2/17 participants randomised to exenatide versus 1/16 participants randomised to placebo developed T2DM (very low‐quality evidence). This trial did not provide a definition of T2DM. One trial reported serious adverse events in 230/1524 (15.1%) participants in the liraglutide 3.0 mg arm versus 96/755 (12.7%) participants in the placebo arm (very low quality evidence). There were no serious adverse events in the trial using exenatide. Non‐fatal myocardial infarction was reported in 1/1524 participants in the liraglutide arm and in 0/55 participants in the placebo arm at 172 weeks (very low‐quality evidence). One trial reported congestive heart failure in 1/1524 participants in the liraglutide arm and in 1/755 participants in the placebo arm (very low‐quality evidence). Participants receiving liraglutide compared with placebo had a small mean improvement in the physical component of the 36‐item Short Form scale showing a difference of 0.87 points (95% CI 0.17 to 1.58; P = 0.02; 1 trial; 1791 participants; very low‐quality evidence). No trial evaluating GLP‐1‐analogues reported data on stroke, microvascular complications or socioeconomic effects. </p> </section> <section id="CD012204-sec-0007"> <h3 class="title" id="CD012204-sec-0007">Authors' conclusions</h3> <p>There is no firm evidence that DPP‐4 inhibitors or GLP‐1 analogues compared mainly with placebo substantially influence the risk of T2DM and especially its associated complications in people at increased risk for the development of T2DM. Most trials did not investigate patient‐important outcomes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012204-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012204-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012204-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012204-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012204-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012204-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012204-abs-0004" lang="en"> <h3>Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus </h3> <p><b>Review question</b> </p> <p>Are the glucose‐lowering medicines, DPP‐4 inhibitors (e.g. linagliptin or vildagliptin) and GLP‐1 analogues (e.g. exenatide or liraglutide) able to prevent or delay the development of type 2 diabetes and its associated complications in people at risk for the development of type 2 diabetes? </p> <p><b>Background</b> </p> <p>DPP‐4 inhibitors and GLP‐1 analogues are widely used to treat people with type 2 diabetes. People with moderately elevated blood glucose are said to be at an increased risk for developing type 2 diabetes (often referred to as 'prediabetes'). It is currently not known whether DPP‐4 inhibitors or GLP‐1 analogues should be prescribed for people with raised blood glucose levels who do not have type 2 diabetes. We wanted to find out whether these medicines could prevent or delay type 2 diabetes in people at increased risk. We also wanted to know the effects on patient‐important outcomes such as complications of diabetes (e.g. kidney and eye disease, heart attacks, strokes), death from any cause, health‐related quality of life (a measure of a person's satisfaction with their life and health) and side effects of the medicines. </p> <p><b>Study characteristics</b> </p> <p>Participants had to have blood glucose levels higher than considered normal, but below the glucose levels that are used to diagnose type 2 diabetes mellitus. We found seven randomised controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) with 2702 participants. The duration of the treatments varied from 12 weeks to 160 weeks. One study investigating liraglutide dominated the evidence (2285/2702 participants). The participants in this study were overweight or obese. </p> <p>This evidence is up to date as of January 2017.</p> <p><b>Key results</b> </p> <p>DPP‐4 inhibitors did not reduce the risk of developing type 2 diabetes compared with placebo (a dummy medicine). In the big study investigating the GLP‐1‐analogue liraglutide, given in a dose used for obese people (3.0 mg), the development of type 2 diabetes was delayed: 26/1472 (1.8%) participants randomised to liraglutide compared with 46/738 (6.2%) participants randomised to placebo developed type 2 diabetes after 160 weeks. On the other side, 970/1472 (66%) participants randomised to liraglutide compared with 268/738 (36%) participants randomised to placebo switched back to normal glucose levels. This study was extended for another 12 weeks without treatment and five additional participants developed diabetes in the liraglutide group, compared with one participant in the placebo group. After the 12 weeks without treatment, 740/1472 (50%) participants in the liraglutide group compared with 263/738 (36%) participants in the placebo group had glucose levels considered as normal. This means that to keep chances high to prevent type 2 diabetes in people at risk one probably needs to continuously take this drug. Of note, serious adverse events (e.g. defined as hospitalisation or a hazard putting the participant at risk, such as an interaction with another medicine) happened more often following liraglutide treatment (230/1524 (15%) participants in the liraglutide group and 96/755 (13%) participants in the placebo group) and it is unclear whether taking this drug is safe in the long term. </p> <p>We detected neither an advantage nor a disadvantage of DPP‐4 inhibitors or GLP‐1 analogues in relation to non‐fatal heart attacks, non‐fatal strokes or heart failure. Our included studies did not report on other complications of diabetes such as kidney or eye disease. The effects on health‐related quality of life were inconclusive. In the included studies, very few participants died and there was no apparent relation to treatment. </p> <p>Future studies should investigate more patient‐important outcomes like complications of diabetes and especially the side effects of the medications, because we do not know for sure whether 'prediabetes' is just a condition arbitrarily defined by a laboratory measurement, is in fact a real risk factor for type 2 diabetes mellitus and whether treatment of this condition translates into better patient‐important outcomes. </p> <p><b>Quality of the evidence</b> </p> <p>All included trials had deficiencies in the way they were conducted or how key items were reported. For the individual comparisons, the number of participants was small, resulting in a high risk of random errors (play of chance). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012204-sec-0173" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012204-sec-0173"></div> <h3 class="title" id="CD012204-sec-0174">Implications for practice</h3> <section id="CD012204-sec-0174"> <p>There is no firm evidence whether dipeptidyl‐peptidase (DPP)‐4 inhibitors or glucagon‐like peptide (GLP)‐1 analogues compared with other pharmacological glucose‐lowering interventions, placebo, behaviour‐changing interventions or no intervention substantially influence the risk of type 2 diabetes mellitus and its associated complications. Data on patient‐important outcomes such as mortality, and macrovascular and microvascular complications are sparse. </p> </section> <h3 class="title" id="CD012204-sec-0175">Implications for research</h3> <section id="CD012204-sec-0175"> <p>It remains to be clarified whether there are any substantial beneficial or harmful effects of DPP‐4 inhibitors or GLP‐1 analogues in people with intermediate hyperglycaemia if given for a prolonged period of time. Several ongoing trials are investigating this topic. Future randomised controlled clinical trials should focus on patient‐important outcomes. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012204-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012204-sec-0022"></div> <div class="table" id="CD012204-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">DPP‐4 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>DPP‐4 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population</b>: people at risk for development of T2DM </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: DPP‐4 inhibitors </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trial(s))</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>DPP‐4 inhibitors</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial on vildagliptin reported that none of the participants died (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of T2DM</b> </p> <p>Definition: WHO criteria</p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported that 3/90 in the vildagliptin group vs 1/89 in the placebo group developed T2DM (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported that 1/90 in the vildagliptin group vs 2/89 in the placebo group experienced a serious adverse event (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported that none of the participants died (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) Non‐fatal myocardial infarction</b> </p> <p><b>(2) Non‐fatal stroke</b> </p> <p><b>(3) Congestive heart failure</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) ‐</p> <p>(2) ‐</p> <p>(3) 179 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) + (2): not reported</p> <p>(3): 1 trial on vildagliptin reported 1/90 in the vildagliptin group vs 0/89 in the placebo group experienced heart failure (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Socioeconomic effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>DPP‐4:</b> dipeptidyl‐peptidase‐4; <b>RR:</b> risk ratio; <b>T2DM:</b> type 2 diabetes mellitus; <b>WHO:</b> World Health Organization. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*Assumed risk was derived from the event rates in the comparator groups.</p> <p><sup>a</sup>Downgraded by three levels because of indirectness, imprecision (very sparse data) and risk of publication bias (see <a href="./appendices#CD012204-sec-0193">Appendix 15</a>). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012204-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">GLP‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GLP‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population</b>: people at risk for development of T2DM </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: GLP‐1 analogues </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>GLP‐1 analogues</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (trial(s))</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: up to 172 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2281 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported that 2/1501 in the liraglutide group vs 2/747 in the placebo group died after 160 weeks of intervention. </p> <p>Liraglutide used in doses approved for weight‐reducing purposes (3.0 mg) (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). </p> <p>1 trial using exenatide reported that none of the participants died (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of T2DM</b> </p> <p>Definition/description: 1 trial established the diagnosis of T2DM defined as HbA1c ≥ 6.5%, or fasting plasma glucose ≥ 7.0 mmol/L, or 2‐hour plasma glucose post‐challenge (oral glucose tolerance test) ≥ 11.1 mmol/L (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Other trial did not report how the diagnosis of T2DM was established. </p> <p>Follow‐up: up to 172 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2243 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 160 weeks, 26/1472 (1.8%) participants in the liraglutide group vs 46/738 (6.2%) participants in the placebo group developed T2DM (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). The incidence of T2DM after the 12‐week off‐treatment extension period (i.e. after 172 weeks) showed that 5 additional participants were diagnosed with T2DM in the liraglutide group, compared with 1 participant in the placebo group. </p> <p>Liraglutide used in doses approved for weight‐reducing purposes (3.0 mg).</p> <p>1 trial reported that 2/17 in the exenatide group vs1/16 in the placebo group developed T2DM (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: up to 172 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2312 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial on liraglutide reported that 227/1501 (15.1%) participants in the liraglutide 3.0 mg group vs 96/747 (12.7%) participants in the placebo group experienced a serious adverse event after 160 weeks (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). </p> <p>1 trial on exenatide reported that none of the participants experienced a serious adverse event (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> <p>Follow‐up: up to 172 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2281 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported that none of the participants died (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). 1 trial reported that 1/1501 participants in the liraglutide group died from cardiac arrest; no participant in the placebo group died of cardiovascular reasons (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) Non‐fatal myocardial infarction</b> </p> <p><b>(2) Non‐fatal stroke</b> </p> <p><b>(3) Congestive heart failure</b> </p> <p>Follow‐up: up to 172 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 2279 (1)</p> <p>(2) See comments</p> <p>(3) 2279 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 1 trial reported 1/1524 participants in the liraglutide 3.0 mg group vs 0/755 participants in the placebo group (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>) </p> <p>(2) Not reported</p> <p>(3) 1 trial reported 1/1524 in the liraglutide 3.0 mg group vs 1/755 participants in the placebo group (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p>SF‐36 scale: total score 0‐100, 8 subscales. Higher values mean better health‐related quality of life. </p> <p>Follow‐up: 160 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1791 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Physical functioning component score had mean difference of 0.87 in favour of liraglutide (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Socioeconomic effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>GLP‐1</b> : glucagon‐like peptide‐1; <b>HbA1c:</b> glycosylated haemoglobin A1c; <b>RR:</b> risk ratio; <b>SF‐36:</b> 36‐item Short Form health survey; <b>T2DM:</b> type 2 diabetes mellitus. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by three levels because of indirectness, imprecision (sparse data) and risk of attrition and publication bias (see <a href="./appendices#CD012204-sec-0194">Appendix 16</a>).<br/> <sup>b</sup>Downgraded by two levels because of imprecision (sparse data) and risk of attrition and publication bias (see <a href="./appendices#CD012204-sec-0194">Appendix 16</a>). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012204-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012204-sec-0023"></div> <section id="CD012204-sec-0024"> <h3 class="title" id="CD012204-sec-0024">Description of the condition</h3> <p>'Prediabetes', 'borderline diabetes', the 'prediabetic stage', 'high risk of diabetes', 'dysglycaemia' or 'intermediate hyperglycaemia' are often characterised by various measurements of elevated blood glucose concentrations, such as isolated impaired fasting glucose (IFG), isolated impaired glucose tolerance (IGT), isolated elevated glycosylated haemoglobin A1c (HbA1c) or combinations thereof (<a href="./references#CD012204-bbs2-0162" title="World Health Organization/International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf2006; Vol. (assessed 7 May 2017). ">WHO/IDF 2006</a>). These elevated blood glucose levels that indicate hyperglycaemia are too high to be considered normal, but are below the diagnostic threshold for type 2 diabetes mellitus (T2DM). Therefore, due to the continuous glycaemic spectrum from the normal to the diabetic stage, a sound evidence base is needed to define glycaemic thresholds for people at high risk of T2DM. The different terms used to describe various stages of hyperglycaemia may cause people to have different emotional reactions. For example, the term 'prediabetes' may imply (at least for lay people) that the disease diabetes is unavoidable, whereas (high) risk of diabetes has the positive connotation of possibly being able to avoid the disease altogether. In addition to the disputable construct of intermediate health states termed 'prediseases' (<a href="./references#CD012204-bbs2-0157" title="VieraAJ . Predisease: when does it make sense?. Epidemiologic Reviews2011;33:122‐34. ">Viera 2011</a>), many people may associate the label 'prediabetes' with dire consequences. Alternatively, any diagnosis of 'prediabetes' may be an opportunity to review, for example, eating habits and physical activity levels, thus enabling affected people to actively change their way of life. </p> <p>The American Diabetes Association (ADA) and the World Health Organization (WHO) established the most commonly used criteria to define people who are at a high risk of developing T2DM. IGT was the first glycaemic measurement used by the US National Diabetes Data Group to define the prediabetes stage (<a href="./references#CD012204-bbs2-0140" title="National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes1979;28(12):1039‐57. [PUBMED: 510803] ">NDDG 1979</a>). It is based on the measurement of plasma glucose two hours after ingestion of glucose 75 g. The dysglycaemic range is defined as plasma glucose concentrations between 7.8 mmol/L and 11.1 mmol/L (140 mg/dL and 200 mg/dL) two hours after the glucose load. Studies indicate that IGT is caused by insulin resistance and defective insulin secretion (<a href="./references#CD012204-bbs2-0076" title="Abdul‐GhaniMA , JenkinsonCP , RichardsonDK , TripathyD , DeFronzoRA . Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes2006;55(5):1430‐5. [PUBMED: 16644701] ">Abdul‐Ghani 2006</a>; <a href="./references#CD012204-bbs2-0127" title="JensenCC , CnopM , HullRL , FujimotoWY , KahnSE . Beta‐cell function is a major contributor to oral glucose tolerance in high‐risk relatives of four ethnic groups in the U.S. Diabetes2002;51(7):2170‐8. [PUBMED: 12086947] ">Jensen 2002</a>). In 1997, the ADA and later the WHO introduced the IFG concept to define 'prediabetes' and intermediate hyperglycaemia (<a href="./references#CD012204-bbs2-0077" title="The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care1997;20(7):1183‐97. ">ADA 1997</a>; <a href="./references#CD012204-bbs2-0161" title="World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus. Geneva: WHO, 1999. ">WHO 1999</a>). The initial definition of IFG was fasting blood glucose concentrations between 6.1 mmol/L and 6.9 mmol/L (110 mg/dL and 125 mg/dL). Later, the ADA reduced the lower threshold for defining IFG to 5.6 mmol/L (100 mg/dL) (<a href="./references#CD012204-bbs2-0078" title="Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care2003;26(Suppl 1):S5‐20. ">ADA 2003</a>). However, the WHO did not endorse this lower cut‐off point for IFG to define 'prediabetes' (<a href="./references#CD012204-bbs2-0162" title="World Health Organization/International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf2006; Vol. (assessed 7 May 2017). ">WHO/IDF 2006</a>). IFG seems to be associated with β‐cell dysfunction (impaired insulin secretion) and an increase in the hepatic glucose output (<a href="./references#CD012204-bbs2-0097" title="DeFronzoRA , FerranniniE , SimonsonDC . Fasting hyperglycemia in non‐insulin‐dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism: Clinical and Experimental1989;38(4):387‐95. [PUBMED: 2657323] ">DeFronzo 1989</a>). More recently, HbA1c has been introduced to identify people at high risk of developing T2DM. In 2009, the International Expert Committee (IEC) suggested certain HbA1c ranges to identify people at a high risk of T2DM. People with HbA1c measurements between 6.0% and 6.4% fulfilled this criterion (<a href="./references#CD012204-bbs2-0125" title="International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care2009;32(7):1327‐34. [PUBMED: 19502545] ">IEC 2009</a>). Shortly afterwards, the ADA redefined this HbA1c level as 5.7% to 6.4% to identify people at a high risk of developing T2DM (<a href="./references#CD012204-bbs2-0080" title="American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care2010;33(Suppl 1):S62‐9. [PUBMED: 20042775] ">ADA 2010</a>), a decision not endorsed by WHO, IEC or other organisations. Unlike IFG and IGT, HbA1c reflects longer‐term glycaemic control, that is how a person's blood glucose concentrations have been during the preceding two to three months (<a href="./references#CD012204-bbs2-0126" title="InzucchiSE . Clinical practice. Diagnosis of diabetes. New England Journal of Medicine2012;367(6):542‐50. [PUBMED: 22873534] ">Inzucchi 2012</a>). </p> <p>In 2010, the International Diabetes Federation (IDF) estimated the prevalence of IGT to be 343 million people, and this is predicted to increase to 642 million people by 2040 (<a href="./references#CD012204-bbs2-0124" title="International Diabetes Federation. IDF Diabetes Atlas. 7th Edition. Brussels: International Diabetes Federation, 2015. ">IDF 2015</a>). Studies have shown poor correlations between HbA1c and IFG/IGT (<a href="./references#CD012204-bbs2-0108" title="GosmanovAR , WanJ . Low positive predictive value of hemoglobin A1c for diagnosis of prediabetes in clinical practice. American Journal of the Medical Sciences2014;348(3):191‐4. [PUBMED: 24556928] ">Gosmanov 2014</a>; <a href="./references#CD012204-bbs2-0151" title="SelvinE , SteffesMW , BallantyneCM , HoogeveenRC , CoreshJ , BrancatiFL . Racial differences in glycemic markers: a cross‐sectional analysis of community‐based data. Annals of Internal Medicine2011;154(5):303‐9. [PUBMED: 21357907] ">Selvin 2011</a>). Notably, the various glycaemic tests do not seem to identify the same people, as there is an imperfect overlap among the glycaemic modalities available to define intermediate hyperglycaemia (<a href="./references#CD012204-bbs2-0108" title="GosmanovAR , WanJ . Low positive predictive value of hemoglobin A1c for diagnosis of prediabetes in clinical practice. American Journal of the Medical Sciences2014;348(3):191‐4. [PUBMED: 24556928] ">Gosmanov 2014</a>; <a href="./references#CD012204-bbs2-0151" title="SelvinE , SteffesMW , BallantyneCM , HoogeveenRC , CoreshJ , BrancatiFL . Racial differences in glycemic markers: a cross‐sectional analysis of community‐based data. Annals of Internal Medicine2011;154(5):303‐9. [PUBMED: 21357907] ">Selvin 2011</a>). The risk of progression from people at risk to T2DM depends on the diagnostic criteria used to identify the risk. Some people with intermediate risk will never develop T2DM, and some people will return to normoglycaemia. IGT is often accepted as the best glycaemic variable for risk to predict progression to T2DM. However, studies indicate that less than half of the people defined as 'prediabetic' by means of IGT will develop T2DM in the following 10 years (<a href="./references#CD012204-bbs2-0136" title="MorrisDH , KhuntiK , AchanaF , SrinivasanB , GrayLJ , DaviesMJ , et al. Progression rates from HbA1c 6.0‐6.4% and other prediabetes definitions to type 2 diabetes: a meta‐analysis. Diabetologia2013;56(7):1489‐93. [PUBMED: 23584433] ">Morris 2013</a>). IFG and HbA1c are thought to predict a different risk spectrum for developing T2DM (<a href="./references#CD012204-bbs2-0092" title="ChengC , KushnerH , FalknerBE . The utility of fasting glucose for detection of prediabetes. Metabolism: Clinical and Experimental2006;55(4):434‐8. [PUBMED: 16546472] ">Cheng 2006</a>; <a href="./references#CD012204-bbs2-0136" title="MorrisDH , KhuntiK , AchanaF , SrinivasanB , GrayLJ , DaviesMJ , et al. Progression rates from HbA1c 6.0‐6.4% and other prediabetes definitions to type 2 diabetes: a meta‐analysis. Diabetologia2013;56(7):1489‐93. [PUBMED: 23584433] ">Morris 2013</a>). Most importantly, dysglycaemia is commonly an asymptomatic condition, and naturally often remains 'undiagnosed' (<a href="./references#CD012204-bbs2-0091" title="Centers for Disease Control and Prevention. 2014 National Diabetes Statistics Report. www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html (accessed 15 October 2015). ">CDC 2015</a>). </p> <p>It has not been clarified whether any particular intervention, especially glucose‐lowering drugs, should be recommended for people at risk for T2DM (<a href="./references#CD012204-bbs2-0166" title="YudkinJS , MontoriVM . The epidemic of pre‐diabetes: the medicine and the politics. BMJ2014;349:g4485. ">Yudkin 2014</a>). Trials have indicated that the progression to T2DM is reduced, or possibly only delayed, with behavioural interventions (increased physical activity, dietary changes, or both) (<a href="./references#CD012204-bbs2-0099" title="Diabetes Prevention Program Research Group, KnowlerWC , FowlerSE , HammanRF , ChristophiCA , HoffmanHJ , et al. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9702):1677‐86. [DOI: 10.1016/S0140‐6736(09)61457‐4; PUBMED: 19878986] ">Diabetes Prevention Program 2009</a>; <a href="./references#CD012204-bbs2-0129" title="KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. [PUBMED: 11832527] ">Knowler 2002</a>; <a href="./references#CD012204-bbs2-0155" title="TuomilehtoJ , LindstromJ , ErikssonJG , ValleTT , HamalainenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. [PUBMED: 11333990] ">Tuomilehto 2001</a>). One meta‐analysis of 22 trials with interventions that changed behaviour in people at high risk of T2DM concluded that the effect of these interventions on longer‐term diabetes prevention is unclear (<a href="./references#CD012204-bbs2-0100" title="DunkleyAJ , BodicoatDH , GreavesCJ , RussellC , YatesT , DaviesMJ , et al. Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta‐analysis. Diabetes Care2014;37(4):922‐33. [PUBMED: 24652723] ">Dunkley 2014</a>). Therefore, more research is needed to establish optimal strategies for reducing T2DM with behavioural approaches (<a href="./references#CD012204-bbs2-0100" title="DunkleyAJ , BodicoatDH , GreavesCJ , RussellC , YatesT , DaviesMJ , et al. Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta‐analysis. Diabetes Care2014;37(4):922‐33. [PUBMED: 24652723] ">Dunkley 2014</a>). </p> <p>International diabetes associations and clinicians do not generally accept the prescription of pharmacological glucose‐lowering interventions for the prevention of T2DM. Several groups of pharmacological glucose‐lowering interventions have been investigated for people at risk of T2DM. Some findings indicate that the progression to T2DM is reduced or may only be delayed (<a href="./references#CD012204-bbs2-0129" title="KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. [PUBMED: 11832527] ">Knowler 2002</a>; <a href="./references#CD012204-bbs2-0099" title="Diabetes Prevention Program Research Group, KnowlerWC , FowlerSE , HammanRF , ChristophiCA , HoffmanHJ , et al. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9702):1677‐86. [DOI: 10.1016/S0140‐6736(09)61457‐4; PUBMED: 19878986] ">Diabetes Prevention Program 2009</a>). However, the ADA recommends metformin for people at risk of T2DM, especially for those with a body mass index (BMI) over 35 kg/m², aged less than 60 years, women with prior gestational diabetes mellitus, people with rising HbA1c despite lifestyle intervention, or a combination of these (<a href="./references#CD012204-bbs2-0083" title="American Diabetes Association. Standards of medical care in diabetes ‐ 2017. Diabetes Care2017;40(Suppl 1):S4‐S5. ">ADA 2017</a>). </p> </section> <section id="CD012204-sec-0025"> <h3 class="title" id="CD012204-sec-0025">Description of the intervention</h3> <p>Sitagliptin was the first dipeptidyl‐peptidase (DPP)‐4 inhibitor approved as a glucose‐lowering intervention for people with T2DM (<a href="./references#CD012204-bbs2-0106" title="USFood , DrugAdministration . FDA approves new treatment for diabetes. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108770 (assessed 26 February 2016). ">FDA 2006</a>). Since then, several other types of DPP‐4 inhibitors have been approved for T2DM, such as alogliptin, anagliptin, linagliptin, saxagliptin, teneligliptin and vildagliptin. The DPP‐4 inhibitors are administered orally. </p> <p>Exenatide was the first glucagon‐like peptide 1 (GLP‐1) analogue approved as a glucose‐lowering intervention for people with T2DM (<a href="./references#CD012204-bbs2-0105" title="USFood , DrugAdministration . Drug approval package: Byetta (exenatide) injection. www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_ByettaTOC.cfm (accessed 26 February 2016). ">FDA 2005</a>). Since then, several other types of GLP‐1 analogues have been approved. The GLP‐1 analogues can be categorised as either short‐acting (e.g. exenatide) or long‐acting (e.g. liraglutide). Currently available GLP‐1 analogues are administered subcutaneously. Peroral GLP‐1 analogues are in the pipeline (<a href="./references#CD012204-bbs2-0139" title="NCT02161588 . A trial to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy male Japanese and Caucasian subjects. clinicaltrials.gov/ct2/show/NCT02161588 Date first received: 10 June 2014. ">NCT02161588</a>). </p> <p>For people with T2DM, GLP‐1 analogues and DPP‐4 inhibitors can be prescribed as monotherapy or in combination with existing glucose‐lowering interventions (<a href="./references#CD012204-bbs2-0081" title="American Diabetes Association. Standards of medical care in diabetes ‐ 2014. Diabetes Care2014;37 Suppl 1:S14‐80. [PUBMED: 24357209] ">ADA 2014</a>). Currently, the GLP‐1 analogues or DPP‐4 inhibitors are not recommended for people with intermediate hyperglycaemia (<a href="./references#CD012204-bbs2-0081" title="American Diabetes Association. Standards of medical care in diabetes ‐ 2014. Diabetes Care2014;37 Suppl 1:S14‐80. [PUBMED: 24357209] ">ADA 2014</a>). However, it has been shown that people with IGT have alterations in circulating incretin hormones (<a href="./references#CD012204-bbs2-0144" title="RaskE , OlssonT , SoderbergS , HolstJJ , TuraA , PaciniG , et al. Insulin secretion and incretin hormones after oral glucose in non‐obese subjects with impaired glucose tolerance. Metabolism: Clinical and Experimental2004;53(5):624‐31. [PUBMED: 15131768] ">Rask 2004</a>). </p> <section id="CD012204-sec-0026"> <h4 class="title">Adverse effects of the intervention</h4> <p>The most common adverse effects of GLP‐1 analogues are gastrointestinal disturbances and nausea. Nausea and vomiting associated with the GLP‐1 analogues are dose‐dependent and appear to decrease over time (<a href="./references#CD012204-bbs2-0146" title="ReidTS . Practical use of glucagon‐like peptide‐1 receptor agonist therapy in primary care. Clinical Diabetes2014;31(4):148‐57. ">Reid 2014</a>). For DPP‐4 inhibitors, the most common adverse effects reported are gastrointestinal disturbances (<a href="./references#CD012204-bbs2-0146" title="ReidTS . Practical use of glucagon‐like peptide‐1 receptor agonist therapy in primary care. Clinical Diabetes2014;31(4):148‐57. ">Reid 2014</a>). </p> <p>Both the GLP‐1 analogues and the DPP‐4 inhibitors have been suggested to increase risk of pancreatitis and potentially pancreatic cancer (<a href="./references#CD012204-bbs2-0137" title="NagelAK , Ahmed‐SarwarN , WernerPM , CiprianoGC , vanManenRP , BrownJE . Dipeptidyl peptidase‐4 inhibitor‐associated pancreatic carcinoma: a review of the FAERS database. Annals of Pharmacotherapy2015; Vol. 50, issue 1:27‐31. ">Nagel 2015</a>). The incidence of acute pancreatitis has been low in large‐scale randomised controlled trials (RCTs), and was slightly increased compared with placebo (<a href="./references#CD012204-bbs2-0150" title="SciricaBM , BhattDL , BraunwaldE , StegPG , DavidsonJ , HirshbergB , et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. New England Journal of Medicine2013;369(14):1317‐26. [DOI: 10.1056] ">Scirica 2013</a>; <a href="./references#CD012204-bbs2-0167" title="ZannadF , CannonCP , CushmanWC , BakrisGL , MenonV , PerezAT , et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double‐blind trial. Lancet2015;385(9982):2067‐76. [PUBMED: 25765696] ">Zannad 2015</a>). The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have made comprehensive evaluations of the safety of the incretin‐based interventions based on post‐marketing reports of pancreatitis and pancreatic cancer in people with T2DM. These post‐marketing data have not been convincing regarding these adverse effects (<a href="./references#CD012204-bbs2-0101" title="EganAG , BlindE , DunderK , deGraeffPA , HummerBT , BourcierT , et al. Pancreatic safety of incretin‐based drugs ‐ FDA and EMA assessment. New England Journal of Medicine2014;370(9):794‐7. [PUBMED: 24571751] ">Egan 2014</a>). Nevertheless, current opinion holds that DPP‐4 inhibitors should not be prescribed to people at risk of or having existing pancreatitis (<a href="./references#CD012204-bbs2-0096" title="DeHeerJ , GökeB . Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?. Expert Opinion on Drug Safety2014;13(11):1469‐81. ">De Heer 2014</a>). Besides, the DPP‐4 inhibitors have been reported to increase the risk of heart failure; however, this is still not clarified (<a href="./references#CD012204-bbs2-0103" title="ElgendyIY , MahmoudAN , BarakatAF , ElgendyAY , SaadM , AbuzaidA , et al. Cardiovascular safety of dipeptidyl‐peptidase IV inhibitors: a meta‐analysis of placebo‐controlled randomized trials. American Journal of Cardiovascular Drugs2017;17(2):143‐55. [PUBMED: 27873238] ">Elgendy 2017</a>; <a href="./references#CD012204-bbs2-0145" title="RehmanMB , TudrejBV , SoustreJ , BuissonM , ArchambaultP , PouchainD , et al. Efficacy and safety of DPP‐4 inhibitors in patients with type 2 diabetes: Meta‐analysis of placebo‐controlled randomized clinical trials. Diabetes &amp; Metabolism2017;43(1):48‐58. ">Rehman 2017</a>). However, one large‐scale trial investigating the DPP‐4 inhibitor, saxagliptin, was associated with an increased risk of heart failure leading to hospitalisation (hazard ratio (HR) 1.27, 95% confidence interval (CI) 1.07 to 1.51) (<a href="./references#CD012204-bbs2-0150" title="SciricaBM , BhattDL , BraunwaldE , StegPG , DavidsonJ , HirshbergB , et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. New England Journal of Medicine2013;369(14):1317‐26. [DOI: 10.1056] ">Scirica 2013</a>). </p> <p>Results of systematic reviews are conflicting and adverse effects could vary with the type of DPP‐4 inhibitor used (<a href="./references#CD012204-bbs2-0103" title="ElgendyIY , MahmoudAN , BarakatAF , ElgendyAY , SaadM , AbuzaidA , et al. Cardiovascular safety of dipeptidyl‐peptidase IV inhibitors: a meta‐analysis of placebo‐controlled randomized trials. American Journal of Cardiovascular Drugs2017;17(2):143‐55. [PUBMED: 27873238] ">Elgendy 2017</a>). </p> <p>An increased risk of thyroid cell neoplasm has been observed in rodents exposed to GLP‐1 analogues. However, this increased risk has not been observed in people (<a href="./references#CD012204-bbs2-0146" title="ReidTS . Practical use of glucagon‐like peptide‐1 receptor agonist therapy in primary care. Clinical Diabetes2014;31(4):148‐57. ">Reid 2014</a>). </p> </section> </section> <section id="CD012204-sec-0027"> <h3 class="title" id="CD012204-sec-0027">How the intervention might work</h3> <p>A two‐ to three‐fold greater increase in plasma insulin is observed when glucose is administered orally compared with an intravenous application (<a href="./references#CD012204-bbs2-0138" title="NauckMA , HombergerE , SiegelEG , AllenRC , EatonRP , EbertR , et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C‐peptide responses. Journal of Clinical Endocrinology and Metabolism1986;63(2):492‐8. [PUBMED: 3522621] ">Nauck 1986</a>). This phenomenon is called the incretin effect and accounts for approximately 70% to 80% of total insulin release after orally administered glucose (<a href="./references#CD012204-bbs2-0138" title="NauckMA , HombergerE , SiegelEG , AllenRC , EatonRP , EbertR , et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C‐peptide responses. Journal of Clinical Endocrinology and Metabolism1986;63(2):492‐8. [PUBMED: 3522621] ">Nauck 1986</a>). The incretin effect is mediated mainly by GLP‐1 and glucose‐dependent insulinotropic polypeptide (GIP) (<a href="./references#CD012204-bbs2-0138" title="NauckMA , HombergerE , SiegelEG , AllenRC , EatonRP , EbertR , et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C‐peptide responses. Journal of Clinical Endocrinology and Metabolism1986;63(2):492‐8. [PUBMED: 3522621] ">Nauck 1986</a>). GLP‐1 is a 30‐amino acid polypeptide produced in the intestinal L cell upon processing of the precursor proglucagon (<a href="./references#CD012204-bbs2-0085" title="BellML , McKenzieJE . Designing psycho‐oncology randomised trials and cluster randomised trials: variance components and intra‐cluster correlation of commonly used psychosocial measures. Psycho‐oncology2013;22:1738‐47. ">Bell 2013</a>). GLP‐1 and GIP exert powerful and strictly glucose‐dependent insulinotropic activity via specific GLP‐1 and GIP receptors in the plasma membrane of pancreatic β‐cells (<a href="./references#CD012204-bbs2-0119" title="HolstJJ . The physiology of glucagon‐like peptide 1. Physiological Reviews2007;87(4):1409‐39. [PUBMED: 17928588] ">Holst 2007</a>). In addition, GLP‐1 reduces glucagon secretion, an effect that might be as clinically important as the insulinotropic effect of GLP‐1 (<a href="./references#CD012204-bbs2-0119" title="HolstJJ . The physiology of glucagon‐like peptide 1. Physiological Reviews2007;87(4):1409‐39. [PUBMED: 17928588] ">Holst 2007</a>; <a href="./references#CD012204-bbs2-0141" title="OrskovC , HolstJJ , NielsenOV . Effect of truncated glucagon‐like peptide‐1 [proglucagon‐(78‐107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology1988;123(4):2009‐13. [PUBMED: 2901341] ">Orskov 1988</a>). Furthermore, GLP‐1 reduces food intake (most likely via activation of GLP‐1 receptors in the central nervous system) and delays gastric emptying, whereby postprandial glucose excursions and food intake are reduced (<a href="./references#CD012204-bbs2-0119" title="HolstJJ . The physiology of glucagon‐like peptide 1. Physiological Reviews2007;87(4):1409‐39. [PUBMED: 17928588] ">Holst 2007</a>). Lastly, in animal models GLP‐1 promotes β‐cell growth and inhibits β‐cell apoptosis (<a href="./references#CD012204-bbs2-0119" title="HolstJJ . The physiology of glucagon‐like peptide 1. Physiological Reviews2007;87(4):1409‐39. [PUBMED: 17928588] ">Holst 2007</a>; <a href="./references#CD012204-bbs2-0120" title="HolzGG4th , KuhtreiberWM , HabenerJF . Pancreatic beta‐cells are rendered glucose‐competent by the insulinotropic hormone glucagon‐like peptide‐1(7‐37). Nature1993;361(6410):362‐5. [PUBMED: 8381211] ">Holz 1993</a>). During the progression from normal glucose tolerance to insulin resistance and eventually to T2DM, some studies have shown that plasma GLP‐1 concentrations decline (<a href="./references#CD012204-bbs2-0144" title="RaskE , OlssonT , SoderbergS , HolstJJ , TuraA , PaciniG , et al. Insulin secretion and incretin hormones after oral glucose in non‐obese subjects with impaired glucose tolerance. Metabolism: Clinical and Experimental2004;53(5):624‐31. [PUBMED: 15131768] ">Rask 2004</a>; <a href="./references#CD012204-bbs2-0154" title="Toft‐NielsenMB , DamholtMB , MadsbadS , HilstedLM , HughesTE , MichelsenBK , et al. Determinants of the impaired secretion of glucagon‐like peptide‐1 in type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism2001;86(8):3717‐23. [PUBMED: 11502801] ">Toft‐Nielsen 2001</a>). However, one meta‐analysis suggested that people with T2DM do not exhibit reduced GLP‐1 secretion in response to an oral glucose tolerance test (OGTT) or meal test (<a href="./references#CD012204-bbs2-0090" title="CalannaS , ChristensenM , HolstJJ , LaferrereB , GluudLL , VilsbollT , et al. Secretion of glucagon‐like peptide‐1 in patients with type 2 diabetes mellitus: systematic review and meta‐analyses of clinical studies. Diabetologia2013;56(5):965‐72. [PUBMED: 23377698] ">Calanna 2013</a>). </p> <p>Native GLP‐1 and GIP are rapidly inactivated (half‐life: GLP‐1: 2 minutes; GIP: 5 to 7 minutes) by the enzyme DPP‐4, expressed in many tissues (e.g. kidney and intestine) (<a href="./references#CD012204-bbs2-0095" title="CreutzfeldtW . The incretin concept today. Diabetologia1979;16(2):75‐85. [PUBMED: 32119] ">Creutzfeldt 1979</a>). DPP‐4 inhibitors exert competitive inhibition of DPP‐4 and thereby increase the concentrations of active (endogenous) GLP‐1 and GIP (<a href="./references#CD012204-bbs2-0119" title="HolstJJ . The physiology of glucagon‐like peptide 1. Physiological Reviews2007;87(4):1409‐39. [PUBMED: 17928588] ">Holst 2007</a>). GLP‐1 analogues are resistant to DPP‐4 degradation (<a href="./references#CD012204-bbs2-0119" title="HolstJJ . The physiology of glucagon‐like peptide 1. Physiological Reviews2007;87(4):1409‐39. [PUBMED: 17928588] ">Holst 2007</a>). </p> </section> <section id="CD012204-sec-0028"> <h3 class="title" id="CD012204-sec-0028">Why it is important to do this review</h3> <p>There has been an increased focus on the prevention or delay of T2DM with non‐pharmacological interventions and glucose‐lowering medications. Currently, several trials are being conducted to clarify whether the progression from an at‐risk status to T2DM can be stopped or postponed with glucose‐lowering agents (<a href="./references#CD012204-bbs2-0093" title="Search terms: prediabetes drugs. clinicaltrials.gov/ct2/results?term=prediabetes+drugs&amp;Search=Search (accessed 12 February 2016). ">ClinicalTrials.gov</a>). However, a more important issue for people with dysglycaemia is whether these interventions reduce the risk of death or complications ‐ especially cardiovascular disease ‐ related to T2DM. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012204-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012204-sec-0029"></div> <p>To assess the effects of DPP‐4 inhibitors and GLP‐1 analogues on the prevention or delay of T2DM and its associated complications in people with impaired glucose tolerance, impaired fasting blood glucose, moderately elevated glycosylated haemoglobin A1c (HbA1c) or any combination of these. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012204-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012204-sec-0030"></div> <section id="CD012204-sec-0031"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012204-sec-0032"> <h4 class="title">Types of studies</h4> <p>We included RCTs.</p> </section> <section id="CD012204-sec-0033"> <h4 class="title">Types of participants</h4> <p>We included non‐diabetic people with increased risk of T2DM.</p> <section id="CD012204-sec-0034"> <h5 class="title">Diagnostic criteria for people at risk of type 2 diabetes mellitus development</h5> <p>To be consistent with changes to the classification of, and diagnostic criteria for, intermediate hyperglycaemia (IFG, IGT and elevated HbA1c) over the years, the diagnosis should be established using the standard criteria valid at the trial start (e.g. <a href="./references#CD012204-bbs2-0077" title="The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care1997;20(7):1183‐97. ">ADA 1997</a>; <a href="./references#CD012204-bbs2-0080" title="American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care2010;33(Suppl 1):S62‐9. [PUBMED: 20042775] ">ADA 2010</a>; <a href="./references#CD012204-bbs2-0140" title="National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes1979;28(12):1039‐57. [PUBMED: 510803] ">NDDG 1979</a>; <a href="./references#CD012204-bbs2-0161" title="World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus. Geneva: WHO, 1999. ">WHO 1999</a>). Ideally, the diagnostic criteria should have been described. If necessary, we used the trial authors' definition of risk but we contacted trial authors for additional information. Differences in the glycaemic measurements used to define risk may introduce substantial heterogeneity. Therefore, we planned to subject the diagnostic criteria to a subgroup analysis. </p> </section> </section> <section id="CD012204-sec-0035"> <h4 class="title">Types of interventions</h4> <p>We planned to investigate the following comparisons of DPP‐4 inhibitors or GLP‐1 analogues versus all other pharmacological glucose‐lowering interventions, behaviour‐changing interventions, placebo or no intervention. </p> <section id="CD012204-sec-0036"> <h5 class="title">Intervention</h5> <p> <ul id="CD012204-list-0001"> <li> <p>DPP‐4 inhibitors as monotherapy.</p> </li> <li> <p>DPP‐4 inhibitors as a part of a combination therapy.</p> </li> <li> <p>GLP‐1 analogues as monotherapy.</p> </li> <li> <p>GLP‐1 analogues as a part of a combination therapy.</p> </li> </ul> </p> </section> <section id="CD012204-sec-0037"> <h5 class="title">Comparator</h5> <p> <ul id="CD012204-list-0002"> <li> <p>Any pharmacological glucose‐lowering intervention (e.g. acarbose, metformin, sulphonylurea) compared with DPP‐4 inhibitors as monotherapy or GLP‐1 analogues as monotherapy. </p> </li> <li> <p>Any pharmacological glucose‐lowering agent (e.g. acarbose, metformin, sulphonylurea) compared with DPP‐4 inhibitors as a part of a combination therapy or GLP‐1 analogues as a part of a combination therapy if this glucose‐lowering agent was the same in both the intervention and comparator groups (e.g. DPP‐4 inhibitor plus metformin versus metformin). </p> </li> <li> <p>Behaviour‐changing interventions (e.g. diet, exercise, diet and exercise) compared with DPP‐4 inhibitors as monotherapy or GLP‐1 analogues as monotherapy. </p> </li> <li> <p>Placebo compared with DPP‐4 inhibitors as monotherapy or GLP‐1 analogues as monotherapy.</p> </li> <li> <p>No intervention compared with DPP‐4 inhibitors as monotherapy or GLP‐1 analogues as monotherapy. </p> </li> </ul> </p> <p>Other concomitant interventions (e.g. educational programmes or additional pharmacotherapy) had to be the same in both the intervention and comparator groups to establish fair comparisons. </p> </section> <section id="CD012204-sec-0038"> <h5 class="title">Minimum duration of intervention</h5> <p>We included trials with a duration of the intervention of 12 weeks or more.</p> </section> <section id="CD012204-sec-0039"> <h5 class="title">Exclusion criteria</h5> <p> <ul id="CD012204-list-0003"> <li> <p>We excluded trials of people diagnosed with the 'metabolic syndrome' because this is a special population which is not representative of people with only intermediate hyperglycaemia. Also, the composite of risk indicators such as elevated blood lipids, insulin resistance, obesity and hypertension which is termed 'metabolic syndrome' is of doubtful clinical usefulness and uncertain distinct disease entity. However, should we identify trials investigating participants with any definition of the metabolic syndrome, we summarised some basic trial information in an additional table. </p> </li> <li> <p>We excluded trials evaluating participants with intermediate hyperglycaemia in combination with another condition (e.g. cystic fibrosis). </p> </li> <li> <p>We excluded trials evaluating participants with intermediate hyperglycaemia because of other medical interventions (e.g. glucocorticoids). </p> </li> </ul> </p> <p>We tried to include trials explicitly describing that a portion of the included participants had intermediate hyperglycaemia. We contacted the investigators to obtain separate data on the group with intermediate hyperglycaemia and include these in the meta‐analyses. </p> <p>We included trials in obese people and participants with previous gestational diabetes, if trial investigators described that the participants had intermediate hyperglycaemia. </p> <p>We included a trial even if it did not report one or more of our primary or secondary outcome measures in the publication. If a trial did not report any of our primary or secondary outcomes, we included this trial and contacted the corresponding trial author for supplementary data. We listed information about trials with a duration of the intervention shorter than 12 weeks in <a href="./appendices#CD012204-sec-0179">Appendix 1</a>. </p> <p>Some trials evaluated GLP‐1 analogues in doses recommended for achieving a weight‐reducing effect rather than a glucose‐lowering effect. We included such trials and performed subgroup analyses according to the dose of GLP‐1 analogues. </p> </section> </section> <section id="CD012204-sec-0040"> <h4 class="title">Types of outcome measures</h4> <section id="CD012204-sec-0041"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012204-list-0004"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Incidence of T2DM.</p> </li> <li> <p>Serious adverse events.</p> </li> </ul> </p> </section> <section id="CD012204-sec-0042"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012204-list-0005"> <li> <p>Cardiovascular mortality.</p> </li> <li> <p>Non‐fatal myocardial infarction.</p> </li> <li> <p>Non‐fatal stroke.</p> </li> <li> <p>Congestive heart failure.</p> </li> <li> <p>Amputation of lower extremity.</p> </li> <li> <p>Blindness or severe vision loss.</p> </li> <li> <p>End‐stage renal disease.</p> </li> <li> <p>Non‐serious adverse events.</p> </li> <li> <p>Hypoglycaemia.</p> </li> <li> <p>Health‐related quality of life (HRQoL).</p> </li> <li> <p>Time to progression to T2DM.</p> </li> <li> <p>Measures of blood glucose control.</p> </li> <li> <p>Socioeconomic effects.</p> </li> </ul> </p> <section id="CD012204-sec-0043"> <h6 class="title">Method and timing of outcome measurement</h6> <p> <ul id="CD012204-list-0006"> <li> <p>All‐cause mortality: defined as death from any cause. Measured at any time of the intervention and during follow‐up. </p> </li> <li> <p>Incidence of T2DM and time to progression to T2DM: defined according to diagnostic criteria valid at the time the diagnosis was established using the standard criteria valid at the time of the trial commencing (e.g. <a href="./references#CD012204-bbs2-0079" title="American Diabetes Association. Standards of medical care in diabetes ‐ 2008. Diabetes Care2008;31(Suppl 1):S12‐54. [PUBMED: 18165335] ">ADA 2008</a>; <a href="./references#CD012204-bbs2-0160" title="AlbertiKM , ZimmetPZ . Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine1998;15(7):539‐53. ">WHO 1998</a>). If necessary, we used the trial authors' definition of T2DM. Measured at the end of the intervention and the end of follow‐up. We also investigated regression from intermediate hyperglycaemia back to normoglycaemia. </p> </li> <li> <p>Serious adverse events: defined according to the International Conference on Harmonization Guidelines as any event that led to death, was life‐threatening, required hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability, or any important medical event which may have had jeopardised the person or required intervention to prevent it (<a href="./references#CD012204-bbs2-0123" title="International Conference on Harmonisation Expert Working Group. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice 1997 CFR &amp; ICH Guidelines. Philadelphia (PA): Barnett International/PAREXEL, 1997. ">ICH 1997</a>), or as reported in trials. Measured at any time of the intervention and during follow‐up. </p> </li> <li> <p>Cardiovascular mortality, non‐fatal myocardial infarction, non‐fatal stroke, congestive heart failure, amputation of lower extremity, blindness or severe vision loss, hypoglycaemia (mild, moderate, severe/serious): defined as reported in trials. Measured at the end of the intervention and at the end of follow‐up. </p> </li> <li> <p>End‐stage renal disease: defined as dialysis, renal transplantation or death due to renal disease. Measured at the end of the intervention and at the end of follow‐up. </p> </li> <li> <p>Non‐serious adverse events: defined as the number of participants with any untoward medical occurrence not necessarily having a causal relationship with the intervention. Measured at any time of the intervention and during follow‐up. </p> </li> <li> <p>HRQoL: defined as mental and physical HRQoL as separate domains and combined, evaluated by a validated instrument such as the 36‐item Short‐Form (SF‐36). Measured at the end of the intervention and at the end of follow‐up. </p> </li> <li> <p>Measures of blood glucose control: fasting blood glucose, blood glucose two hours after ingestion of glucose 75 g and HbA1c measurements. Measured at the end of the intervention and at the end of follow‐up. </p> </li> <li> <p>Socioeconomic effects: for example, costs of the intervention, absence from work and medication consumption. Measured at the end of the intervention and at the end of follow‐up. </p> </li> </ul> </p> </section> <section id="CD012204-sec-0044"> <h6 class="title">Specification of key prognostic variables</h6> <p> <ul id="CD012204-list-0007"> <li> <p>Age.</p> </li> <li> <p>Gender.</p> </li> <li> <p>Equity issues (access to health care, social determinants).</p> </li> <li> <p>Ethnicity.</p> </li> <li> <p>Hypertension.</p> </li> <li> <p>Cardiovascular disease.</p> </li> <li> <p>Obesity.</p> </li> <li> <p>Previous gestational diabetes.</p> </li> </ul> </p> </section> <section id="CD012204-sec-0045"> <h6 class="title">'Summary of findings' table</h6> <p>We present a 'Summary of findings' table to report the following outcomes, listed according to priority. </p> <p> <ol id="CD012204-list-0008"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Incidence of T2DM.</p> </li> <li> <p>Serious adverse events.</p> </li> <li> <p>Cardiovascular mortality.</p> </li> <li> <p>Non‐fatal myocardial infarction/stroke and congestive heart failure.</p> </li> <li> <p>HRQoL.</p> </li> <li> <p>Socioeconomic effects.</p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD012204-sec-0046"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012204-sec-0047"> <h4 class="title">Electronic searches</h4> <p>We searched the following sources from inception of each database to the specified date, and placed no restrictions on the language of publication. </p> <p> <ul id="CD012204-list-0009"> <li> <p>Cochrane Central Register of Controlled Trials (26 January 2017).</p> </li> <li> <p>Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to 26 January 2017). </p> </li> <li> <p>PubMed (subsets not available on Ovid) (12 February 2016).</p> </li> <li> <p>Embase (1974 to 2017 week 4, 26 January 2017).</p> </li> <li> <p>ClinicalTrials.gov (26 January 2017).</p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP) Search Portal (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) (26 January 2017). </p> </li> </ul> </p> <p>We continuously used a MEDLINE (via OvidSP) email alert service established by the Cochrane Metabolic and Endocrine Disorders (CMED) Group to identify newly published trials using the same search strategy as described for MEDLINE (for details on search strategies, see <a href="./appendices#CD012204-sec-0180">Appendix 2</a>). </p> <p>We obtained evaluations of all relevant non‐English articles.</p> </section> <section id="CD012204-sec-0048"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of retrieved included trials, systematic reviews, meta‐analyses and health technology assessment reports for other potentially eligible trials or ancillary publications. In addition, we contacted authors of included trials to identify any additional information on the retrieved trials and if further trials existed, that we may have missed. </p> <p>As none of the existing DPP‐4 inhibitors or GLP‐1 analogues is approved in glucose‐lowering doses for intermediate hyperglycaemia, we did not search databases of the regulatory agencies (EMA, US FDA). However, GLP‐1 analogues in higher doses are approved as a weight‐reducing intervention in obese people with intermediate hyperglycaemia. Therefore, we searched EMA and FDA for GLP‐1 analogues approved as a weight‐reducing intervention. </p> </section> </section> <section id="CD012204-sec-0049"> <h3 class="title" id="CD012204-sec-0049">Data collection and analysis</h3> <section id="CD012204-sec-0050"> <h4 class="title">Selection of studies</h4> <p>Two review authors (BH and DS) independently scanned the abstract, title, or both, of every record we retrieved in the literature searches, to determine which trials should be assessed further. We investigated the full text of all potentially relevant articles. We resolved discrepancies through consensus or by recourse to a third review author (BR). We prepared a flow diagram of the number of trials identified and excluded at each stage in accordance with the PRISMA flow diagram of trial selection (<a href="./references#CD012204-bbs2-0132" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJPA , et al. The PRISMA statement for reporting systematic and meta‐analyses of studies that evaluate interventions: explanation and elaboration. PLoS Medicine2009;6(7):1‐28. [DOI: 10.1371/journal.pmed.1000100] ">Liberati 2009</a>). </p> </section> <section id="CD012204-sec-0051"> <h4 class="title">Data extraction and management</h4> <p>For trials that fulfilled the inclusion criteria, two review authors (BH and DS) independently extracted outcome data and assessed the risk of bias. Key characteristics of participants and interventions were extracted by one review author (BH) and controlled by another (DS). We reported data on efficacy outcomes and adverse events using standard data extraction sheets from the CMED Group. We resolved any disagreements by discussion or, if required, by consultation with a third review author (BR) (for details, see <a href="./references#CD012204-sec-0205" title="">Characteristics of included studies</a> table; <a href="#CD012204-tbl-0003">Table 1</a>; <a href="./appendices#CD012204-sec-0181">Appendix 3</a>; <a href="./appendices#CD012204-sec-0182">Appendix 4</a>; <a href="./appendices#CD012204-sec-0183">Appendix 5</a>; <a href="./appendices#CD012204-sec-0184">Appendix 6</a>; <a href="./appendices#CD012204-sec-0185">Appendix 7</a>; <a href="./appendices#CD012204-sec-0186">Appendix 8</a>; <a href="./appendices#CD012204-sec-0187">Appendix 9</a>; <a href="./appendices#CD012204-sec-0188">Appendix 10</a>; <a href="./appendices#CD012204-sec-0189">Appendix 11</a>; <a href="./appendices#CD012204-sec-0190">Appendix 12</a>; <a href="./appendices#CD012204-sec-0191">Appendix 13</a>; <a href="./appendices#CD012204-sec-0192">Appendix 14</a>; <a href="./appendices#CD012204-sec-0193">Appendix 15</a>; <a href="./appendices#CD012204-sec-0195">Appendix 17</a>; <a href="./appendices#CD012204-sec-0196">Appendix 18</a>). </p> <div class="table" id="CD012204-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of trial populations</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial (design)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention and comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description of power and sample size calculation and handling of missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Screened/eligible<br/> (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised<br/> (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ITT<br/> (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysed<br/> (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Finishing trial<br/> (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised finishing trial<br/> (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up<br/> (extended follow‐up)<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Ariel 2014</b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: liraglutide 1.8 mg, once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Targeted sample size of 30 subjects in each group provided 90% power to detect a 20% difference (2.2 mmol/L) in SSPG concentration. With 24 subjects per group, there was 82% power to detect a 20% difference. A difference of 20% was chosen because this is the degree of difference in SSPG concentration seen with modest weight loss of 7%." </p> <p>"Only subjects who had end‐of‐study testing were included in the analyses."</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>14 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo, once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.8</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Kelly 2012</b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: exenatide 10 μg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 1000 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Martinez‐Abundis 2015</b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: linagliptin 5 mg + placebo in the evening</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>90 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 500 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>McLaughlin 2011</b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: exenatide 10 μg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>30 weeks (1 year)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Rosenstock 2008</b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: vildagliptin 50 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>956</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.4</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Rosenstock 2010</b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: exenatide 10 μg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Includes participants that received at least 1 dose of study drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>322<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>SCALE</b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I: liraglutide 3.0 mg, once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"The power for the primary endpoint weight change is calculated based on a two sided t‐test with a significance level of 5%. The power with regard to the co‐primary dichotomous endpoints proportion of subjects with a weight loss of at least 5% or more than 10%, respectively, is calculated based on a two‐sided chi‐square test." </p> <p>"The large number of randomised subjects also provides sufficient power for the fourth primary endpoint new onset of diabetes among subjects with pre‐diabetes. The endpoint new onset of diabetes will be analysed using methods for analysis of interval censored failure time data. A conservative estimate of the power may be calculated as if the endpoint diabetes yes/no among completers during the 160 weeks is analysed by use of a two‐sided Chisquare test with a significance level of 5%. </p> <p>It is assumed that the annual conversion rate of subjects with pre‐diabetes to diabetes equals 7% among placebo treated subjects, whereas it is 60% lower, 2.1%, among liraglutide treated subjects. After 160 weeks of treatment with liraglutide/placebo, the percentage of subjects with diabetes is therefore equal to 1‐(1‐0.07)3 = 20% among liraglutide placebo treated subjects and 1‐(1‐0.021)<sup>3</sup> = 6% among liraglutide treated subjects. It is assumed that the drop‐out during the 160 weeks may be as large as 65% in both groups. The power for conversion rates for placebo of 5, 7 and 9% and conversion rates 60 and 70% lower in the liraglutide group may be seen in Table 18‐1." </p> <p>From the numbers in Table 18‐1 following numbers are specified:</p> <p>"Based on these figures it is apparent that a sample size of 2400 liraglutide treated subjects and 1200 liraglutide placebo treated subjects will provide sufficient power also for the fourth primary endpoint onset of diabetes" </p> <p>"Missing values were imputed with the use of the last‐observation‐carried‐forward method for measurements made after baseline." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>4992<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Period week 0‐56: 1528</p> <p>Period week 0‐172: 1505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1472<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1472<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Period week 0‐56: 1110</p> <p>Period week 0‐172: 783<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Period week 0‐56: 72.6</p> <p>Period week 0‐172: 52.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>160 weeks (172 weeks)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Period week 0‐56: 757</p> <p>Period week 0‐172: 749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>738<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>738<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Period week 0‐56: 505</p> <p>Period week 0‐172: 327<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Period week 0‐56: 66.7</p> <p>Period week 0‐172: 43.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b><i>Grand total</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All interventions<sup>h</sup> </i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>1718</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>924</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All c</i> <i>omparators<sup>h</sup> </i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>946</i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>471</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All interventions and c</i> <i>omparators<sup>i</sup> </i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>2702</i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>1428<sup>j</sup> </i> </b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>‐ denotes not reported.</p> <p><sup>a</sup>Follow‐up under randomised conditions until end of trial or if not available, duration of intervention; extended follow‐up refers to follow‐up of participants once the original study was terminated as specified in the power calculation.<br/> <sup>b</sup>Total number of screened.<br/> <sup>c</sup>Article stated that 38 participants out of the total randomised population had impaired fasting glucose or impaired glucose tolerance, or both.<br/> <sup>d</sup>Number retrieved from abstract.<br/> <sup>e</sup>One of the abstracts reports that 68 participants were randomised and another abstract reports 66 participants.<br/> <sup>f</sup>The SCALE had different number of participants included in the analyses depending on outcome. A full analyses set is reported in the table and was defined as: "All randomised subjects exposed to at least one dose of the trial product and with at least one post baseline assessment of any efficacy endpoint will be included. Subjects in the FAS will be analysed according to randomised treatment." Beside safety analysis set was defined as: "All randomised subjects who have been exposed to at least one dose of trial product. Subjects in the safety analysis set will be analysed "as treated" ". The number of participants started in the trial according to clinicaltrial.gov varied from the period of week 0 to week 56 and from week 0 to 172 due to misclassification of screened participants.<br/> <sup>g</sup>In the publication reporting long‐term data, it was stated that 791 (53%) participants in the liraglutide group and 337 (15%) participants in the placebo group completed the trial (<a href="./references#CD012204-bbs2-0131" title="Lle RouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] ">Le Roux 2017</a>).<br/> <sup>h</sup>Not all trials described the number of participants randomised to each intervention/comparator group.<br/> <sup>i</sup>One trial did not report the number of randomised participants per intervention group. Therefore, numbers do not add up accurately.<br/> <sup>j</sup>Not all trials reported the number of participants finishing the trial. </p> <p>C: comparator; I: intervention; ITT: intention to treat; n: number of participants; N/A: not applicable; RCT: randomised controlled trial; SCALE: Satiety and Clinical Adiposity ‐ Liraglutide Evidence in Nondiabetic and Diabetic Individuals; SSPG: steady‐state plasma glucose. </p> </div> </div> <p>We provided information about potentially relevant ongoing trials including trial identifier in the <a href="./references#CD012204-sec-0208" title="">Characteristics of ongoing studies</a> table and in <a href="./appendices#CD012204-sec-0185">Appendix 7</a> 'Matrix of trial endpoint (publications and trial documents)'. For each included trial, we tried to retrieve the protocol. If not available from the search of the databases, reference screening or Internet searches, we asked authors to provide a copy of the protocol. Predefined outcomes were entered in a 'Matrix of trial endpoint (publications and trial documents)' (see <a href="./appendices#CD012204-sec-0185">Appendix 7</a>). </p> <p>We emailed all authors of the included trials to enquire whether they were willing to answer questions regarding their trials. We presented the results of this survey in 'Survey of trial investigators providing information on included trials' (see <a href="./appendices#CD012204-sec-0192">Appendix 14</a>). We sought relevant missing information on the trial from the primary author(s) of the articles, if possible. </p> <section id="CD012204-sec-0052"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>In the event of duplicate publications, companion documents or multiple reports of a primary trial, we maximised the information yield by collating all available data and used the most complete data set aggregated across all known publications. Duplicate publications, companion documents or multiple reports of a primary trial would be listed as secondary references under the primary reference of the included, ongoing or excluded trial. </p> </section> <section id="CD012204-sec-0053"> <h5 class="title">Data from clinical trial registers</h5> <p>If data of included trials were available as study results in clinical trial registers such as <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> or similar sources, we made full use of this information and extracted data. If there was also a full publication of the trial, we collated and critically appraised all available data. </p> </section> </section> <section id="CD012204-sec-0054"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (BH and DS) independently assessed the risk of bias of each included trial. We resolved any disagreements by consensus, or by consultation with a third review author (BR). If adequate information was not available from the trial publication, trial protocol, or both we contacted trial authors for missing data on 'Risk of bias' items. </p> <p>We used the Cochrane 'Risk of bias' assessment tool (<a href="./references#CD012204-bbs2-0116" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>; <a href="./references#CD012204-bbs2-0117" title="HigginsJPT , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. ">Higgins 2011b</a>), and judged 'Risk of bias' criteria as 'low', 'high' or 'unclear' risk and evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012204-bbs2-0116" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>), where any of the specified criteria for a judgement on 'low', unclear' or 'high' risk of bias justified the associated categorisation. </p> <section id="CD012204-sec-0055"> <h5 class="title">Random sequence generation (selection bias due to inadequate generation of a randomised sequence) ‐ assessment at trial level </h5> <p>We described for each included trial the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p> <ul id="CD012204-list-0010"> <li> <p>Low risk of bias: sequence generation was achieved using computer random number generation or a random number table. Drawing of lots, tossing a coin, shuffling cards or envelopes, and throwing dice were adequate if performed by an independent person not otherwise involved in the trial. Use of the minimisation technique was considered as equivalent to being random. </p> </li> <li> <p>Unclear risk of bias: insufficient information about the sequence generation process.</p> </li> <li> <p>High risk of bias: the sequence generation method was non‐random (e.g. sequence generated by odd or even date of birth; sequence generated by some rule based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number; allocation by judgement of the clinician; allocation by preference of the participant; allocation based on the results of a laboratory test or a series of tests; allocation by availability of the intervention). Such trials were excluded. </p> </li> </ul> </p> </section> <section id="CD012204-sec-0056"> <h5 class="title">Allocation concealment (selection bias due to inadequate concealment of allocations prior to assignment) ‐ assessment at trial level </h5> <p>We described for each included trial the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. </p> <p> <ul id="CD012204-list-0011"> <li> <p>Low risk of bias: central allocation (including telephone, interactive voice‐recorder, web‐based and pharmacy‐controlled randomisation); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes. </p> </li> <li> <p>Unclear risk of bias: insufficient information about the allocation concealment.</p> </li> <li> <p>High risk of bias: used an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards; alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure. Such trials were excluded. </p> </li> </ul> </p> <p>We also evaluated trial baseline data to incorporate assessment of baseline imbalance into the 'Risk of bias' judgement for selection bias (<a href="./references#CD012204-bbs2-0094" title="CorbettMS , HigginsJP , WoolacottNF . Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool. Research Synthesis Methods2014;5:79‐85. ">Corbett 2014</a>; <a href="./references#CD012204-bbs2-0102" title="EgbewaleBE , LewisM , SimJ . Bias, precision and statistical power of analysis of covariance in the analysis of randomized trials with baseline imbalance: a simulation study. BMC Medical Research Methodology2014;14:49. [DOI: 10.1186/1471‐2288‐14‐49] ">Egbewale 2014</a>; <a href="./references#CD012204-bbs2-0149" title="RileyRD , KauserI , BlandM , ThijsL , StaessenJA , WangJ , et al. Meta‐analysis of randomised trials with a continuous outcome according to baseline imbalance and availability of individual participant data. Statistics in Medicine2013;32(16):2747‐66. ">Riley 2013</a>). Chance imbalances may also affect judgements on the risk of attrition bias. In the case of unadjusted analyses, we distinguished between trials we rated as at low risk of bias on the basis of both randomisation methods and baseline similarity, and trials rated as at low risk of bias on the basis of baseline similarity alone (<a href="./references#CD012204-bbs2-0094" title="CorbettMS , HigginsJP , WoolacottNF . Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool. Research Synthesis Methods2014;5:79‐85. ">Corbett 2014</a>). We reclassified judgements of unclear, low or high risk of selection bias as specified in 'Selection bias decisions' (<a href="./appendices#CD012204-sec-0196">Appendix 18</a>). </p> </section> <section id="CD012204-sec-0057"> <h5 class="title">Blinding of participants and study personnel (performance bias due to knowledge of the allocated interventions by participants and personnel during the trial) ‐ assessment at outcome level </h5> <p>We evaluated the risk of performance bias separately for each outcome (<a href="./references#CD012204-bbs2-0122" title="HróbjartssonA , ThomsenAS , EmanuelssonF , TendalB , HildenJ , BoutronI , et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Canadian Medical Association Journal2013;185(4):E201‐11. ">Hróbjartsson 2013</a>). We noted whether outcomes were self‐reported, investigator‐assessed or adjudicated outcome measures (see below). </p> <p> <ul id="CD012204-list-0012"> <li> <p>Low risk of bias: blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken; no blinding or incomplete blinding, but the review authors judged that the outcome was not likely to be influenced by lack of blinding. </p> </li> <li> <p>Unclear risk of bias: insufficient information about the blinding of participants and study personnel; the trial did not address this outcome. </p> </li> <li> <p>High risk of bias: no blinding or incomplete blinding, and the outcome was likely to be influenced by lack of blinding; blinding of trial participants and key personnel attempted, but likely that the blinding could have been broken, and the outcome was likely to be influenced by lack of blinding. </p> </li> </ul> </p> </section> <section id="CD012204-sec-0058"> <h5 class="title">Blinding of outcome assessment (detection bias due to knowledge of the allocated interventions by outcome assessment) ‐ assessment at outcome level </h5> <p>We evaluated the risk of detection bias separately for each outcome (<a href="./references#CD012204-bbs2-0122" title="HróbjartssonA , ThomsenAS , EmanuelssonF , TendalB , HildenJ , BoutronI , et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Canadian Medical Association Journal2013;185(4):E201‐11. ">Hróbjartsson 2013</a>). We noted whether outcomes were self‐reported, investigator‐assessed or adjudicated outcome measures (see below). </p> <p> <ul id="CD012204-list-0013"> <li> <p>Low risk of bias: blinding of outcome assessment ensured, and unlikely that the blinding could have been broken; no blinding of outcome assessment, but the review authors judged that the outcome measurement was not likely to be influenced by lack of blinding. </p> </li> <li> <p>Unclear risk of bias: insufficient information about the blinding of outcome assessors; the trial did not address this outcome. </p> </li> <li> <p>High risk of bias: no blinding of outcome assessment, and the outcome measurement was likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement was likely to be influenced by lack of blinding. </p> </li> </ul> </p> </section> <section id="CD012204-sec-0059"> <h5 class="title">Incomplete outcome data (attrition bias due to amount, nature or handling of incomplete outcome data) ‐ assessment at outcome level </h5> <p>We described for each included trial, and for each outcome, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the number included in the analysis at each stage (compared with the number of randomised participants per intervention/comparator groups), if reasons for attrition or exclusion were reported, and whether missing data were balanced across groups or were related to outcomes. We considered the implications of missing outcome data per outcome such as high dropout rates (e.g. above 15%) or disparate attrition rates (e.g. difference of 10% or more between trial arms). </p> <p> <ul id="CD012204-list-0014"> <li> <p>Low risk of bias: no missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (mean difference (MD) or standardised mean difference (SMD)) among missing outcomes not enough to have a clinically relevant impact on observed effect size; appropriate methods, such as multiple imputation, were used to handle missing data. </p> </li> <li> <p>Unclear risk of bias: insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias; the trial did not address this outcome. </p> </li> <li> <p>High risk of bias: reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (MD or SMD) among missing outcomes enough to induce clinically relevant bias in observed effect size; 'as‐treated' or similar analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation. </p> </li> </ul> </p> </section> <section id="CD012204-sec-0060"> <h5 class="title">Selective reporting (reporting bias due to selective outcome reporting) ‐ assessment at trial level </h5> <p>We assessed outcome reporting bias by integrating the results of the appendix 'Matrix of trial endpoints (publications and trial documents' (<a href="./appendices#CD012204-sec-0185">Appendix 7</a>) (<a href="./references#CD012204-bbs2-0088" title="BoutronI , AltmanDG , HopewellS , Vera‐BadilloF , TannockI , RavaudP . Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial. Journal of Clinical Oncology2014;32:4120‐6. ">Boutron 2014</a>; <a href="./references#CD012204-bbs2-0134" title="MathieuS , BoutronI , MoherD , AltmanDG , RavaudP . Comparison of registered and published primary outcomes in randomized controlled trials. JAMA2009;302:977‐84. ">Mathieu 2009</a>), with those of the appendix 'High risk of outcome reporting bias according to ORBIT classification' (<a href="./appendices#CD012204-sec-0186">Appendix 8</a>) (<a href="./references#CD012204-bbs2-0128" title="KirkhamJJ , DwanKM , AltmanDG , GambleC , DoddS , SmythR , et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ2010;340:c365. [DOI: 10.1136/bmj.c365] ">Kirkham 2010</a>). This analysis formed the basis for the judgement of selective reporting. </p> <p> <ul id="CD012204-list-0015"> <li> <p>Low risk of bias: the trial protocol was available and all the trial's prespecified (primary and secondary) outcomes that were of interest in the review were reported in the prespecified way; the study protocol was not available but it was clear that the published reports include all expected outcomes (ORBIT classification). </p> </li> <li> <p>Unclear risk of bias: insufficient information about selective reporting.</p> </li> <li> <p>High risk of bias: not all the trial's prespecified primary outcomes have been reported; one or more primary outcomes was reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not prespecified; one or more reported primary outcomes were not prespecified (unless clear justification for their reporting was provided, such as an unexpected adverse effect); one or more outcomes of interest in the review were reported incompletely so that they could not be entered in a meta‐analysis; the trial report failed to include results for a key outcome that would be expected to have been reported for such a trial (ORBIT classification). </p> </li> </ul> </p> </section> <section id="CD012204-sec-0061"> <h5 class="title">Other bias (bias due to problems not covered elsewhere) ‐ assessment at trial level</h5> <p>Other risk of bias reflected other circumstances that may threaten the validity of the trials. </p> <p> <ul id="CD012204-list-0016"> <li> <p>Low risk of bias: the trial appeared to be free of other sources of bias.</p> </li> <li> <p>Unclear risk of bias: insufficient information to assess whether an important risk of bias existed; insufficient rationale or evidence that an identified problem introduced bias. </p> </li> <li> <p>High risk of bias: had a potential source of bias related to the specific trial design used; has been claimed to have been fraudulent; had some other serious problem. </p> </li> </ul> </p> <p>We established a 'Risk of bias' graph and a 'Risk of bias' summary figure.</p> <p>We distinguished between self‐reported, investigator‐assessed and adjudicated outcome measures. </p> <p>We defined the following outcomes as self‐reported.</p> <p> <ul id="CD012204-list-0017"> <li> <p>Non‐serious adverse events.</p> </li> <li> <p>Hypoglycaemia, if reported by participants.</p> </li> <li> <p>HRQoL.</p> </li> <li> <p>Measures of blood glucose control, if measured by trial participants.</p> </li> </ul> </p> <p>We defined the following outcomes as investigator‐assessed.</p> <p> <ul id="CD012204-list-0018"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Incidence of T2DM.</p> </li> <li> <p>Serious adverse events.</p> </li> <li> <p>Cardiovascular mortality.</p> </li> <li> <p>Non‐fatal myocardial infarction.</p> </li> <li> <p>Non‐fatal stroke.</p> </li> <li> <p>Congestive heart failure.</p> </li> <li> <p>Amputation of lower extremity.</p> </li> <li> <p>Blindness or severe vision loss.</p> </li> <li> <p>End‐stage renal disease.</p> </li> <li> <p>Hypoglycaemia, if measured by trial personnel.</p> </li> <li> <p>Time to progression to T2DM.</p> </li> <li> <p>Blood glucose control, if measured by trial personnel.</p> </li> <li> <p>Socioeconomic effects.</p> </li> </ul> </p> </section> <section id="CD012204-sec-0062"> <h5 class="title">Summary assessment of risk of bias</h5> <p><b>Risk of bias for a trial across outcomes</b>: some risk of bias domains, such as selection bias (sequence generation and allocation sequence concealment), affected the risk of bias across all outcome measures in a trial. Otherwise, we did not perform a summary assessment of the risk of bias across all outcomes for a trial. In case of high risk of selection bias, we excluded the trial. </p> <p><b>Risk of bias for an outcome within a trial and across domains</b>: we assessed the risk of bias for an outcome measure by including all entries relevant to that outcome (i.e. both trial‐level entries and outcome‐specific entries). 'Low' risk of bias was defined as low risk of bias for all key domains, 'unclear' risk of bias as unclear risk of bias for one or more key domains and 'high' risk as high risk of bias for one or more key domains. </p> <p><b>Risk of bias for an outcome across trials and across domains</b>: these were our main summary assessments that were incorporated in our judgements about the quality of evidence in the 'Summary of findings' tables. 'Low' risk of bias was defined as most information coming from trials at low risk of bias, 'unclear' risk of bias as most information coming from trials at low or unclear risk of bias and 'high' risk of bias as sufficient proportion of information coming from trials at high risk of bias. </p> </section> </section> <section id="CD012204-sec-0063"> <h4 class="title">Measures of treatment effect</h4> <p>When at least two trials were available for a comparison of a given outcome, we expressed dichotomous data as risk ratio (RR) with 95% CIs and with Trial Sequential Analysis (TSA)‐adjusted 95% CIs if the diversity‐adjusted required information size was not reached. We expressed continuous data reported on the same scale as MD with 95% CIs and with TSA‐adjusted 95% CIs if the diversity‐adjusted required information size was not reached. For trials addressing the same outcome but using different outcome measure scales, we used SMD with 95% CI. We planned to calculate time‐to‐event data as HR with 95% CI with the generic inverse variance method. Unadjusted HRs would have been preferred, as adjustment may differ among the included trials. For outcomes meta‐analysed as SMD and the generic inverse variance method, we are presently unable to conduct TSA and adjust the 95% CIs. </p> <p>The scales measuring HRQoL may go in different directions. Some scales increase in values with improved HRQoL, whereas other scales decrease in values with improved HRQoL. To adjust for the different directions of the scales, we planned to multiply the scales that reported better HRQoL with decreasing values by ‐1. </p> </section> <section id="CD012204-sec-0064"> <h4 class="title">Unit of analysis issues</h4> <p>We took into account the level at which randomisation occurred, such as cross‐over trials, cluster‐randomised trials and multiple observations for the same outcome. If more than one comparison from the same trial was eligible for inclusion in the same meta‐analysis, we would have either combined groups to create a single pair‐wise comparison or appropriately reduced the sample size so that the same participants do not contribute multiply (splitting the 'shared' group into two or more groups). While the latter approach offers some solution to adjusting the precision of the comparison, it does not account for correlation arising from the same set of participants being in multiple comparisons (<a href="./references#CD012204-bbs2-0116" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). </p> <p>We planned to reanalyse cluster‐randomised trials that did not appropriately adjust for potential clustering of participants within clusters in their analyses. The variance of the intervention effects was planned to be inflated by a design effect (DEFF). Calculation of a DEFF involves estimation of an intra‐cluster correlation (ICC). We planned to obtain estimates of ICCs through contact with authors, or impute using estimates from other included studies that report ICCs, or using external estimates from empirical research (e.g. <a href="./references#CD012204-bbs2-0085" title="BellML , McKenzieJE . Designing psycho‐oncology randomised trials and cluster randomised trials: variance components and intra‐cluster correlation of commonly used psychosocial measures. Psycho‐oncology2013;22:1738‐47. ">Bell 2013</a>). We planned to examine the impact of clustering using sensitivity analyses. </p> </section> <section id="CD012204-sec-0065"> <h4 class="title">Dealing with missing data</h4> <p>We tried to obtain missing data from trial authors and carefully evaluate important numerical data such as screened, randomly assigned participants as well as intention‐to‐treat (ITT), and as‐treated and per‐protocol populations. </p> <p>We investigated attrition rates (e.g. dropouts, losses to follow‐up, withdrawals), and we critically appraised issues concerning missing data and imputation methods (e.g. last observation carried forward (LOCF)). </p> <p>We converted standard errors and CIs to standard deviations (SD) (<a href="./references#CD012204-bbs2-0116" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). When there were no differences in means and SDs from baseline, we used the end‐of follow‐up values (<a href="./references#CD012204-bbs2-0116" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). Where means and SDs for outcomes were not reported and we did not receive the needed information from trial authors, we calculated the SDs from standard errors, if possible. Otherwise, we would have imputed the values by assuming the SDs of the missing outcome to be the mean of the SDs from the trials that reported this information. </p> <p>We planned to investigate the impact of imputation on meta‐analyses by performing sensitivity analyses. </p> </section> <section id="CD012204-sec-0066"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the event of substantial clinical or methodological heterogeneity, we planned not to report trial results as the pooled effect estimate in a meta‐analysis. </p> <p>We investigated heterogeneity (inconsistency) by visually inspecting the forest plots and by using a standard Chi² test with a significance level of 0.1. In view of the low power of this test, we also considered the I² statistic, which quantifies inconsistency across trials to assess the impact of heterogeneity on the meta‐analysis (<a href="./references#CD012204-bbs2-0113" title="HigginsJPT , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21:1539‐58. ">Higgins 2002</a>; <a href="./references#CD012204-bbs2-0114" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analysis. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>); an I² statistic of 75% or greater indicated a considerable level of heterogeneity (<a href="./references#CD012204-bbs2-0116" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). </p> </section> <section id="CD012204-sec-0067"> <h4 class="title">Assessment of reporting biases</h4> <p>If we included 10 or more trials investigating a particular outcome, we planned to use funnel plots to assess small‐trial effects. Several explanations may account for funnel plot asymmetry, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence bias of small trials) and publication bias. Therefore, we planned to interpret results carefully (<a href="./references#CD012204-bbs2-0153" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials. BMJ2011;343:d4002. ">Sterne 2011</a>). </p> </section> <section id="CD012204-sec-0068"> <h4 class="title">Data synthesis</h4> <p>Unless good evidence showed homogeneous effects across trials, we would primarily summarise low risk of bias data using a random‐effects model (<a href="./references#CD012204-bbs2-0165" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601‐5. ">Wood 2008</a>). We interpreted random‐effects meta‐analyses with consideration to the whole distribution of effects, ideally by presenting a prediction interval (<a href="./references#CD012204-bbs2-0115" title="HigginsJPT , ThompsonSG , SpiegelhalterDJ . A re‐evaluation of random‐effects meta‐analysis. Journal of the Royal Statistical Society. Series A, (Statistics in Society)2009;172(1):137‐59. ">Higgins 2009</a>). A prediction interval specifies a predicted range for the true treatment effect in an individual trial (<a href="./references#CD012204-bbs2-0148" title="RileyRD , HigginsJP , DeeksJJ . Interpretation of random effects meta‐analyses. BMJ2011;342:d549. ">Riley 2011</a>). In addition, we performed statistical analyses according to the statistical guidelines presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012204-bbs2-0116" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). </p> <section id="CD012204-sec-0069"> <h5 class="title">Trial Sequential Analyses</h5> <p>In a single trial, sparse data and interim analyses increase the risk of type I and type II errors. To avoid type I errors, group sequential monitoring boundaries are applied to decide whether a trial could be terminated early because of a sufficiently small P value (i.e. the cumulative Z‐curve crosses the monitoring boundaries) (<a href="./references#CD012204-bbs2-0130" title="LanKKG , DeMetsDL . Discrete sequential boundaries for clinical trials. Biometrika1983;70:659‐63. ">Lan 1983</a>). Likewise, before reaching the planned sample size of a trial, the trial may be stopped due to futility if the cumulative Z‐score crosses the futility monitoring boundaries (<a href="./references#CD012204-bbs2-0116" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). Sequential monitoring boundaries for benefit, harm or futility can be applied to meta‐analyses as well (termed trial sequential monitoring boundaries) (<a href="./references#CD012204-bbs2-0118" title="HigginsJP , WhiteheadA , SimmondsM . Sequential methods for random‐effects meta‐analysis. Statistics in Medicine2011;30(9):903‐21. [PUBMED: 21190240] ">Higgins 2011c</a>; <a href="./references#CD012204-bbs2-0159" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). In TSA, the addition of each trial in a cumulative meta‐analysis is regarded as an interim meta‐analysis and helps to clarify whether significance or futility is reached, or whether additional trials are needed (<a href="./references#CD012204-bbs2-0159" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). </p> <p>TSA combines a calculation of the diversity‐adjusted required information size (cumulated meta‐analysis sample size to detect or reject a specific relative intervention effect) for meta‐analysis with the threshold of data associated with statistics. We performed TSA on all outcomes (<a href="./references#CD012204-bbs2-0089" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [PUBMED: 18824466] ">Brok 2009</a>; <a href="./references#CD012204-bbs2-0143" title="PogueJM , YusufS . Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta‐analysis. Controlled Clinical Trials1997;18(6):580‐93; discussion 661‐6. [PUBMED: 9408720] ">Pogue 1997</a>; <a href="./references#CD012204-bbs2-0159" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). </p> <p>The idea in TSA is that if the cumulative Z‐curve crosses the boundary for benefit or harm before a diversity‐adjusted required information size is reached, a sufficient level of evidence for the anticipated intervention effect has been reached with the assumed type I error and no further trials may be needed. If the cumulative Z‐curve crosses the boundary for futility before a diversity‐adjusted required information size is reached, the assumed intervention effect can be rejected with the assumed type II error and no further trials may be needed. If the Z‐curve does not cross any boundary, then there is insufficient evidence to reach a conclusion. To construct the trial sequential monitoring boundaries, the required information size is needed and is calculated as the least number of participants needed in a well‐powered single trial and subsequently adjusted for diversity among the included trials in the meta‐analysis (<a href="./references#CD012204-bbs2-0089" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [PUBMED: 18824466] ">Brok 2009</a>; <a href="./references#CD012204-bbs2-0159" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). We applied TSA as it decreases the risk of type I and II errors due to sparse data and multiple updating in a cumulative meta‐analysis, and it provides us with important information to estimate the risks of imprecision when the required information size is not reached. Additionally, TSA provides important information regarding the need for additional trials and the required information size of such trials (<a href="./references#CD012204-bbs2-0159" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). </p> <p>We applied trial sequential monitoring boundaries according to an estimated clinically important effect. We based the required information size on an a priori effect corresponding to a 10% relative risk reduction (RRR) for beneficial effects of the interventions and a 30% relative risk increase for harmful effects of the interventions. </p> <p>TSA for continuous outcomes was performed with MDs, by using trials applying the same scale to calculate the required sample size. For continuous outcomes, we tested the evidence for the achieved differences in cumulative meta‐analyses. </p> <p>For adjustment of heterogeneity of the required information size we used the diversity (D²) estimated in the meta‐analyses of included trials. When diversity was zero in a meta‐analysis, we performed a sensitivity analysis using an assumed diversity of 20%. </p> </section> <section id="CD012204-sec-0070"> <h5 class="title">Quality of evidence</h5> <p>We presented the overall quality of the evidence for each outcome according to the GRADE approach, which takes into account issues relating not only to internal validity (risk of bias, inconsistency, imprecision, publication bias) but also to external validity, such as directness of results<i>.</i> Two review authors (BH and DS) independently rated the quality of evidence for each outcome. We presented a summary of the evidence in <a href="./full#CD012204-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD012204-tbl-0002">summary of findings Table 2</a>. This provides key information about the best estimate of the magnitude of the effect, in relative terms and as absolute differences, for each relevant comparison of alternative management strategies, the numbers of participants and trials addressing each important outcome, and rates the overall confidence in effect estimates for each outcome. We created the 'Summary of findings' tables on the basis of methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012204-bbs2-0116" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>) by means of the table editor in Review Manager 5 (<a href="./references#CD012204-bbs2-0147" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), and included two appendices (<a href="./appendices#CD012204-sec-0195">Appendix 17</a>; <a href="./appendices#CD012204-sec-0196">Appendix 18</a>) providing checklists as guides to the consistency and reproducibility of GRADE assessments (<a href="./references#CD012204-bbs2-0135" title="MeaderN , KingK , LlewellynA , NormanG , BrownJ , RodgersM , et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews2014;3:82. ">Meader 2014</a>) to help with the standardisation of the 'Summary of findings' tables. Alternatively, we would have used the GRADEpro GDT software (<a href="./references#CD012204-bbs2-0109" title="GRADE Working Group, McMaster University. GRADEpro GDT. Hamilton (ON): GRADE Working Group, McMaster University, 2015. ">GRADEpro GDT 2015</a>) and presented evidence profile tables as an appendix. We presented results for the outcomes as described in the <a href="#CD012204-sec-0040">Types of outcome measures</a> section. If meta‐analysis was not possible, we presented the results in a narrative format in the 'Summary of findings' tables. We justified all decisions to downgrade the quality using footnotes, and we made comments to aid the reader's understanding of the review where necessary. </p> </section> </section> <section id="CD012204-sec-0071"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to introduce clinical heterogeneity, and planned to carry out the following subgroup analyses with investigation of interactions. </p> <p> <ul id="CD012204-list-0019"> <li> <p>Type of DPP‐4 inhibitor or GLP‐1 analogue.</p> </li> <li> <p>Trials with long duration (two years or greater) versus trials with short duration (less than two years). </p> </li> <li> <p>Diagnostic criteria (IFG, IGT, HbA1c).</p> </li> <li> <p>Age, depending on data.</p> </li> <li> <p>Gender.</p> </li> <li> <p>Ethnicity, depending on data.</p> </li> <li> <p>Comorbid conditions, such as hypertension, obesity, or both.</p> </li> <li> <p>Participants with previous gestational diabetes mellitus.</p> </li> <li> <p>GLP‐1 analogues dose (up to the recommended dose for a glucose‐lowering effect in people with T2DM versus higher doses). </p> </li> </ul> </p> </section> <section id="CD012204-sec-0072"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses to explore the influence of the certain factors (when applicable) on effect sizes by restricting analysis to the following. </p> <p> <ul id="CD012204-list-0020"> <li> <p>Published trials.</p> </li> <li> <p>Taking into account risk of bias, as specified in the <a href="#CD012204-sec-0054">Assessment of risk of bias in included studies</a> section. </p> </li> <li> <p>Very long or large trials, to establish the extent to which they dominated the results.</p> </li> <li> <p>Trials using the following filters: diagnostic criteria, imputation, language of publication, source of funding (industry versus other) or country. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012204-sec-0073" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012204-sec-0073"></div> <section id="CD012204-sec-0074"> <h3 class="title">Description of studies</h3> <p>For a detailed description of trials, see <a href="#CD012204-tbl-0003">Table 1</a>; and the <a href="./references#CD012204-sec-0205" title="">Characteristics of included studies</a>, <a href="./references#CD012204-sec-0206" title="">Characteristics of excluded studies</a>, <a href="./references#CD012204-sec-0207" title="">Characteristics of studies awaiting classification</a> and <a href="./references#CD012204-sec-0208" title="">Characteristics of ongoing studies</a> tables. </p> <section id="CD012204-sec-0075"> <h4 class="title">Results of the search</h4> <p>The initial search of the databases identified 2074 records after duplicates were removed. The applied MEDLINE (via OvidSP) email alert service established by the CMED Group to identify newly published trials using the same search strategy as described for MEDLINE (for details on search strategies, see <a href="./appendices#CD012204-sec-0180">Appendix 2</a>) did not identify any additional references. We excluded most of the references on the basis of their titles and abstracts because they clearly did not meet the inclusion criteria (<a href="#CD012204-fig-0001">Figure 1</a>). We evaluated 164 references further. After screening the full texts, seven RCTs published in 50 records met our inclusion criteria. One trial published in three references did not report any of the primary or secondary outcomes of this review (<a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>). The trial was only published in abstracts. The investigators were asked for additional data, but stated they would not provide additional data before the trial was published in full (<a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>) (see <a href="./appendices#CD012204-sec-0192">Appendix 14</a>). </p> <div class="figure" id="CD012204-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012204-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We excluded 73 references after full‐text evaluation.</p> <p>We identified two applications for approval of liraglutide 3.0 mg in people with obesity when searching the US FDA and the EMA websites (<a href="./references#CD012204-bbs2-0104" title="European Medicines Agency. Assessment Report. Saxenda. International non‐proprietary name: liraglutide. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_assessment_report/human/003780/WC500185788.pdf (accessed 21 September 2016). ">EMA/143005/2015</a>; <a href="./references#CD012204-bbs2-0107" title="USFood , DrugAdministration . Saxenda Injection (Liraglutide [rDNA origin]). www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206321Orig1s000TOC.cfm (assessed 22 September 2016). ">FDA 2014</a>). As some of these people might have had intermediate hyperglycaemia and therefore fulfilled the inclusion criteria, these applications were screened for trials and data to be included. We screened the statistical and medical reviews in the FDA application, but did not identify additional trials or data with relevance for this review (<a href="./references#CD012204-bbs2-0104" title="European Medicines Agency. Assessment Report. Saxenda. International non‐proprietary name: liraglutide. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_assessment_report/human/003780/WC500185788.pdf (accessed 21 September 2016). ">EMA/143005/2015</a>; <a href="./references#CD012204-bbs2-0107" title="USFood , DrugAdministration . Saxenda Injection (Liraglutide [rDNA origin]). www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206321Orig1s000TOC.cfm (assessed 22 September 2016). ">FDA 2014</a>). We did not find a health technology assessment report for DPP‐4 inhibitors or GLP‐1 analogues in people at increased risk for the development of T2DM. Furthermore, no systematic review or meta‐analysis focusing on the DPP‐4 inhibitors or GLP‐1 analogues in people at increased risk for the development of T2DM could be identified. Four systematic reviews published in five records in people at increased risk for the development of T2DM did not include any trials using a DPP‐4 inhibitor or GLP‐1 analogue as a comparator (<a href="./references#CD012204-bbs2-0084" title="AndersonDCJr . Pharmacologic prevention or delay of type 2 diabetes mellitus. Annals of Pharmacotherapy2005;39(1):102‐9. [PUBMED: 15562143] ">Anderson 2005</a>; <a href="./references#CD012204-bbs2-0086" title="BhardwajA , AgarwalV , PhungOJ , BakerWL , TongbramV , ColemanCI . Can oral hypoglycemic agents restore normoglycemia in individuals with insulin resistance?. 70th Scientific Sessions of the American Diabetes Association; 2010 25‐29 June; Orlando (FL). 2010. ">Bhardwaj 2010</a>; <a href="./references#CD012204-bbs2-0121" title="HopperI , BillahB , SkibaM , KrumH . Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta‐analysis of randomised controlled clinical trials. European Journal of Cardiovascular Prevention and Rehabilitation2011;18(6):813‐23. [PUBMED: 21878448] ">Hopper 2011</a>; <a href="./references#CD012204-bbs2-0142" title="PhungOJ , BakerWL , TongbramV , BhardwajA , ColemanCI . Oral antidiabetic drugs and regression from prediabetes to normoglycemia: a meta‐analysis. Annals of Pharmacotherapy2012;46(4):469‐76. [PUBMED: 22474136] ">Phung 2012</a>; <a href="./references#CD012204-bbs2-0156" title="Van deLaarFA , LucassenPL , AkkermansRP , Van deLisdonkEH , DeGrauwWJ . Alpha‐glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD005061.pub2] ">Van de Laar 2006</a>). We evaluated all these systematic reviews but did not identify additional trials. </p> <p>Through Internet searches of retrieved trials, we retrieved seven references with additional information on four trials (<a href="./references#CD012204-bbs2-0053" title="AstrupA , CarraroR , FinerN , HarperA , KunesovaM , LeanME , et al. Safety, tolerability and sustained weight loss over 2 years with the once‐daily human GLP‐1 analog, liraglutide. International Journal of Obesity (2005)2012;36(6):843‐54. [PUBMED: 21844879] AstrupA , RossnerS , VanGaalL , RissanenA , NiskanenL , Al HakimM , et al. Effects of liraglutide in the treatment of obesity: a randomised, double‐blind, placebo‐controlled study. Lancet2009;374(9701):1606‐16. [PUBMED: 19853906] EudraCT2006‐004481‐13 . Effect of liraglutide on body weight in obese subjects without diabetes. A 20‐week randomised, double‐blind, placebo‐controlled, six armed parallel group, multi‐centre, multinational trial with an open label orlistat comparator arm with an 84 week extension period. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004481‐13/DK Date first received: 3 October 2006. FinerN , AstrupA , CarraroR , HartvigH , KunesovaM , LeanME , et al. Liraglutide once daily reduces the prevalence of prediabetes and metabolic syndrome in obese non‐diabetic adults over two years. Journal of Diabetes2011;3:30. FinerN , HakimMA , AstrupA , HarperA , LeanM , NiskanenL , et al. Liraglutide, a once‐daily human GLP‐1 analog, reverses indices of prediabetes in obese subjects: a randomized placebo‐controlled 20‐week trial. Diabetes2009;58. FinerN , HakimMA , AstrupA , HarperA , LeanM , Niskanen , L , et al. Liraglutide, a once‐daily human GLP‐1 analogue, reduces the prevalence of prediabetes in obese subjects over 20 weeks: a randomized placebo‐controlled trial. Diabetologia2009;52(0):S11‐2. LeanME , CarraroR , FinerN , HartvigH , LindegaardML , RossnerS , et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non‐diabetic adults. International Journal of Obesity2014;38(5):689‐97. [PUBMED: 23942319] NCT00422058 . The effect of liraglutide on body weight in obese subjects without diabetes. clinicaltrials.gov/ct2/show/NCT00422058 Date first received: 12 January 2007. NN8022‐1807 . The effect of liraglutide on body weight in obese subjects without diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221807.pdf (assessed 3 July 2016). NiskanenL , AstrupA , HakimMA , CarraroR , FinerN , HartvigH , et al. Liraglutide once daily reduces the prevalence of prediabetes and metabolic syndrome in obese non‐diabetic adults: a 2‐year randomized trial. Obesity2010;18:S56. SynopsisNN8022‐1807 . Effect of liraglutide on body weight in obese subjects without diabetes. A 20‐week randomised, double‐blind, placebo‐controlled, six armed parallel group, multi‐centre, multinational trial with an open label orlistat comparator arm with an 84 week extension period. novonordisk‐trials.com/website/pdf/registry/bin_20110928‐123116‐617.pdf (assessed 3 July 2016). ">Astrup 2009</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>; <a href="./references#CD012204-bbs2-0059" title="BlackmanA , FosterGD , ZammitG , RosenbergR , AronneL , WaddenT , et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. International Journal of Obesity2016;40(8):1310‐9. [PUBMED: 27005405] NCT01557166 . Effect of liraglutide in obese subjects with moderate or severe obstructive sleep apnoea: SCALE™ ‐ sleep apnoea. clinicaltrials.gov/ct2/show/NCT01272232 Date first received: 6 January 2011. NN8022‐3970 . Effect of liraglutide in obese subjects with moderate or severe obstructive sleep apnoea: SCALE™ ‐ sleep apnoea. novonordisk‐trials.com/Website/pdf/registry/nn80223970.pdf (accessed 30 September 2016). ">SCALE‐SLEEP</a>). </p> <p>We sent all corresponding trial authors of the included trials a reference list and a request for information on additional trials of relevance. All the investigators of the included trials replied, except one (<a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>). Two of the investigators provided information that we could not retrieve from the publications (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>) (see <a href="./appendices#CD012204-sec-0192">Appendix 14</a>). Another trial could be included in the quantitative analyses as the investigators provided information on some of the outcomes of interest for this review. These data were not presented in the published abstract (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>). </p> <section id="CD012204-sec-0076"> <h5 class="title">Studies awaiting classification</h5> <p>We classified seven trials in 26 references as studies awaiting classification (see <a href="./references#CD012204-sec-0207" title="">Characteristics of studies awaiting classification</a> table). Three of the trials awaiting classification were performed by Novo Nordisk and we requested separate information on the people with intermediate hyperglycaemia (<a href="./references#CD012204-bbs2-0053" title="AstrupA , CarraroR , FinerN , HarperA , KunesovaM , LeanME , et al. Safety, tolerability and sustained weight loss over 2 years with the once‐daily human GLP‐1 analog, liraglutide. International Journal of Obesity (2005)2012;36(6):843‐54. [PUBMED: 21844879] AstrupA , RossnerS , VanGaalL , RissanenA , NiskanenL , Al HakimM , et al. Effects of liraglutide in the treatment of obesity: a randomised, double‐blind, placebo‐controlled study. Lancet2009;374(9701):1606‐16. [PUBMED: 19853906] EudraCT2006‐004481‐13 . Effect of liraglutide on body weight in obese subjects without diabetes. A 20‐week randomised, double‐blind, placebo‐controlled, six armed parallel group, multi‐centre, multinational trial with an open label orlistat comparator arm with an 84 week extension period. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004481‐13/DK Date first received: 3 October 2006. FinerN , AstrupA , CarraroR , HartvigH , KunesovaM , LeanME , et al. Liraglutide once daily reduces the prevalence of prediabetes and metabolic syndrome in obese non‐diabetic adults over two years. Journal of Diabetes2011;3:30. FinerN , HakimMA , AstrupA , HarperA , LeanM , NiskanenL , et al. Liraglutide, a once‐daily human GLP‐1 analog, reverses indices of prediabetes in obese subjects: a randomized placebo‐controlled 20‐week trial. Diabetes2009;58. FinerN , HakimMA , AstrupA , HarperA , LeanM , Niskanen , L , et al. Liraglutide, a once‐daily human GLP‐1 analogue, reduces the prevalence of prediabetes in obese subjects over 20 weeks: a randomized placebo‐controlled trial. Diabetologia2009;52(0):S11‐2. LeanME , CarraroR , FinerN , HartvigH , LindegaardML , RossnerS , et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non‐diabetic adults. International Journal of Obesity2014;38(5):689‐97. [PUBMED: 23942319] NCT00422058 . The effect of liraglutide on body weight in obese subjects without diabetes. clinicaltrials.gov/ct2/show/NCT00422058 Date first received: 12 January 2007. NN8022‐1807 . The effect of liraglutide on body weight in obese subjects without diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221807.pdf (assessed 3 July 2016). NiskanenL , AstrupA , HakimMA , CarraroR , FinerN , HartvigH , et al. Liraglutide once daily reduces the prevalence of prediabetes and metabolic syndrome in obese non‐diabetic adults: a 2‐year randomized trial. Obesity2010;18:S56. SynopsisNN8022‐1807 . Effect of liraglutide on body weight in obese subjects without diabetes. A 20‐week randomised, double‐blind, placebo‐controlled, six armed parallel group, multi‐centre, multinational trial with an open label orlistat comparator arm with an 84 week extension period. novonordisk‐trials.com/website/pdf/registry/bin_20110928‐123116‐617.pdf (assessed 3 July 2016). ">Astrup 2009</a>; <a href="./references#CD012204-bbs2-0059" title="BlackmanA , FosterGD , ZammitG , RosenbergR , AronneL , WaddenT , et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. International Journal of Obesity2016;40(8):1310‐9. [PUBMED: 27005405] NCT01557166 . Effect of liraglutide in obese subjects with moderate or severe obstructive sleep apnoea: SCALE™ ‐ sleep apnoea. clinicaltrials.gov/ct2/show/NCT01272232 Date first received: 6 January 2011. NN8022‐3970 . Effect of liraglutide in obese subjects with moderate or severe obstructive sleep apnoea: SCALE™ ‐ sleep apnoea. novonordisk‐trials.com/Website/pdf/registry/nn80223970.pdf (accessed 30 September 2016). ">SCALE‐SLEEP</a>; <a href="./references#CD012204-bbs2-0058" title="HollanderP , AronneL , KleinS , NiswenderK , JensenCB , WooV , et al. Diet‐induced weight loss and subsequent addition of liraglutide 3.0 mg reduces impaired fasting glucose in overweight/obese adults in the SCALEtm maintenance 56‐week randomised trial. Journal of Diabetes2013;5:124. KleinS , AronneL , HollanderP , NiswenderK , Bjorn JensenC , LindegaardM , et al. Effect of diet‐induced weight loss and subsequent addition of liraglutide 3.0 MG on impaired fasting glucose in overweight/obese adults in the SCALEtm maintenance 56‐week phase 3 randomised trial. Obesity Facts2012;5:206. KleinS , AronneLJ , HollanderP , NiswenderK , WooV , HalePM , et al. Effect of liraglutide on cardiovascular (CV) risk factors in adults without diabetes after diet‐induced weight loss: the SCALE 56‐week randomized study. Obesity (Silver Spring, Md.)2011; Vol. 19:S177. NCT00781937 . Comparison of liraglutide versus placebo in weight loss maintenance in obese subjects: SCALE ‐ maintenance. clinicaltrials.gov/show/NCT00781937 Date first received: 28 October 2008. WaddenTA , HollanderP , KleinS , NiswenderK , WooV , HalePM , et al. NN8022‐1923 Investigators. Weight maintenance and additional weight loss with liraglutide after low‐calorie‐diet‐induced weight loss: the SCALE maintenance randomized study. International Journal of Obesity2013;37(11):1443‐51. [DOI: 10.1038/ijo.2013.120] ">SCALE 2013</a>). Novo Nordisk has replied that we would get access to trial data. Once available, these data will be used in updates of this review. One completed trial included participants both with intermediate hyperglycaemia and T2DM (<a href="./references#CD012204-bbs2-0057" title="SantilliF , GuagnanoM , TartaroA , SimeonePG , LianiR , TripaldiR , et al. Effects of liraglutide vs lifestyle changes on subcutaneous and visceral fat, liver steatosis, insulin sensitivity and beta cell function after comparable weight loss. Diabetologia2015;58(1):S375. SantilliF , GuagnanoMT , TartaroA , AngelucciE , SimeonePG , LarongaG , et al. Liraglutide is more effective than lifestyle changes in modulating subcutaneous and visceral fat distribution, liver steatosis, insulin sensitivity and beta‐cell function after comparable weight loss. European Heart Journal2015;36(0):473. SantilliF , TartaroA , GuagnanoMT , SimeonePG , LarongaG , SborgiaC , et al. Effects of liraglutide or lifestyle counseling on subcutaneous and visceral fat distribution, liver fat content, insulin sensitivity, and beta‐cell performance. Diabetes2015;64:A287. ">Santilli 2015</a>). The investigators replied to our request and will provide separate data on the people with intermediate hyperglycaemia when all data are published (<a href="./references#CD012204-bbs2-0057" title="SantilliF , GuagnanoM , TartaroA , SimeonePG , LianiR , TripaldiR , et al. Effects of liraglutide vs lifestyle changes on subcutaneous and visceral fat, liver steatosis, insulin sensitivity and beta cell function after comparable weight loss. Diabetologia2015;58(1):S375. SantilliF , GuagnanoMT , TartaroA , AngelucciE , SimeonePG , LarongaG , et al. Liraglutide is more effective than lifestyle changes in modulating subcutaneous and visceral fat distribution, liver steatosis, insulin sensitivity and beta‐cell function after comparable weight loss. European Heart Journal2015;36(0):473. SantilliF , TartaroA , GuagnanoMT , SimeonePG , LarongaG , SborgiaC , et al. Effects of liraglutide or lifestyle counseling on subcutaneous and visceral fat distribution, liver fat content, insulin sensitivity, and beta‐cell performance. Diabetes2015;64:A287. ">Santilli 2015</a>). Three trials were listed in ClinicalTrials.gov as completed in September 2014 (<a href="./references#CD012204-bbs2-0054" title="NCT01521312 . Acute and chronic effects of saxagliptin (ACCES). clinicaltrials.gov/ct2/show/NCT01521312 Date first received: 22 November 2011. ">NCT01521312</a>), December 2014 (<a href="./references#CD012204-bbs2-0055" title="NCT01960205 . Effect of saxagliptin on pre‐diabetes mellitus and obesity. clinicaltrials.gov/ct2/show/NCT01960205 Date first received: 7 October 2013. ">NCT01960205</a>), and May 2016 (<a href="./references#CD012204-bbs2-0056" title="EudraCT:2014‐003532‐39 . The effect of the diabetes medication sitagliptin on brown fat and whole‐body metabolism in men with overweight and impaired glucose tolerance (or 'pre‐diabetes'). www.clinicaltrialsregister.eu/ctr‐search/trial/2014‐003532‐39/NL Date first registered: 15 October 2014. NCT02294084 . Sitagliptin and brown adipose tissue (Sita01). clinicaltrials.gov/ct2/show/NCT02294084 Date first received: 17 November 2014. ">NCT02294084</a>). The corresponding investigators were contacted for each trial. Two of the investigators replied that data were not yet available (<a href="./references#CD012204-bbs2-0055" title="NCT01960205 . Effect of saxagliptin on pre‐diabetes mellitus and obesity. clinicaltrials.gov/ct2/show/NCT01960205 Date first received: 7 October 2013. ">NCT01960205</a>; <a href="./references#CD012204-bbs2-0056" title="EudraCT:2014‐003532‐39 . The effect of the diabetes medication sitagliptin on brown fat and whole‐body metabolism in men with overweight and impaired glucose tolerance (or 'pre‐diabetes'). www.clinicaltrialsregister.eu/ctr‐search/trial/2014‐003532‐39/NL Date first registered: 15 October 2014. NCT02294084 . Sitagliptin and brown adipose tissue (Sita01). clinicaltrials.gov/ct2/show/NCT02294084 Date first received: 17 November 2014. ">NCT02294084</a>). One investigator did not reply (<a href="./references#CD012204-bbs2-0054" title="NCT01521312 . Acute and chronic effects of saxagliptin (ACCES). clinicaltrials.gov/ct2/show/NCT01521312 Date first received: 22 November 2011. ">NCT01521312</a>) (see <a href="./appendices#CD012204-sec-0192">Appendix 14</a>). </p> </section> <section id="CD012204-sec-0077"> <h5 class="title">Ongoing trials</h5> <p>We found 16 ongoing RCTs in 22 references (<a href="./references#CD012204-bbs2-0060" title="Unpublished protocol. Provided by the investigators. EUCTR2013‐000418‐39‐AT . Early prevention of diabetes complications in people with hyperglycaemia in Europe ‐ e‐PREDICE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013‐000418‐39‐AT (accessed 8 April 2016). EudraCT2013‐000418‐39 . Early prevention of diabetes complications in people with hyperglycaemia in Europe. www.clinicaltrialsregister.eu/ctr‐search/search?query=2013‐000418‐39 (accessed 17 March 2016). ePRECIDE . The project. www.epredice.eu/en/the‐project (accessed 17 March 2016). ">EudraCT 2013‐000418‐39</a>; <a href="./references#CD012204-bbs2-0061" title="NaidooP , WingJ , RambiritchV . Effect of sitagliptin and metformin on prediabetes progression to type 2 diabetes ‐ a randomized, double‐blind, double‐arm, multicenter clinical trial: protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) study. JMIR Research Protocols2016;5(3):e145. [PUBMED: 27491324] ">Naidoo 2016</a>; <a href="./references#CD012204-bbs2-0062" title="NCT01234649 . Combined liraglutide and metformin therapy in women with previous gestational diabetes mellitus (GDM). clinicaltrials.gov/ct2/show/NCT01234649 Date first received: 3 November 2010. ">NCT01234649</a>; <a href="./references#CD012204-bbs2-0063" title="NCT01336322 . Metformin and sitagliptin in women with previous gestational diabetes. clinicaltrials.gov/ct2/show/NCT01336322 Date first received: 13 April 2011. ">NCT01336322</a>; <a href="./references#CD012204-bbs2-0064" title="NCT01548651 . Effect of saxagliptin treatment on myocardial fat content, and monocyte inflammation. clinicaltrials.gov/ct2/show/NCT01548651 Date first received: 6 February 2012. ">NCT01548651</a>; <a href="./references#CD012204-bbs2-0065" title="NCT01779362 . RISE adult medication study (RISE Adult). clinicaltrials.gov/ct2/show/NCT01779362 Date first received: 28 January 2013. RISE Consortium. Restoring Insulin Secretion (RISE): design of studies of beta‐cell preservation in prediabetes and early type 2 diabetes across the life span. Diabetes Care2014;37(3):780‐8. [PUBMED: 24194506] ">NCT01779362</a>; <a href="./references#CD012204-bbs2-0066" title="EudraCT2012‐001371‐37 . GDM‐TREAT. www.clinicaltrialsregister.eu/ctr‐search/trial/2012‐001371‐37/DK Date first registered: 9 July 2012. FoghsgaardS , VedtofteL , MathiesenER , SvareJA , GluudLL , HolstJJ , et al. The effect of a glucagon‐like peptide‐1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator‐initiated, randomised, placebo‐controlled, double‐blinded, parallel intervention trial. BMJ Open2013;3(10):e003834. [PUBMED: 24176797] NCT01795248 . The impact of liraglutide on glucose tolerance and the risk of type 2 diabetes in women with previous pregnancy‐induced diabetes. clinicaltrials.gov/ct2/show/NCT01795248 Date first received: 18 February 2013. ">NCT01795248</a>; <a href="./references#CD012204-bbs2-0067" title="NCT01856907 . Sitagliptin + metformin compared to metformin monotherapy and placebo in women with a recent GDM. clinicaltrials.gov/ct2/show/NCT01856907 Date first received: 14 May 2013. ">NCT01856907</a>; <a href="./references#CD012204-bbs2-0068" title="NCT02104739 . Effects of antidiabetic medications on the postprandial state in prediabetes. clinicaltrials.gov/ct2/show/NCT02104739 Date first received: 1 April 2014. ">NCT02104739</a>; <a href="./references#CD012204-bbs2-0069" title="NCT02140983 . Effects of liraglutide on hippocampal structure and function in aging adults with prediabetes (LGT). clinicaltrials.gov/ct2/show/NCT02140983 Date first received: 27 January 2014. ">NCT02140983</a>; <a href="./references#CD012204-bbs2-0070" title="NCT02488057 . Improving beta cell function in Mexican American women with prediabetes. clinicaltrials.gov/ct2/show/NCT02488057 Date first received: 11 June 2015. ">NCT02488057</a>; <a href="./references#CD012204-bbs2-0071" title="NCT02576288 . Sitagliptin effects on arterial vasculature and inflammation in obesity (SAVORO). clinicaltrials.gov/ct2/show/NCT02576288 Date first received: 12 October 2015. ">NCT02576288</a>; <a href="./references#CD012204-bbs2-0072" title="NCT02847403 . Long‐acting exenatide and cognitive decline in dysglycemic patients (DRINN). clinicaltrials.gov/show/NCT02847403 Date first received: 21 July 2016. ">NCT02847403</a>; <a href="./references#CD012204-bbs2-0073" title="NCT02969798 . Pre‐diabetes in subject with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). clinicaltrials.gov/show/NCT02969798 Date first received: 16 March 2016. ">NCT02969798</a>; <a href="./references#CD012204-bbs2-0074" title="NCT03004612 . Effect of linagliptin + metformin vs metformin alone in patients with prediabetes (PRELLIM). clinicaltrials.gov/show/NCT03004612 Date first received: 21 December 2016. ">NCT03004612</a>; <a href="./references#CD012204-bbs2-0075" title="UMIN000008620 . The impact of DPP‐4 inhibitor on daily glucose profile and coronary plaque character in impaired glucose tolerance patients with coronary artery disease. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;recptno=R000010058&amp;type=summary&amp;language=E Date first received: 6 August 2012. ">UMIN000008620</a>) (see <a href="./references#CD012204-sec-0208" title="">Characteristics of ongoing studies</a> table). When insufficient information was reported in the available protocol documents, we asked investigators for additional information (see <a href="./appendices#CD012204-sec-0192">Appendix 14</a>). We estimate the ongoing trials to include 5921 participants. Three of the ongoing trials have predefined the assessment of one or more of the primary outcomes included in our review (<a href="./references#CD012204-bbs2-0060" title="Unpublished protocol. Provided by the investigators. EUCTR2013‐000418‐39‐AT . Early prevention of diabetes complications in people with hyperglycaemia in Europe ‐ e‐PREDICE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013‐000418‐39‐AT (accessed 8 April 2016). EudraCT2013‐000418‐39 . Early prevention of diabetes complications in people with hyperglycaemia in Europe. www.clinicaltrialsregister.eu/ctr‐search/search?query=2013‐000418‐39 (accessed 17 March 2016). ePRECIDE . The project. www.epredice.eu/en/the‐project (accessed 17 March 2016). ">EudraCT 2013‐000418‐39</a>; <a href="./references#CD012204-bbs2-0061" title="NaidooP , WingJ , RambiritchV . Effect of sitagliptin and metformin on prediabetes progression to type 2 diabetes ‐ a randomized, double‐blind, double‐arm, multicenter clinical trial: protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) study. JMIR Research Protocols2016;5(3):e145. [PUBMED: 27491324] ">Naidoo 2016</a>; <a href="./references#CD012204-bbs2-0066" title="EudraCT2012‐001371‐37 . GDM‐TREAT. www.clinicaltrialsregister.eu/ctr‐search/trial/2012‐001371‐37/DK Date first registered: 9 July 2012. FoghsgaardS , VedtofteL , MathiesenER , SvareJA , GluudLL , HolstJJ , et al. The effect of a glucagon‐like peptide‐1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator‐initiated, randomised, placebo‐controlled, double‐blinded, parallel intervention trial. BMJ Open2013;3(10):e003834. [PUBMED: 24176797] NCT01795248 . The impact of liraglutide on glucose tolerance and the risk of type 2 diabetes in women with previous pregnancy‐induced diabetes. clinicaltrials.gov/ct2/show/NCT01795248 Date first received: 18 February 2013. ">NCT01795248</a>). Seven ongoing trials did not predefine the primary outcomes of our review; however, one or more of our secondary outcomes were planned to be assessed (<a href="./references#CD012204-bbs2-0062" title="NCT01234649 . Combined liraglutide and metformin therapy in women with previous gestational diabetes mellitus (GDM). clinicaltrials.gov/ct2/show/NCT01234649 Date first received: 3 November 2010. ">NCT01234649</a>; <a href="./references#CD012204-bbs2-0065" title="NCT01779362 . RISE adult medication study (RISE Adult). clinicaltrials.gov/ct2/show/NCT01779362 Date first received: 28 January 2013. RISE Consortium. Restoring Insulin Secretion (RISE): design of studies of beta‐cell preservation in prediabetes and early type 2 diabetes across the life span. Diabetes Care2014;37(3):780‐8. [PUBMED: 24194506] ">NCT01779362</a>; <a href="./references#CD012204-bbs2-0067" title="NCT01856907 . Sitagliptin + metformin compared to metformin monotherapy and placebo in women with a recent GDM. clinicaltrials.gov/ct2/show/NCT01856907 Date first received: 14 May 2013. ">NCT01856907</a>; <a href="./references#CD012204-bbs2-0070" title="NCT02488057 . Improving beta cell function in Mexican American women with prediabetes. clinicaltrials.gov/ct2/show/NCT02488057 Date first received: 11 June 2015. ">NCT02488057</a>; <a href="./references#CD012204-bbs2-0073" title="NCT02969798 . Pre‐diabetes in subject with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). clinicaltrials.gov/show/NCT02969798 Date first received: 16 March 2016. ">NCT02969798</a>; <a href="./references#CD012204-bbs2-0074" title="NCT03004612 . Effect of linagliptin + metformin vs metformin alone in patients with prediabetes (PRELLIM). clinicaltrials.gov/show/NCT03004612 Date first received: 21 December 2016. ">NCT03004612</a>; <a href="./references#CD012204-bbs2-0075" title="UMIN000008620 . The impact of DPP‐4 inhibitor on daily glucose profile and coronary plaque character in impaired glucose tolerance patients with coronary artery disease. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;recptno=R000010058&amp;type=summary&amp;language=E Date first received: 6 August 2012. ">UMIN000008620</a>). Six other trials did not predefine any outcomes of relevance to our review (<a href="./references#CD012204-bbs2-0063" title="NCT01336322 . Metformin and sitagliptin in women with previous gestational diabetes. clinicaltrials.gov/ct2/show/NCT01336322 Date first received: 13 April 2011. ">NCT01336322</a>; <a href="./references#CD012204-bbs2-0064" title="NCT01548651 . Effect of saxagliptin treatment on myocardial fat content, and monocyte inflammation. clinicaltrials.gov/ct2/show/NCT01548651 Date first received: 6 February 2012. ">NCT01548651</a>; <a href="./references#CD012204-bbs2-0068" title="NCT02104739 . Effects of antidiabetic medications on the postprandial state in prediabetes. clinicaltrials.gov/ct2/show/NCT02104739 Date first received: 1 April 2014. ">NCT02104739</a>; <a href="./references#CD012204-bbs2-0069" title="NCT02140983 . Effects of liraglutide on hippocampal structure and function in aging adults with prediabetes (LGT). clinicaltrials.gov/ct2/show/NCT02140983 Date first received: 27 January 2014. ">NCT02140983</a>; <a href="./references#CD012204-bbs2-0071" title="NCT02576288 . Sitagliptin effects on arterial vasculature and inflammation in obesity (SAVORO). clinicaltrials.gov/ct2/show/NCT02576288 Date first received: 12 October 2015. ">NCT02576288</a>; <a href="./references#CD012204-bbs2-0072" title="NCT02847403 . Long‐acting exenatide and cognitive decline in dysglycemic patients (DRINN). clinicaltrials.gov/show/NCT02847403 Date first received: 21 July 2016. ">NCT02847403</a>). </p> <p>Six ongoing RCTs, estimated to include 1115 participants have a GLP‐1 analogue as the intervention (<a href="./references#CD012204-bbs2-0062" title="NCT01234649 . Combined liraglutide and metformin therapy in women with previous gestational diabetes mellitus (GDM). clinicaltrials.gov/ct2/show/NCT01234649 Date first received: 3 November 2010. ">NCT01234649</a>; <a href="./references#CD012204-bbs2-0065" title="NCT01779362 . RISE adult medication study (RISE Adult). clinicaltrials.gov/ct2/show/NCT01779362 Date first received: 28 January 2013. RISE Consortium. Restoring Insulin Secretion (RISE): design of studies of beta‐cell preservation in prediabetes and early type 2 diabetes across the life span. Diabetes Care2014;37(3):780‐8. [PUBMED: 24194506] ">NCT01779362</a>; <a href="./references#CD012204-bbs2-0066" title="EudraCT2012‐001371‐37 . GDM‐TREAT. www.clinicaltrialsregister.eu/ctr‐search/trial/2012‐001371‐37/DK Date first registered: 9 July 2012. FoghsgaardS , VedtofteL , MathiesenER , SvareJA , GluudLL , HolstJJ , et al. The effect of a glucagon‐like peptide‐1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator‐initiated, randomised, placebo‐controlled, double‐blinded, parallel intervention trial. BMJ Open2013;3(10):e003834. [PUBMED: 24176797] NCT01795248 . The impact of liraglutide on glucose tolerance and the risk of type 2 diabetes in women with previous pregnancy‐induced diabetes. clinicaltrials.gov/ct2/show/NCT01795248 Date first received: 18 February 2013. ">NCT01795248</a>; <a href="./references#CD012204-bbs2-0068" title="NCT02104739 . Effects of antidiabetic medications on the postprandial state in prediabetes. clinicaltrials.gov/ct2/show/NCT02104739 Date first received: 1 April 2014. ">NCT02104739</a>; <a href="./references#CD012204-bbs2-0069" title="NCT02140983 . Effects of liraglutide on hippocampal structure and function in aging adults with prediabetes (LGT). clinicaltrials.gov/ct2/show/NCT02140983 Date first received: 27 January 2014. ">NCT02140983</a>; <a href="./references#CD012204-bbs2-0070" title="NCT02488057 . Improving beta cell function in Mexican American women with prediabetes. clinicaltrials.gov/ct2/show/NCT02488057 Date first received: 11 June 2015. ">NCT02488057</a>). The largest of the ongoing RCTs plans to include around 3000 participants allocated to a DPP‐4 inhibitor, metformin or placebo. The intervention period has been estimated to be three years and the total follow‐up period will be five years (<a href="./references#CD012204-bbs2-0060" title="Unpublished protocol. Provided by the investigators. EUCTR2013‐000418‐39‐AT . Early prevention of diabetes complications in people with hyperglycaemia in Europe ‐ e‐PREDICE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013‐000418‐39‐AT (accessed 8 April 2016). EudraCT2013‐000418‐39 . Early prevention of diabetes complications in people with hyperglycaemia in Europe. www.clinicaltrialsregister.eu/ctr‐search/search?query=2013‐000418‐39 (accessed 17 March 2016). ePRECIDE . The project. www.epredice.eu/en/the‐project (accessed 17 March 2016). ">EudraCT 2013‐000418‐39</a>). The trial is estimated to be completed in 2018 (<a href="./references#CD012204-bbs2-0060" title="Unpublished protocol. Provided by the investigators. EUCTR2013‐000418‐39‐AT . Early prevention of diabetes complications in people with hyperglycaemia in Europe ‐ e‐PREDICE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013‐000418‐39‐AT (accessed 8 April 2016). EudraCT2013‐000418‐39 . Early prevention of diabetes complications in people with hyperglycaemia in Europe. www.clinicaltrialsregister.eu/ctr‐search/search?query=2013‐000418‐39 (accessed 17 March 2016). ePRECIDE . The project. www.epredice.eu/en/the‐project (accessed 17 March 2016). ">EudraCT 2013‐000418‐39</a>). </p> <p>Future updates will include all ongoing trials, if possible.</p> </section> </section> <section id="CD012204-sec-0078"> <h4 class="title">Included studies</h4> <p>A detailed description of the characteristics of included trials is presented elsewhere (see <a href="./references#CD012204-sec-0205" title="">Characteristics of included studies</a> table; <a href="#CD012204-tbl-0003">Table 1</a>; and <a href="./appendices#CD012204-sec-0181">Appendix 3</a>; <a href="./appendices#CD012204-sec-0182">Appendix 4</a>; <a href="./appendices#CD012204-sec-0183">Appendix 5</a>; <a href="./appendices#CD012204-sec-0184">Appendix 6</a>; <a href="./appendices#CD012204-sec-0185">Appendix 7</a>; <a href="./appendices#CD012204-sec-0186">Appendix 8</a>; <a href="./appendices#CD012204-sec-0187">Appendix 9</a>; <a href="./appendices#CD012204-sec-0188">Appendix 10</a>; <a href="./appendices#CD012204-sec-0189">Appendix 11</a>; <a href="./appendices#CD012204-sec-0190">Appendix 12</a>; <a href="./appendices#CD012204-sec-0191">Appendix 13</a>; <a href="./appendices#CD012204-sec-0192">Appendix 14</a>). The following is a succinct overview. </p> <section id="CD012204-sec-0079"> <h5 class="title">Overview of trial populations</h5> <p>Four of the trials reported the total number of participants screened (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). For trials not only including participants with intermediate hyperglycaemia, the total number of screened was reported (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Three trials did not report the number of participants with intermediate hyperglycaemia randomised to each intervention group upon trial initiation (<a href="./references#CD012204-bbs2-0013" title="EUCTR2007‐003963‐31‐SE . BEGAMI. www.clinicaltrialsregister.eu/ctr‐search/trial/2007‐003963‐31/SE Date first registered: 29 August 2007. HageC , BrismarK , EfendicS , LundmanP , RydenL , MellbinL . Sitagliptin improves beta‐cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities ‐ the BEGAMI study. Journal of Internal Medicine2013;273(4):410‐21. [PUBMED: 23331339] HageC , BrismarK , LundmanP , MellbinL , RydenL . The DPP‐4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations. European Heart Journal2013;34(0):793. HageC , BrismarK , LundmanP , NorhammarA , RydenL , MellbinL . The DPP‐4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: a report from the BEGAMI study. Diabetes &amp; Vascular Disease Research2014;11(4):290‐3. [PUBMED: 24845072] NCT00627744 . Beta‐cell function in glucose abnormalities and acute myocardial infarction (BEGAMI). clinicaltrials.gov/ct2/show/NCT00627744 Date first received: 22 February 2008. ">BEGAMI 2013</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). However, one trial provided the number of randomised participants with intermediate hyperglycaemia on request (<a href="./references#CD012204-bbs2-0013" title="EUCTR2007‐003963‐31‐SE . BEGAMI. www.clinicaltrialsregister.eu/ctr‐search/trial/2007‐003963‐31/SE Date first registered: 29 August 2007. HageC , BrismarK , EfendicS , LundmanP , RydenL , MellbinL . Sitagliptin improves beta‐cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities ‐ the BEGAMI study. Journal of Internal Medicine2013;273(4):410‐21. [PUBMED: 23331339] HageC , BrismarK , LundmanP , MellbinL , RydenL . The DPP‐4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations. European Heart Journal2013;34(0):793. HageC , BrismarK , LundmanP , NorhammarA , RydenL , MellbinL . The DPP‐4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: a report from the BEGAMI study. Diabetes &amp; Vascular Disease Research2014;11(4):290‐3. [PUBMED: 24845072] NCT00627744 . Beta‐cell function in glucose abnormalities and acute myocardial infarction (BEGAMI). clinicaltrials.gov/ct2/show/NCT00627744 Date first received: 22 February 2008. ">BEGAMI 2013</a>). About 123 participants were randomised to a DPP‐4 inhibitor (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>), and 1620 participants were randomised to a GLP‐1 analogue (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). All included trials used the intervention as monotherapy. About 946 participants were randomised to a comparator group; five trials used placebo as the comparator (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>), and two trials used metformin as a comparator (<a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>). One trial randomised the participants to a GLP‐1 analogue using a dose approved for weight reduction (liraglutide 3.0 mg) (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). </p> <p>Two trials provided information about sample size calculation (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). </p> <p>The proportion of participants finishing the trial varied from 49% to 100% (<a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). </p> <p>One of the included trials included participants with intermediate hyperglycaemia and T2DM (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). One trial included participants with intermediate hyperglycaemic and normoglycaemia but had prespecified and reported the data on the participants with intermediate hyperglycaemia separately (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). </p> </section> <section id="CD012204-sec-0080"> <h5 class="title">Trial design</h5> <p>All seven included trials were parallel RCTs. Six trials performed blinding of the participants and investigators (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). In addition, one trial had a double‐blind intervention period for the first year (pharmaceutical company, investigators and participants were blinded), and a single‐blind period for the remaining two years (pharmaceutical company was unblinded, whereas investigators and participants remained blinded) (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). One trial had an open‐label design (<a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>).<br/> One trial had a run‐in period where for one week a single‐blind placebo was given (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). The duration of the intervention in the included trials varied from 12 to 160 weeks (<a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). One trial had a duration of the intervention of two years or more (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Two trials had an extended follow‐up period after the intervention period had stopped (<a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). One trial had an intervention period for 30 weeks, but followed the participants for one year (<a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>). Another trial followed the participants 12 weeks after the end of the intervention period (i.e. 172 weeks) (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). </p> <p>The number of participants varied from 16 (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>) to 2285 (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). One trial contributed 85% of the total number of all randomised participants (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Four trials were multicentre trials (<a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>), one trial was single‐centre trial (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>), and two trials did not provide a centre description (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>). All trials were performed in outpatient settings. </p> <p>Five of the included trials stated that they had received grants from a pharmaceutical company (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>), and two trials explicitly acknowledged individuals employed by a pharmaceutical company for their contribution to the trials (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Two trials did not report the funding source (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>). </p> </section> <section id="CD012204-sec-0081"> <h5 class="title">Participants</h5> <p>Three trials reported the ethnicity of the participants; two trials included mainly white people (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>) and another trial only white people (<a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>). Only one trial included participants from low‐income countries (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). </p> <p>One trial did not report the gender of the participants (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>). For the remaining trials authors provided gender information, and both men and women were included in these trials. The age of the included participants varied from 46.1 to 67 years (see <a href="./appendices#CD012204-sec-0183">Appendix 5</a>). </p> <p>Six trials reported fasting glucose values at baseline, which varied from 5.5 mmol/L to 6.2 mmol/L (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Two trials did not report any glycaemic baseline value (<a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). Four trials reported 2‐hour glucose values after a glucose‐load at baseline which varied from 7.4 mmol/L to 9.3 mmol/L (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). HbA1c values were reported at baseline in three trials and varied from 5.7% to 6.2% (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). </p> <p>All trials reported BMI at baseline. All trials reported a baseline mean BMI above 30 kg/m². Three trials had participants with a mean BMI above 35 kg/m² at baseline (<a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). One trial reported the number of participants with previous cardiovascular diseases at baseline (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Most trials excluded participants with other endocrine conditions, or hepatic or kidney disease. </p> <p>The diagnosis applied in the included trials for identifying intermediate hyperglycaemia varied. Two trials included participants with intermediate hyperglycaemia according to the criteria by ADA regarding elevated fasting glucose (5.6 mmol/L to 6.9 mmol/L) or elevated two‐hour glucose concentrations (7.8 mmol/L to 11.0 mmol/L) after an OGTT (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>). HbA1c was not applied as a criterion for intermediate hyperglycaemia in these trials (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>). Two trials used all the glycaemic cut‐off points recommended by ADA, including HbA1c (5.7% to 6.4%) to diagnose intermediate hyperglycaemia (<a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). One trial used the diagnostic criteria for IGT as recommended by the WHO (fasting plasma glucose below 7.0 mmol/L and elevated two‐hour glucose concentration after an OGTT (7.8 mmol/L to 11.0 mmol/L)) (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>). One trial used the diagnostic criteria for both IFG and IGT as recommended by the WHO (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). One trial just reported that participants with IGT were included, with no further details specified (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>). </p> <p>One trial had explicitly defined withdrawal criteria for the participants (see <a href="./references#CD012204-sec-0205" title="">Characteristics of included studies</a> table) (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). One of the applied withdrawal criteria was not tolerating the dose of the study drug (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Another trial explicitly stated that intolerability of the maximum dose led to dose‐reduction (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>). In this trial, one participant received liraglutide 1.2 mg and another participant received liraglutide 0.6 mg due to intolerance to the originally planned dose of 1.8 mg (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>). </p> </section> <section id="CD012204-sec-0082"> <h5 class="title">Interventions</h5> <p>All the participants of the included trials were treatment naive regarding pharmacological glucose‐lowering interventions. Two trials used a DPP‐4 inhibitor in the intervention arm (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>); one used linagliptin 5 mg/day (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>), and one used vildagliptin 50 mg/day (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>). Five trials used GLP‐1 analogues in the intervention arms (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Two trials used liraglutide in the intervention arms (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). One trial used liraglutide 1.8 mg/day (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>), whereas the other trial used liraglutide 3.0 mg/day (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Three trials used exenatide in doses of 10 μg twice daily (<a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). </p> <p>Five of the included trials had placebo as comparator (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Two trials used metformin as comparator (<a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>); one trial used metformin 500 mg twice daily (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>); the other trial used metformin 1000 mg twice daily (<a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>) (see <a href="./appendices#CD012204-sec-0181">Appendix 3</a>).<br/> In two trials, the participants did not take the study drug on the day glycaemic tests were performed (<a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). In two trials, the participants received the study drug after the glycaemic test had been performed (<a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). In one trial, the study drug was withheld on the days where the OGTTs were performed (every sixth month) (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). However, the participants were allowed to take the study medication on the days where FPG was measured (except if OGTT was planned to be measured at the same visit) (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Three trials did not specify if the study drug was withheld the days of measuring glycaemic variables (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>). In one trial, it was explicitly stated that the study drug was not given before the test meal at baseline but was given 15 minutes before the test meal at week 12. However, it was not described if the study drug was provided before the measurement of OGTT and fasting glucose (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>). </p> </section> <section id="CD012204-sec-0083"> <h5 class="title">Outcomes</h5> <p>Six trials had specified primary outcomes (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Five trials had not defined the secondary outcomes (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). One trial did not specify primary or secondary outcomes (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>). Six trials were registered at ClinicalTrials.gov (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). The documented changes at ClinicalTrials.gov varied from 0 to 20 (see <a href="./appendices#CD012204-sec-0185">Appendix 7</a>). </p> <p>Four trials reported one or more of the primary outcomes of relevance for this review (<a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Three of them assessed the incidence of T2DM as an outcome (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). The trials reporting data on T2DM applied different definitions. One trial did not report how the incidence of T2DM was defined, but defined T2DM as an exclusion criterion (FPG 7.0 mmol/L or greater or two‐hour post‐challenge plasma glucose (after an OGTT with glucose 75 g) 11.1 mmol/L or greater) (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>). One trial used FPG 7.0 mmol/L or greater or two‐hour post‐challenge plasma glucose (after an OGTT with glucose 75 g) 11.1 mmol/L or greater and HbA1c values of 6.5% or more (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). One trial did not report how T2DM was defined (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). </p> <p>The reporting of adverse events was lacking in most trials. Four trials reported non‐serious adverse events experienced during the trial (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>) (see <a href="./appendices#CD012204-sec-0189">Appendix 11</a>; <a href="./appendices#CD012204-sec-0190">Appendix 12</a>; <a href="./appendices#CD012204-sec-0191">Appendix 13</a>). </p> <p>One trial reported data on HRQoL (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>) (see <a href="./appendices#CD012204-sec-0195">Appendix 17</a>). </p> <p>Six trials reported one or more glycaemic variables predefined to be assessed in our review (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). One trial reported glycaemic variables in a format that made them unsuitable for meta‐analysis (<a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>). </p> <p>None of the included trials reported microvascular outcomes or socioeconomic effects.</p> </section> <section id="CD012204-sec-0084"> <h5 class="title">Source of data</h5> <p>We contacted all trial authors or investigators through email (see <a href="./appendices#CD012204-sec-0192">Appendix 14</a>). One trial could only be included when the investigators provided additional information on the trial (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>). When important information was lacking on ongoing studies and excluded studies, we contacted investigators for clarification (see <a href="./appendices#CD012204-sec-0192">Appendix 14</a>). </p> </section> </section> <section id="CD012204-sec-0085"> <h4 class="title">Excluded studies</h4> <p>We excluded 73 articles or records (45 trials) after full‐text evaluation (<a href="#CD012204-fig-0001">Figure 1</a>). These references are listed in <a href="./references#CD012204-sec-0206" title="">Characteristics of excluded studies</a> table and some are detailed in <a href="./appendices#CD012204-sec-0179">Appendix 1</a>. </p> <p>We excluded seven trials published in 11 references due to the trial design (<a href="./references#CD012204-bbs2-0011" title="AokiK , KamiyamaH , MasudaK , KamikoK , NoguchiY , TajimaK , et al. Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels. Endocrine Journal2014;61(3):249‐56. [PUBMED: 24389993] AokiK , MasudaK , MiyazakiT , TogashiY , TerauchiY . Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non‐diabetic men. Endocrine Journal2010;57(8):667‐72. [PUBMED: 20519806] UMIN000010481 . Effect of miglitol and vildagliptin on gastrointestinal hormone. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000012252&amp;language=E Date first registered: 13 April 2013. ">Aoki 2014</a>; <a href="./references#CD012204-bbs2-0012" title="ArmatoJ , DeFronzoRA , Abdul‐GhaniM , RubyR . Successful treatment of prediabetes in clinical practice: targeting insulin resistance and beta‐cell dysfunction. Endocrine Practice2012;18(3):342‐50. [PUBMED: 22068250] ">Armato 2012</a>; <a href="./references#CD012204-bbs2-0020" title="EudraCT2013‐001240‐64 . Effect of intact GLP‐1 (7‐36) and GLP‐1 metabolite (9‐36) on coronary microvascular function in adults with prediabetes. www.clinicaltrialsregister.eu/ctr‐search/search?query=2013‐001240‐64 (accessed 5 April 2016). ">EudraCT 2013‐001240‐64</a>; <a href="./references#CD012204-bbs2-0021" title="Gonzalez‐OrtizM , Perez‐RubioKG , MartinezabundisE . Lixisenatide vs. exenatide on metabolic control, insulin secretion, and insulin sensitivity in impaired glucose tolerance patients. Diabetes2015; Vol. 64:A297. ">Gonzalez‐Ortiz 2015</a>; <a href="./references#CD012204-bbs2-0025" title="KoskaJ , SandsM , BurciuC , D'SouzaKM , RaravikarK , LiuJ , et al. Exenatide protects against glucose‐ and lipid‐induced endothelial dysfunction: evidence for direct vasodilation effect of GLP‐1 receptor agonists in humans. Diabetes2015;64(7):2624‐35. [PUBMED: 25720388] NCT01181986 . The study of exenatide action on vessel function in type 2 diabetes and prediabetes. clinicaltrials.gov/ct2/show/NCT01181986 Date first received: 13 August 2010. ">Koska 2015</a>; <a href="./references#CD012204-bbs2-0049" title="UMIN000006197 . Therapeutic efficacy of sitagliptin in patients with nonalcoholic fatty liver disease (NAFLD) in impaired glucose tolerance (IGT): a pilot study. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;recptno=R000007311&amp;type=summary&amp;language=E Date first registered: 1 September 2011. ">UMIN000006197</a>; <a href="./references#CD012204-bbs2-0051" title="NCT00312130 . A study to evaluate the effects of vildagliptin on the insulin response to glucose in subjects with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00312130 Date first received: 6 April 2006. UtzschneiderKM , TongJ , MontgomeryB , UdayasankarJ , GerchmanF , MarcovinaSM , et al. The dipeptidyl peptidase‐4 inhibitor vildagliptin improves beta‐cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care2008;31(1):108‐13. [PUBMED: 17909087] ">Utzschneider 2008</a>); three trials did not allocate the participants to DPP‐4 inhibitors or GLP‐1 analogues by randomisation (<a href="./references#CD012204-bbs2-0012" title="ArmatoJ , DeFronzoRA , Abdul‐GhaniM , RubyR . Successful treatment of prediabetes in clinical practice: targeting insulin resistance and beta‐cell dysfunction. Endocrine Practice2012;18(3):342‐50. [PUBMED: 22068250] ">Armato 2012</a>; <a href="./references#CD012204-bbs2-0049" title="UMIN000006197 . Therapeutic efficacy of sitagliptin in patients with nonalcoholic fatty liver disease (NAFLD) in impaired glucose tolerance (IGT): a pilot study. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;recptno=R000007311&amp;type=summary&amp;language=E Date first registered: 1 September 2011. ">UMIN000006197</a>; <a href="./references#CD012204-bbs2-0051" title="NCT00312130 . A study to evaluate the effects of vildagliptin on the insulin response to glucose in subjects with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00312130 Date first received: 6 April 2006. UtzschneiderKM , TongJ , MontgomeryB , UdayasankarJ , GerchmanF , MarcovinaSM , et al. The dipeptidyl peptidase‐4 inhibitor vildagliptin improves beta‐cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care2008;31(1):108‐13. [PUBMED: 17909087] ">Utzschneider 2008</a>); one trial compared two different types of GLP‐1 analogues with each other (<a href="./references#CD012204-bbs2-0021" title="Gonzalez‐OrtizM , Perez‐RubioKG , MartinezabundisE . Lixisenatide vs. exenatide on metabolic control, insulin secretion, and insulin sensitivity in impaired glucose tolerance patients. Diabetes2015; Vol. 64:A297. ">Gonzalez‐Ortiz 2015</a>); and three trials were excluded as they used the study drug intravenously (<a href="./references#CD012204-bbs2-0011" title="AokiK , KamiyamaH , MasudaK , KamikoK , NoguchiY , TajimaK , et al. Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels. Endocrine Journal2014;61(3):249‐56. [PUBMED: 24389993] AokiK , MasudaK , MiyazakiT , TogashiY , TerauchiY . Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non‐diabetic men. Endocrine Journal2010;57(8):667‐72. [PUBMED: 20519806] UMIN000010481 . Effect of miglitol and vildagliptin on gastrointestinal hormone. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000012252&amp;language=E Date first registered: 13 April 2013. ">Aoki 2014</a>; <a href="./references#CD012204-bbs2-0020" title="EudraCT2013‐001240‐64 . Effect of intact GLP‐1 (7‐36) and GLP‐1 metabolite (9‐36) on coronary microvascular function in adults with prediabetes. www.clinicaltrialsregister.eu/ctr‐search/search?query=2013‐001240‐64 (accessed 5 April 2016). ">EudraCT 2013‐001240‐64</a>; <a href="./references#CD012204-bbs2-0025" title="KoskaJ , SandsM , BurciuC , D'SouzaKM , RaravikarK , LiuJ , et al. Exenatide protects against glucose‐ and lipid‐induced endothelial dysfunction: evidence for direct vasodilation effect of GLP‐1 receptor agonists in humans. Diabetes2015;64(7):2624‐35. [PUBMED: 25720388] NCT01181986 . The study of exenatide action on vessel function in type 2 diabetes and prediabetes. clinicaltrials.gov/ct2/show/NCT01181986 Date first received: 13 August 2010. ">Koska 2015</a>). </p> <p>We excluded 21 trials in 28 references as they did not include participants of relevance for this review (<a href="./references#CD012204-bbs2-0008" title="AcostaA , CamilleriM , BurtonD , O'NeillJ , EckertD , CarlsonP , et al. Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study. Physiological Reports2015;3(11):e12610. [DOI: 10.14814/phy2.12610] ">Acosta 2015</a>; <a href="./references#CD012204-bbs2-0009" title="ACTRN12615001029583 . Does exenatide improve post prandial glycaemic control in young people with cystic fibrosis related diabetes or impaired glucose tolerance?. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369121 Date first registered: 1 October 2015. ">ACTRN12615001029583</a>; <a href="./references#CD012204-bbs2-0013" title="EUCTR2007‐003963‐31‐SE . BEGAMI. www.clinicaltrialsregister.eu/ctr‐search/trial/2007‐003963‐31/SE Date first registered: 29 August 2007. HageC , BrismarK , EfendicS , LundmanP , RydenL , MellbinL . Sitagliptin improves beta‐cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities ‐ the BEGAMI study. Journal of Internal Medicine2013;273(4):410‐21. [PUBMED: 23331339] HageC , BrismarK , LundmanP , MellbinL , RydenL . The DPP‐4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations. European Heart Journal2013;34(0):793. HageC , BrismarK , LundmanP , NorhammarA , RydenL , MellbinL . The DPP‐4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: a report from the BEGAMI study. Diabetes &amp; Vascular Disease Research2014;11(4):290‐3. [PUBMED: 24845072] NCT00627744 . Beta‐cell function in glucose abnormalities and acute myocardial infarction (BEGAMI). clinicaltrials.gov/ct2/show/NCT00627744 Date first received: 22 February 2008. ">BEGAMI 2013</a>; <a href="./references#CD012204-bbs2-0014" title="BestC , StruthersH , LacinyE , RoyalM , ReedsDN , YarasheskiKE . Sitagliptin reduces inflammation and chronic immune cell activation in HIV+ adults with impaired glucose tolerance. Journal of Clinical Endocrinology and Metabolism2015;100(7):2621‐9. [PUBMED: 25938633] ">Best 2015</a>; <a href="./references#CD012204-bbs2-0016" title="CuiJ , PhiloL , NguyenP , HofflichH , HernandezC , BettencourtR , et al. Sitagliptin vs. placebo for non‐alcoholic fatty liver disease: a randomized controlled trial. Journal of Hepatology2016;65(2):369‐76. [PUBMED: 27151177] ">Cui 2016</a>; <a href="./references#CD012204-bbs2-0019" title="EudraCT2011‐005980‐26 . Metformin and sitagliptin in patients with impaired glucose tolerance and a recent TIA or minor ischemic stroke ‐ a multicenter, randomized, open‐label phase II trial. www.clinicaltrialsregister.eu/ctr‐search/trial/2011‐005980‐26/NL Date first registered: 13 February 2012. OseiE , FonvilleS , ZandbergenAA , BrouwersPJ , MulderLJ , LingsmaHF , et al. Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial. Trials2015;16:332. [PUBMED: 26242578] ">EudraCT 2011‐005980‐26</a>; <a href="./references#CD012204-bbs2-0022" title="Effect of exenatide, sitagliptin or glimepiride on functional β‐cell mass. clinicaltrials.gov/ct2/show/NCT00775684 Date first received: 17 October 2008. GudipatyL , FullerC , RosenfeldN , RickelsMR . No effect of exenatide or sitagliptin therapy on beta‐cell secretory capacity in early type 2 diabetes. Diabetes2013; Vol. 62:A288. GudipatyL , RosenfeldNK , FullerCS , GallopR , SchuttaMH , RickelsMR . Effect of exenatide, sitagliptin, or glimepiride on beta‐cell secretory capacity in early type 2 diabetes. Diabetes Care2014;37(9):2451‐8. [PUBMED: 24969577] ">Gudipaty 2014</a>; <a href="./references#CD012204-bbs2-0026" title="LarsenJR , VedtofteL , HolstJJ , OturaiP , KjaerA , CorrellCU , et al. Does a GLP‐1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double‐blinded, placebo‐controlled clinical trial. BMJ Open2014;4(3):e004227. [PUBMED: 24667381] ">Larsen 2014</a>; <a href="./references#CD012204-bbs2-0027" title="NCT00101712 . Efficacy and safety of vildagliptin compared to placebo in patients with type 2 diabetes and mild hyperglycemia. clinicaltrials.gov/ct2/show/NCT00101712 Date first received: 12 January 2005. ">NCT00101712</a>; <a href="./references#CD012204-bbs2-0028" title="NCT00198146 . Prevention of Diabetes Progression Trial (PDPT). clinicaltrials.gov/ct2/show/NCT00198146 Date first received: 12 September 2005. ">NCT00198146</a>; <a href="./references#CD012204-bbs2-0029" title="NCT00721552 . Sitagliptin prophylaxis for glucocorticoid‐induced impairment of glucose metabolism in males with the metabolic syndrome (SPHINX). clinicaltrials.gov/ct2/show/NCT00721552 Date first received: 22 July 2008. ">NCT00721552</a>; <a href="./references#CD012204-bbs2-0032" title="NCT00886626 . GLP‐1 therapy for weight loss and improved glucose tolerance in obese children. clinicaltrials.gov/ct2/show/NCT00886626 Date first received: 22 April 2009. ">NCT00886626</a>; <a href="./references#CD012204-bbs2-0037" title="NCT01054118 . A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of JNJ‐38431055, sitagliptin, and co‐administration of JNJ‐38431055 and sitagliptin. clinicaltrials.gov/ct2/show/NCT01054118 Date first received: 15 January 2010. ">NCT01054118</a>; <a href="./references#CD012204-bbs2-0039" title="NCT01346254 . Glucose control in pre‐diabetic renal transplant patients (GCPD). clinicaltrials.gov/ct2/show/NCT01346254 Date first received: 29 April 2011. ">NCT01346254</a>; <a href="./references#CD012204-bbs2-0041" title="NCT01845259 . Does a GLP‐1 receptor agonist change glucose tolerance in antipsychotic‐treated patients? (GREAT). clinicaltrials.gov/ct2/show/NCT01845259 Date first received: 14 April 2013. ">NCT01845259</a>; <a href="./references#CD012204-bbs2-0042" title="NCT01970462 . Use of sitagliptin for stress hyperglycemia or mild diabetes following cardiac surgery. clinicaltrials.gov/ct2/show/NCT01970462 Date first received: 22 October 2013. ">NCT01970462</a>; <a href="./references#CD012204-bbs2-0043" title="NCT02016846 . Liraglutide efficacy on glucocorticoid induced hyperglycemia in patients high risk for diabetes. clinicaltrials.gov/ct2/show/NCT02016846 Date first received: 15 December 2013. ">NCT02016846</a>; <a href="./references#CD012204-bbs2-0044" title="NCT02022007 . Saxagliptin + metformin compared to saxagliptin or metformin monotherapy in PCOS women Wwith impaired glucose homeostasis (BMS‐AZPCOS). clinicaltrials.gov/ct2/show/NCT02022007 Date first received: 17 December 2013. [NCT02022007] ">NCT02022007</a>; <a href="./references#CD012204-bbs2-0046" title="NCT02446834 . Research of intensive lifestyle Intervention for PCOS patients with IGT. clinicaltrials.gov/ct2/show/NCT02446834 Date first received: 6 May 2015. ">NCT02446834</a>; <a href="./references#CD012204-bbs2-0050" title="UMIN000014249 . Efficacy and safety of combination therapy with GLP‐1 analog lixisenatide and long‐acting insulin glargine in patients with glucose intolerance or diabetes caused by hyposecretion of endogenous insulin who underwent partial pancreatectomy. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000016598&amp;language=E Date first registered: 12 June 2014. ">UMIN000014249</a>; <a href="./references#CD012204-bbs2-0052" title="WerzowaJ , HeckingM , HaidingerM , LechnerF , DollerD , PaciniG , et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo‐controlled clinical trial. Transplantation2013;95(3):456‐62. [PUBMED: 23380864] ">Werzowa 2013</a>). One of these trials included participants with acute coronary disease and intermediate hyperglycaemia (<a href="./references#CD012204-bbs2-0013" title="EUCTR2007‐003963‐31‐SE . BEGAMI. www.clinicaltrialsregister.eu/ctr‐search/trial/2007‐003963‐31/SE Date first registered: 29 August 2007. HageC , BrismarK , EfendicS , LundmanP , RydenL , MellbinL . Sitagliptin improves beta‐cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities ‐ the BEGAMI study. Journal of Internal Medicine2013;273(4):410‐21. [PUBMED: 23331339] HageC , BrismarK , LundmanP , MellbinL , RydenL . The DPP‐4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations. European Heart Journal2013;34(0):793. HageC , BrismarK , LundmanP , NorhammarA , RydenL , MellbinL . The DPP‐4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: a report from the BEGAMI study. Diabetes &amp; Vascular Disease Research2014;11(4):290‐3. [PUBMED: 24845072] NCT00627744 . Beta‐cell function in glucose abnormalities and acute myocardial infarction (BEGAMI). clinicaltrials.gov/ct2/show/NCT00627744 Date first received: 22 February 2008. ">BEGAMI 2013</a>). Participants were randomised to sitagliptin 100 mg/day or placebo for 12 weeks. The trial reported that none participants died; 1/24 participants in the sitagliptin group versus 4/23 participants in the placebo group developed T2DM according to the criteria for the WHO (FPG 7.0 mmol/L or greater (126 mg/dL or greater) or two‐hour plasma glucose 11.1 mmol/L or greater (200 mg/dL or greater)). </p> <p>We excluded eight trials published in 15 records as it was not possible to obtain separate data on the participants of interest for our review, neither from the publication nor through correspondence with the investigators (<a href="./references#CD012204-bbs2-0017" title="DanieleG , IozzoP , Molina‐CarrionM , LancasterJ , CiociaroD , CersosimoE , et al. Exenatide regulates cerebral glucose metabolism in brain areas associated with glucose homeostasis and reward system. Diabetes2015;64(10):3406‐12. [PUBMED: 26116695] DanieleG , IozzoP , Molina‐WilkinsM , LancasterJ , CiociaroD , TriplittC , et al. Effect of exenatide on postprandial cerebral and liver glucose metabolism: a double‐blind randomised clinical trial. Diabetologia2014;57(1):S37‐8. DanieleG , Molina‐WilkinsM , LancasterJ , CiociaroD , TriplittC , CersosimoE , et al. Exenatide affects the distribution of cerebral postprandial glucose uptake: a double‐blind, randomized clinical trial. Diabetes2014;63:A85. NCT01588418 . Effect of exenatide on brain, adipose tissue, pancreas, and liver function. clinicaltrials.gov/ct2/show/NCT01588418 Date first received: 19 March 2012. ">Daniele 2015</a>; <a href="./references#CD012204-bbs2-0018" title="DushayJ , GaoC , GopalakrishnanGS , CrawleyM , MittenEK , WilkerE , et al. Short‐term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabetes Care2012;35(1):4‐11. [DOI: 10.2337/dc11‐0931] NCT00456885 . The effect of exenatide on weight and hunger in obese, healthy women. clinicaltrials.gov/ct2/show/NCT00456885 Date first received: 4 April 2007. ">Dushay 2012</a>; <a href="./references#CD012204-bbs2-0023" title="IshikawaS , ShimanoM , WataraiM , KoyasuM , UchikawaT , IshiiH , et al. Impact of sitagliptin on carotid intima‐media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus. American Journal of Cardiology2014;114(3):384‐8. [PUBMED: 24929624] ">Ishikawa 2014</a>; <a href="./references#CD012204-bbs2-0030" title="NCT00845182 . Effect of pioglitazone and exenatide on body weight and beta cell function (PIO‐EX). clinicaltrials.gov/ct2/show/study/NCT00845182 Date first received: 17 February 2009. ">NCT00845182</a>; <a href="./references#CD012204-bbs2-0035" title="NCT01018602 . PINGUIN (Postpartum Intervention in Women with Gestational Diabetes Using Insulin). clinicaltrials.gov/ct2/show/NCT01018602 Date first received: 20 November 2009. ">NCT01018602</a>; <a href="./references#CD012204-bbs2-0038" title="NCT01122641 . The vascular effects of vildagliptin in insulin resistant individuals. clinicaltrials.gov/ct2/show/NCT01122641 Date first received: 12 May 2010. ">NCT01122641</a>; <a href="./references#CD012204-bbs2-0040" title="NCT01472640 . The effect of liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes mellitus. clinicaltrials.gov/ct2/show/NCT01472640 Date first received: 11 November 2011. ">NCT01472640</a>; <a href="./references#CD012204-bbs2-0048" title="AramakiM . Alogliptin, but not voglibose, ameliorates dyslipidemia and LDL particle size in patients with impaired glucose tolerance or Type 2 diabetes. Clinical Lipidology2013;8(5):533‐40. TsuchiyaM . Alogliptin ameliorates dyslipidemia and LDL‐size in patients with IGT or type 2 diabetes: comparing alogliptin and voglibose. Diabetes2011;60:A280. TsuchiyaM . Alogliptin decreases liver fat content in patients with IGT or type Q2 DM: comparing alogliptin and voglibose. Diabetes2011;60:A595. TsuchiyaM , MaegawaH . DPP4 inhibition ameliorates intramuscular fat content in patients with IGT or type 2 DM: comparing alogliptin and voglibose. Diabetes2013;62:A297. ">Tsuchiya 2011</a>). We contacted trial authors but did not receive additional data (see <a href="./appendices#CD012204-sec-0192">Appendix 14</a>). </p> <p>Six records representing five trials were never initiated or completed (<a href="./references#CD012204-bbs2-0031" title="NCT00845559 . The effects of exenatide on post‐meal sugar peaks and vascular health in obese/pre‐diabetic young adults. clinicaltrials.gov/ct2/show/NCT00845559 Date first received: 16 February 2009. ">NCT00845559</a>; <a href="./references#CD012204-bbs2-0033" title="NCT00961363 . Effect of sitagliptin in impaired glucose tolerance. clinicaltrials.gov/ct2/show/NCT00961363 Date first received: 11 August 2009. ">NCT00961363</a>; <a href="./references#CD012204-bbs2-0034" title="NCT01006018 . DPP‐4 Inhibition and TZD for DM Prevention (DInT DM). clinicaltrials.gov/ct2/show/NCT01006018 Date first received: 27 October 2009. ">NCT01006018</a>; <a href="./references#CD012204-bbs2-0036" title="NCT01038648 . Sitagliptin in Prevention of Type 2 Diabetes Mellitus (SITAGLIPTIN). clinicaltrials.gov/ct2/show/NCT01038648 Date first received: 22 December 2009. ">NCT01038648</a>; <a href="./references#CD012204-bbs2-0045" title="2014‐001778‐32/DK . The LiRA2 study. www.clinicaltrialsregister.eu/ctr‐search/trial/2014‐001778‐32/DK Date first registered: 17 June 2014. NCT02284230 . The effect of liraglutide in patients with prediabetes and kidney failure (LiRA2). clinicaltrials.gov/ct2/show/NCT02284230 Date first received: 3 November 2014. ">NCT02284230</a>). </p> <p>We excluded four trials reported in 13 references because of a trial duration of less than 12 weeks (<a href="./references#CD012204-bbs2-0010" title="Almeda‐ValdesP , Cuevas‐RamosD , Brito‐CordovaG , Gomez‐PerezFJ . Treatment with sitagliptin phosphate in patients with symptomatic reactive hypoglycemia. A randomized, placebo‐controlled, double‐blinded, clinical trial. 94th Annual Meeting and Expo; 2012 23‐26 Jun; Houston (TX)2012:SUN‐209. NCT00847080 . Treatment with sitagliptin for reactive hypoglycemia secondary to dysinsulinism. clinicaltrials.gov/ct2/show/NCT00847080 Date first received: 18 February 2009. ">Almeda‐Valdes 2012</a>; <a href="./references#CD012204-bbs2-0015" title="BockG , Dalla ManC , MichelettoF , BasuR , GieslerPD , LaugenJ , et al. The effect of DPP‐4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clinical Endocrinology2010;73(2):189‐96. [DOI: 10.1111/j.1365‐2265.2009.03764.x] MichelettoF , Dalla ManC , VellaA , CobelliC . Estimation of GLP‐1 induced potentiation of insulin secretion from an oral model. Diabetes2011;60(0):A447. NCT00364377 . Incretins in impaired fasting glucose. clinicaltrials.gov/ct2/show/NCT00364377 Date first received: 14 August 2006. NelsonRH , MilesJM , VellaA . Sitagliptin effects on triglyceride and free fatty acid metabolism. Diabetologia2009;52:S313. ">Bock 2010</a>; <a href="./references#CD012204-bbs2-0024" title="KakuK , KadowakiT , TerauchiY , OkamotoT , SatoA , OkuyamaK , et al. Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2015;17(11):1033‐41. [PUBMED: 26094974] NCT01405911 . Dose response finding study of MK‐0431/ONO‐5435 in Japanese subjects with impaired glucose tolerance (MK‐0431‐105). clinicaltrials.gov/ct2/show/NCT01405911 Date first received: 28 July 2011. ">Kaku 2015</a>; <a href="./references#CD012204-bbs2-0047" title="KoskaJ , SandsM , BurciuC , D'SouzaKM , RaravikarK , LiuJ , et al. Exenatide protects against glucose‐ and lipid‐induced endothelial dysfunction: evidence for direct vasodilation effect of GLP‐1 receptor agonists in humans. Diabetes2015;64(7):2624‐35. [PUBMED: 25720388] KoskaJ , SchwartzEA , MullinMP , SchwenkeDC , ReavenPD . Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent‐onset type 2 diabetes. Diabetes Care2010;33(5):1028‐30. [PUBMED: 20200309] MullinMP , KoskaJ , SchwartzEA , SchwenkeDC , ReavenPD . Acute administration of exenatide improves endothelial function following a high‐fat meal. Diabetes2009;58:P‐640. SchwartzEA , KoskaJ , MullinMP , SchwenkeDC , ReavenPD . Effects of acute exenatide administration on postprandial lipids and lipoproteins in individuals with impaired glucose metabolism. Diabetes2009; Vol. 58:375‐OR. SchwartzEA , KoskaJ , MullinMP , SyoufiI , SchwenkeDC , ReavenPD . Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis2010;212(1):217‐22. [PUBMED: 20557887] ">Schwartz 2010</a>) (<a href="./appendices#CD012204-sec-0179">Appendix 1</a>). We screened five systematic reviews investigating people at increased risk for the development of T2DM for additional data (<a href="./references#CD012204-bbs2-0084" title="AndersonDCJr . Pharmacologic prevention or delay of type 2 diabetes mellitus. Annals of Pharmacotherapy2005;39(1):102‐9. [PUBMED: 15562143] ">Anderson 2005</a>; <a href="./references#CD012204-bbs2-0086" title="BhardwajA , AgarwalV , PhungOJ , BakerWL , TongbramV , ColemanCI . Can oral hypoglycemic agents restore normoglycemia in individuals with insulin resistance?. 70th Scientific Sessions of the American Diabetes Association; 2010 25‐29 June; Orlando (FL). 2010. ">Bhardwaj 2010</a>; <a href="./references#CD012204-bbs2-0121" title="HopperI , BillahB , SkibaM , KrumH . Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta‐analysis of randomised controlled clinical trials. European Journal of Cardiovascular Prevention and Rehabilitation2011;18(6):813‐23. [PUBMED: 21878448] ">Hopper 2011</a>; <a href="./references#CD012204-bbs2-0142" title="PhungOJ , BakerWL , TongbramV , BhardwajA , ColemanCI . Oral antidiabetic drugs and regression from prediabetes to normoglycemia: a meta‐analysis. Annals of Pharmacotherapy2012;46(4):469‐76. [PUBMED: 22474136] ">Phung 2012</a>; <a href="./references#CD012204-bbs2-0156" title="Van deLaarFA , LucassenPL , AkkermansRP , Van deLisdonkEH , DeGrauwWJ . Alpha‐glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD005061.pub2] ">Van de Laar 2006</a>). </p> </section> </section> <section id="CD012204-sec-0086"> <h3 class="title">Risk of bias in included studies</h3> <p>For details on the risk of bias of the included trials, see the <a href="./references#CD012204-sec-0205" title="">Characteristics of included studies</a> table. </p> <p>For an overview of review authors' judgements about each risk of bias item for individual trials and across all trials, see <a href="#CD012204-fig-0002">Figure 2</a> and <a href="#CD012204-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD012204-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials)." data-id="CD012204-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials). </p> </div> </div> </div> <div class="figure" id="CD012204-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial (blank cells indicate that the particular outcome was not measured in some trials)." data-id="CD012204-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial (blank cells indicate that the particular outcome was not measured in some trials). </p> </div> </div> </div> <p>None of the included trials reported on microvascular outcomes or socioeconomic effects.</p> <section id="CD012204-sec-0087"> <h4 class="title">Allocation</h4> <p>We judged two trials at low risk of selection bias regarding the method of randomisation and allocation concealment (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). One trial only reported the method of randomisation but not how allocation concealment was achieved (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>). The remaining trials only reported that the participants were randomised but did not provide any further description (<a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). Therefore, these trials were judged at unclear risk of bias regarding randomisation and allocation concealment. </p> <p>We evaluated trial baseline data for our predefined prognostic baseline variables. Only one trial reported all the prognostic baseline variables of interest, which all were balanced between the intervention groups (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). The remaining trials only reported some of our predefined key prognostic variables of interest (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). None of the trials reporting one or more key prognostic variables showed important differences between the intervention groups (see <a href="./appendices#CD012204-sec-0182">Appendix 4</a>; <a href="./appendices#CD012204-sec-0183">Appendix 5</a>; <a href="./appendices#CD012204-sec-0184">Appendix 6</a>). </p> </section> <section id="CD012204-sec-0088"> <h4 class="title">Blinding</h4> <p>Six trials explicitly reported blinding of participants and investigators (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). The blinding of participants and investigators was ensured by using placebo injections or tablets. In addition, one trial had a double‐blind intervention period for the first year (pharmaceutical company, investigators and participants were blinded), and a single‐blind period for the remaining two years (pharmaceutical company was unblinded, whereas investigators and participants remained blinded) (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). One trial described a blinded outcome committee evaluating mortality, acute coronary syndromes, cerebrovascular events (stroke or transient ischaemic attacks), heart failure requiring hospitalisation, stent thrombosis, coronary revascularisations, pancreatitis or acute severe, persistent abdominal pain leading to a suspicion of pancreatitis, neoplasms, thyroid disorders requiring thyroidectomy, serious adverse events and severe hypoglycaemia (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). None of the remaining trials reported that a blinded outcome committee was instituted to assess any of the reported outcomes. </p> <p>Where measured, all primary outcomes of this review were investigator assessed and we judged these at low risk of performance and detection bias. The trials reporting blood glucose measurements were all performed by the investigators and we judged these outcomes measures at low risk of performance and detection bias. </p> <p>When reported, non‐serious adverse events and mild hypoglycaemia were partly or exclusively self‐reported. Blinding of participants and investigators was ensured in three trials reporting these outcomes (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). One trial with an open‐label design reported that no participants experienced a non‐serious adverse event (<a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>). Overall, the risk of performance bias and detection bias was judged as low or unclear for our secondary outcomes. </p> </section> <section id="CD012204-sec-0089"> <h4 class="title">Incomplete outcome data</h4> <p>Six trials reported the complete number of participants randomised and finishing the trial (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). The percentage of randomised participants completing the trials varied from 49% to 100%. One trial did not describe how many participants were originally randomised but reported the number analysed (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). </p> <p>Two trials stated that all randomised participants completed the trial and were included in the analyses (<a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>). One trial reported the number of missing participants, which were balanced across the intervention groups and the number and reasons were unlikely to introduce clinically relevant bias (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>). </p> <p>One trial reported five participants were missing in each intervention group (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>). Detailed reason were stated (vildagliptin group: adverse events (three participants); withdrew consent (one); protocol violation (one); lost to follow‐up (one); placebo group: adverse events (two); withdrew consent (one); protocol violation (two); lost to follow‐up (none) (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>). </p> <p>We judged two trials to have high risk of incomplete outcome data for the outcomes reported with relevance for our review (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). In one trial, 31% in the liraglutide group and 18% in the placebo group dropped out during the trial. Eight of the dropouts were due to adverse events in the liraglutide group versus no dropouts happened because of adverse events in the placebo group (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>). In one trial, only about half of the participants completed the trial (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Missing data were imputed with the LOCF. We judged this as high risk of attrition bias due to the large proportion of missing data and the method of imputation (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). One trial was judged at unclear risk of bias regarding incomplete outcome data for the reported outcomes with relevance to our review (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). A total of 38 participants were randomised and 33 participants were analysed, which presumably received at least one dose of the study drug. The number of participants with IFG or IGT completing the visits, as well as reasons for the dropping out, were not reported. The method of imputation of missing data was not explained (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). </p> </section> <section id="CD012204-sec-0090"> <h4 class="title">Selective reporting</h4> <p>All included trials, except one, had a published protocol (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>). We judged two of the included trials at high risk of reporting bias on one or more of the outcomes of relevance to our review (<a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>). Two trials had unclear risk of reporting bias (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). Three trials were at low risk of selective outcome reporting bias (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). For more details, see <a href="./appendices#CD012204-sec-0185">Appendix 7</a> and <a href="./appendices#CD012204-sec-0186">Appendix 8</a>. </p> </section> <section id="CD012204-sec-0091"> <h4 class="title">Other potential sources of bias</h4> <p>Five of the included trials stated that they had received support from a pharmaceutical company (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Two trials did not report the funding source (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>). It is known that trials receiving funding or provision of free drug or devices from a pharmaceutical company lead to more favourable results and conclusions than trials sponsored by other sources (<a href="./references#CD012204-bbs2-0133" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3] ">Lundh 2017</a>). Therefore, all eight trials were judged at unclear risk of bias in the 'other sources' bias‐domain. </p> </section> </section> <section id="CD012204-sec-0092"> <h3 class="title" id="CD012204-sec-0092">Effects of interventions</h3> <p>See: <a href="./full#CD012204-tbl-0001"><b>Summary of findings for the main comparison</b> DPP‐4 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus</a>; <a href="./full#CD012204-tbl-0002"><b>Summary of findings 2</b> GLP‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus</a> </p> <p>See <a href="./full#CD012204-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./full#CD012204-tbl-0002">summary of findings Table 2</a> for details. </p> <section id="CD012204-sec-0093"> <h4 class="title">Baseline characteristics</h4> <p>For details of baseline characteristics, see <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012151.pub2/full#CD012151-sec2-0019" target="_blank">Appendix 4</a>; <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012151.pub2/full#CD012151-sec2-0020" target="_blank">Appendix 5</a>; <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012151.pub2/full#CD012151-sec2-0021" target="_blank">Appendix 6</a>. </p> </section> <section id="CD012204-sec-0094"> <h4 class="title">DPP‐4 inhibitors as monotherapy versus any pharmacological glucose‐lowering intervention (e.g. acarbose, metformin, sulphonylurea) </h4> <p>One trial compared a DPP‐4 inhibitor as monotherapy (linagliptin 5 mg in the morning plus a placebo tablet in the evening) with another pharmacological glucose‐lowering intervention (metformin 500 mg twice daily) (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>). The corresponding investigator provided additional information regarding outcomes of relevance for this review (internal correspondence). </p> <p>There were eight participants allocated to each group. None of the participants progressed to T2DM or experienced a serious adverse event. None of the participants experienced mild hypoglycaemia and severe hypoglycaemia was not assessed. One participant in the linagliptin group experienced a non‐serious adverse event versus four participants in the metformin group (<a href="./references#CD012204-fig-0004" title="">Analysis 1.1</a>). </p> <p>The trial evaluated FPG, glucose concentrations two hours after an OGTT and HbA1c. The mean FPG concentration at the end of the intervention in the linagliptin plus placebo group was 5.5 (SD 0.6) mmol/L versus 5.7 (SD 0.7 ) mmol/L in the metformin group (MD ‐0.20 mmol/L, 95% CI ‐0.84 to 0.44; <a href="./references#CD012204-fig-0005" title="">Analysis 1.2</a>). Two‐hour post‐OGTT glucose concentrations were 9.0 (SD 0.9) mmol/L with linagliptin plus placebo versus 9.5 (SD 1.0) mmol/L with metformin (MD ‐0.50 mmol/L, 95% CI ‐1.43 to 0.43; <a href="./references#CD012204-fig-0006" title="">Analysis 1.3</a>). Mean HbA1c was 6.1% (SD 0.6%) linagliptin plus placebo versus 6.2% (SD 0.4%) with metformin (MD ‐0.10%, 95% CI ‐0.60% to 0.40%; <a href="./references#CD012204-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD012204-sec-0095"> <h4 class="title">DPP‐4 inhibitors as monotherapy versus behaviour‐changing interventions (e.g. diet, exercise, diet plus exercise) </h4> <p>We identified no trials comparing DPP‐4 inhibitors as monotherapy with behaviour‐changing interventions. </p> </section> <section id="CD012204-sec-0096"> <h4 class="title">DPP‐4 inhibitors as monotherapy versus placebo</h4> <p>One trial compared a DPP‐4 inhibitor (vildagliptin) as monotherapy with placebo only in people with IGT (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>). The trial had a duration of intervention of 12 weeks. </p> <section id="CD012204-sec-0097"> <h5 class="title">Primary outcomes</h5> <section id="CD012204-sec-0098"> <h6 class="title">All‐cause mortality</h6> <p>The trial reported that none of the participants died (very low‐quality evidence).</p> </section> <section id="CD012204-sec-0099"> <h6 class="title">Incidence of type 2 diabetes mellitus</h6> <p>The trial defined T2DM as FPG 7.0 mmol/L or greater (126 mg/dL or greater) or two‐hour plasma glucose 11.1 mmol/L or greater (200 mg/dL or greater). Three out of 90 in the vildagliptin group versus 1/89 in the placebo group reported T2DM during the trial (<a href="./references#CD012204-fig-0008" title="">Analysis 2.1</a>) (very low‐quality evidence). </p> </section> <section id="CD012204-sec-0100"> <h6 class="title">Serious adverse events</h6> <p>A total of 1/90 participants in the vildagliptin group versus 2/89 participants in the placebo group had a serious adverse event (RR 0.49, 95% CI 0.05 to 5.36; <a href="./references#CD012204-fig-0009" title="">Analysis 2.2</a>) (very‐low quality evidence). </p> </section> </section> <section id="CD012204-sec-0101"> <h5 class="title">Secondary outcomes</h5> <section id="CD012204-sec-0102"> <h6 class="title">Cardiovascular mortality</h6> <p>The trial reported that none of the participants died (very low‐quality evidence).</p> </section> <section id="CD012204-sec-0103"> <h6 class="title">Non‐fatal myocardial infarction</h6> <p>The trial did not report data on non‐fatal myocardial infarction (very low‐quality evidence). </p> </section> <section id="CD012204-sec-0104"> <h6 class="title">Non‐fatal stroke</h6> <p>The trial did not report data on non‐fatal stroke (very low‐quality evidence).</p> </section> <section id="CD012204-sec-0105"> <h6 class="title">Congestive heart failure</h6> <p>One out of 90 participants in the vildagliptin group compared with 0/89 participants in the placebo group experienced heart failure (<a href="./references#CD012204-fig-0010" title="">Analysis 2.3</a>) (very low‐quality evidence). </p> </section> <section id="CD012204-sec-0106"> <h6 class="title">Amputation of lower extremity</h6> <p>The trial did not report data on amputation of lower extremity.</p> </section> <section id="CD012204-sec-0107"> <h6 class="title">Blindness or severe vision loss</h6> <p>The trial did not report data on blindness or severe vision loss.</p> </section> <section id="CD012204-sec-0108"> <h6 class="title">End‐stage renal disease</h6> <p>The trial did not report data on end‐stage renal disease.</p> </section> <section id="CD012204-sec-0109"> <h6 class="title">Non‐serious adverse events</h6> <p>A total of 49/90 participants in the vildagliptin group versus 44/89 participants in the placebo group experienced non‐serious adverse events (RR 1.10, 95% CI 0.83 to 1.46; <a href="./references#CD012204-fig-0011" title="">Analysis 2.4</a>). </p> </section> <section id="CD012204-sec-0110"> <h6 class="title">Hypoglycaemia</h6> <p>None of the participants in the trial experienced either mild or severe hypoglycaemic episodes. </p> </section> <section id="CD012204-sec-0111"> <h6 class="title">Health‐related quality of life</h6> <p>The trial did not report data on HRQoL (very low‐quality evidence).</p> </section> <section id="CD012204-sec-0112"> <h6 class="title">Time to progression to type 2 diabetes mellitus</h6> <p>The trial did not report data on time to progression to T2DM.</p> </section> <section id="CD012204-sec-0113"> <h6 class="title">Measures of blood glucose control</h6> <p>The trial did not describe whether the trial drug was used the day of measuring glycaemic variables (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>). </p> <section id="CD012204-sec-0114"> <p><b>Fasting plasma glucose</b></p> <p>The trial reported FPG concentrations as adjusted mean change from baseline. However, these adjustments were not specified. The MD of FPG for vildagliptin compared with placebo was ‐0.03 mmol/L (95% CI ‐0.21 to 0.15;179 participants; <a href="./references#CD012204-fig-0012" title="">Analysis 2.5</a>). </p> </section> <section id="CD012204-sec-0115"> <p><b>Two‐hour plasma glucose concentrations (oral glucose tolerance test)</b></p> <p>The trial reported glucose values two hours after an OGTT as adjusted mean change from baseline, but these adjustments were not specified (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>). The MD of glucose values after an OGTT for vildagliptin compared with placebo was ‐0.30 mmol/L (95% CI ‐0.57 to ‐0.03; 179 participants; <a href="./references#CD012204-fig-0013" title="">Analysis 2.6</a>). </p> </section> <section id="CD012204-sec-0116"> <p><b>Glycosylated haemoglobin A1c</b></p> <p>The trial reported HbA1c as an adjusted mean change from baseline, but the adjustments were not further specified (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>). The MD in HbA1c for vildagliptin compared with placebo was ‐0.15% (95% CI ‐0.24% to ‐0.06%; 179 participants; <a href="./references#CD012204-fig-0014" title="">Analysis 2.7</a>). </p> </section> </section> <section id="CD012204-sec-0117"> <h6 class="title">Socioeconomic effects</h6> <p>The trial did not report data on socioeconomic effects (very low‐quality evidence).</p> </section> </section> </section> <section id="CD012204-sec-0118"> <h4 class="title">DPP‐4 inhibitors as monotherapy versus no intervention</h4> <p>We identified no trials comparing DPP‐4 inhibitors as monotherapy with no intervention.</p> </section> <section id="CD012204-sec-0119"> <h4 class="title">DPP‐4 inhibitors as a part of a combination therapy versus any other pharmacological glucose‐lowering agent (e.g. acarbose, metformin, sulphonylurea) </h4> <p>We identified no trials comparing DPP‐4 inhibitors as a part of a combination therapy with any other pharmacological glucose‐lowering agent. </p> </section> <section id="CD012204-sec-0120"> <h4 class="title">GLP‐1 analogues as monotherapy versus any other pharmacological glucose‐lowering intervention (e.g. acarbose, metformin, sulphonylurea) </h4> <p>One trial compared a GLP‐1 analogue as monotherapy (exenatide 5 μg twice daily for the first month followed by 10 μg twice daily for the remaining two months) with another glucose‐lowering intervention (metformin initiated at 500 mg twice daily for the first month, and thereafter uptitrated to 1000 mg twice daily for the remaining two months) (<a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>). </p> <section id="CD012204-sec-0121"> <h5 class="title">Primary outcomes</h5> <section id="CD012204-sec-0122"> <h6 class="title">All‐cause mortality</h6> <p>None of the participants died.</p> </section> <section id="CD012204-sec-0123"> <h6 class="title">Incidence of type 2 diabetes mellitus</h6> <p>The trial did not report data on the incidence of T2DM.</p> </section> <section id="CD012204-sec-0124"> <h6 class="title">Serious adverse events</h6> <p>None of the participants experienced serious adverse events.</p> </section> </section> <section id="CD012204-sec-0125"> <h5 class="title">Secondary outcomes</h5> <section id="CD012204-sec-0126"> <h6 class="title">Cardiovascular mortality</h6> <p>None of the participants died.</p> </section> <section id="CD012204-sec-0127"> <h6 class="title">Non‐fatal myocardial infarction</h6> <p>The trial did not report data on non‐fatal myocardial infarction.</p> </section> <section id="CD012204-sec-0128"> <h6 class="title">Non‐fatal stroke</h6> <p>The trial did not report data on non‐fatal stroke.</p> </section> <section id="CD012204-sec-0129"> <h6 class="title">Congestive heart failure</h6> <p>The trial did not report data on congestive heart.</p> </section> <section id="CD012204-sec-0130"> <h6 class="title">Amputation of lower extremity</h6> <p>The trial did not report data on amputation of the lower extremity.</p> </section> <section id="CD012204-sec-0131"> <h6 class="title">Blindness or severe vision loss</h6> <p>The trial did not report data on blindness or severe vision loss.</p> </section> <section id="CD012204-sec-0132"> <h6 class="title">End‐stage renal disease</h6> <p>The trial did not report data on end‐stage renal disease.</p> </section> <section id="CD012204-sec-0133"> <h6 class="title">Non‐serious adverse events</h6> <p>None of the participants reported non‐serious adverse events. The threshold above which other adverse events were reported was 5%. Consequently, non‐serious adverse events may have been under‐reported due to low number of total events. Therefore, this trial was judged at high risk of selective outcome reporting bias regarding non‐serious adverse events. </p> </section> <section id="CD012204-sec-0134"> <h6 class="title">Hypoglycaemia</h6> <p>None of the participants experienced hypoglycaemic events.</p> </section> <section id="CD012204-sec-0135"> <h6 class="title">Health‐related quality of life</h6> <p>The trial did not report data on HRQoL.</p> </section> <section id="CD012204-sec-0136"> <h6 class="title">Time to progression to type 2 diabetes mellitus</h6> <p>The trial did not report data on time to progression to T2DM.</p> </section> <section id="CD012204-sec-0137"> <h6 class="title">Measures of blood glucose control</h6> <p>Glycaemic testing was performed in the morning after fasting. The trial drug was withheld on these mornings. The only glycaemic variable reported in the trial was change in fasting glucose from baseline. The change from baseline was ‐0.2 (SD 0.6) mmol/L in 25 participants allocated to exenatide versus ‐0.2 (SD 0.5) mmol/L in 25 participants allocated to metformin (MD 0.00 mmol/L, 95% CI ‐0.31 to 0.31; <a href="./references#CD012204-fig-0015" title="">Analysis 3.1</a>). </p> </section> <section id="CD012204-sec-0138"> <h6 class="title">Socioeconomic effects</h6> <p>The trial did not report data on socioeconomic effects.</p> </section> </section> </section> <section id="CD012204-sec-0139"> <h4 class="title">GLP‐1 analogues as monotherapy versus behaviour‐changing interventions (e.g. diet, exercise, diet and exercise) </h4> <p>We identified no trials comparing GLP‐1 analogues as monotherapy with behaviour‐changing interventions. </p> </section> <section id="CD012204-sec-0140"> <h4 class="title">GLP‐1 analogues as monotherapy versus placebo</h4> <p>Four trials compared a GLP‐1 analogue as monotherapy with placebo (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). One trial reported no outcomes of relevance to this review (<a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>). Two trials used the GLP‐1 analogue exenatide (<a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>); the other two trials used liraglutide (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). In both the exenatide trials, exenatide was uptitrated to 10 μg twice daily (<a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). One of the trials randomising the participants to liraglutide used a dose of 1.8 mg (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>); the other trial used 3.0 mg (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). One of the trials included participants with and without intermediate hyperglycaemia (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). However, it was possible to retrieve data for some outcomes on the participants with IGT or IFG at baseline (38/152 participants) (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). </p> <section id="CD012204-sec-0141"> <h5 class="title">Primary outcomes</h5> <section id="CD012204-sec-0142"> <h6 class="title">All‐cause mortality</h6> <p>One trial reported that no participants died (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). Another trial reported that four participants died; two in the liraglutide group (due to cardiac arrest and metastatic cholangiocarcinoma) and two in the placebo group (pulmonary failure and cancer (primary tumour unknown) (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>) (very low‐quality evidence). </p> </section> <section id="CD012204-sec-0143"> <h6 class="title">Incidence of type 2 diabetes mellitus</h6> <p>Two trials comparing GLP‐1 analogues as monotherapy with placebo reported data on the incidence of T2DM (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). In the Satiety and Clinical Adiposity ‐ Liraglutide Evidence in Nondiabetic and Diabetic Individuals (SCALE) trial, participants were not supposed to take the study medication in the morning on the OGTT days. The OGTT was performed about every sixth month and FPG and HbA1c were measured every third month. The participants were allowed to take the trial medication on the days when FPG was measured (except if the OGTT was planned at the same visit). The diagnosis of T2DM was defined as HbA1c 6.5% or greater, FPG 7.0 mmol/L or greater or two‐hour plasma glucose 11.1 mmol/L or greater (OGTT). The T2DM incidence was reported after 56 weeks of the intervention and after 160 weeks of the intervention period with an extended follow‐up period of 12 weeks after the intervention was stopped (i.e. 172 weeks). At 56 weeks, four participants in the liraglutide group and 13 participants in the placebo group developed T2DM (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). At 160 weeks, 26 participants in the liraglutide group and 46 participants in the placebo group developed T2DM (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). After the extension period (i.e. after 172 weeks), five additional participants were diagnosed with T2DM in the liraglutide group compared with one participant in the placebo group. Missing data were imputed with LOCF (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>) (very low‐quality evidence). </p> <p>A post‐hoc analysis was performed to address the lack of follow‐up information for withdrawn participants at week 172, and assumed that 1% of those withdrawn in the liraglutide group had undiagnosed T2DM at withdrawal, whereas none of those in the placebo group did (HR 0.34, 95% CI 0.22 to 0.53; P &lt; 0.0001). </p> <p>Of the 1468 participants in the liraglutide group, several glycaemic indices at screening were associated with the later development of T2DM after 160 weeks of the intervention. </p> <p> <ul id="CD012204-list-0021"> <li> <p>173 with IFG: one (0.6%) progressed to T2DM.</p> </li> <li> <p>158 with IGT: two (1.3%) progressed to T2DM.</p> </li> <li> <p>376 with elevated HbA1c: one (0.3%) progressed to T2DM.</p> </li> <li> <p>103 with IFG plus IGT: none (0%) progressed to T2DM.</p> </li> <li> <p>262 with IFG plus elevated HbA1c: nine (3.4%) progressed to T2DM.</p> </li> <li> <p>161 with IGT plus elevated HbA1c: three (1.9%) progressed to T2DM.</p> </li> <li> <p>235 with IFG plus IGT plus elevated HbA1c: 10 (3.8%) progressed to T2DM.</p> </li> </ul> </p> <p>Of the 736 participants in the placebo group, several glycaemic indices at screening were associated with the later development of T2DM after 160 weeks of the intervention. </p> <p> <ul id="CD012204-list-0022"> <li> <p>90 with IFG: four (4.4%) progressed to T2DM.</p> </li> <li> <p>94 with IGT: one (1.1%) progressed to T2DM.</p> </li> <li> <p>187 with elevated HbA1c: five (2.7%) progressed to T2DM.</p> </li> <li> <p>46 with IFG plus IGT: two (4.3%) progressed to T2DM.</p> </li> <li> <p>128 with IFG plus elevated HbA1c: 11 (8.6%) progressed to T2DM.</p> </li> <li> <p>75 with IGT plus elevated HbA1c: four (5.3%) progressed to T2DM.</p> </li> <li> <p>116 with IFG plus IGT plus elevated HbA1c: 18 (15.5%) progressed to T2DM.</p> </li> </ul> </p> <p>The numbers above was presented in an appendix of the publication of the long‐term data from the SCALE trial (<a href="./references#CD012204-bbs2-0131" title="Lle RouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] ">Le Roux 2017</a>). However, the article included 1472 participants in the liraglutide group and 738 in the placebo group (<a href="./references#CD012204-bbs2-0131" title="Lle RouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] ">Le Roux 2017</a>). The reason for the discrepancy in number of participants included in the analysis as well in the number of participants developing T2DM (45 instead of 46 participants) was not stated. The corresponding author of the article was contacted twice, but no reply was provided (<a href="./appendices#CD012204-sec-0192">Appendix 14</a>). </p> <p>In the SCALE trial after 160 weeks of the intervention, 970/1472 (66%) participants had regressed from intermediate hyperglycaemia to normoglycaemia compared with 268/738 (36%) participants in the placebo group. After 12‐week treatment cessation, 740/1472 (50%) participants in the liraglutide group compared with 263/738 (36%) participants in the placebo group had normoglycaemia. </p> <p>The other trial reporting T2DM incidence stated that the trial drug was withheld before the OGTT (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). The trial had a final follow‐up visit four weeks after trial completion. There was no definition of the T2DM diagnosis provided (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). </p> <p>The RR for the incidence of T2DM differed for the analysed GLP‐1 analogues: exenatide therapy compared with placebo was associated with an RR of 1.88 (95% CI 0.19 to 18.80; 2/17 participants in the GLP‐1 analogue group versus 1/16 participants in the placebo group; <a href="./references#CD012204-fig-0016" title="">Analysis 4.1</a>). Liraglutide treatment compared with placebo was associated with an RR of 0.28 (95% CI 0.18 to 0.45; 26/1472 (1.8%) participants in the liraglutide group versus 46/738 (6.2%) participants in the placebo group; <a href="./references#CD012204-fig-0016" title="">Analysis 4.1</a>). </p> <p>TSA showed that 0.36% of the diversity‐adjusted information size was accrued to detect or reject a 10% RRR. Diversity was 93%. As only a minor fraction of the diversity‐adjusted required information size was accrued, the TSA‐adjusted 95% CI could not be calculated. </p> </section> <section id="CD012204-sec-0144"> <h6 class="title">Serious adverse events</h6> <p>Two trials comparing GLP‐1 analogues as monotherapy with placebo reported data on serious adverse events (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). One of the trials reported that none of the participants experienced a serious adverse event (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). The other trial reported two different numbers for serious adverse events in 227/1501 participants (15%) in the liraglutide arm versus 96/747 participants (13%) in the placebo arm after 160 weeks (RR 1.18, 95% CI 0.94 to 1.47; <a href="./references#CD012204-fig-0017" title="">Analysis 4.2</a>; very low‐quality evidence). In ClinicalTrials.gov, serious adverse events were reported in 230/1524 (14.9%) participants the liraglutide arm versus 96/755 (12.7%) participants in the placebo arm after 172 weeks (i.e. including 12 weeks after the intervention had stopped) (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). </p> </section> </section> <section id="CD012204-sec-0145"> <h5 class="title">Secondary outcomes</h5> <section id="CD012204-sec-0146"> <h6 class="title">Cardiovascular mortality</h6> <p>One trial reported that no participants died (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). Another trial reported that 1/1501 participants died from cardiac arrest in the liraglutide group and none of the participants in the placebo group died of cardiovascular reasons (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>) (very low‐quality evidence). </p> </section> <section id="CD012204-sec-0147"> <h6 class="title">Non‐fatal myocardial infarction</h6> <p>One trial reported data on myocardial infarction (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Under the serious adverse events, 1/1524 participants in the liraglutide arm and 0/755 participants in the placebo arm experienced a myocardial infarction at 172 weeks (very low‐quality evidence). </p> </section> <section id="CD012204-sec-0148"> <h6 class="title">Non‐fatal stroke</h6> <p>None of the trials reported data on non‐fatal stroke (very low‐quality evidence).</p> </section> <section id="CD012204-sec-0149"> <h6 class="title">Congestive heart failure</h6> <p>One trial reported data on heart failure (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Under serious adverse events, 1/1524 participants in the liraglutide arm and 1/755 participants in the placebo arm experienced congestive heart failure at 172 weeks (very low‐quality evidence). </p> </section> <section id="CD012204-sec-0150"> <h6 class="title">Amputation of lower extremity</h6> <p>None of the trials reported data on amputation of lower extremity.</p> </section> <section id="CD012204-sec-0151"> <h6 class="title">Blindness or severe vision loss</h6> <p>None of the trials reported data on blindness or severe vision loss.</p> </section> <section id="CD012204-sec-0152"> <h6 class="title">End‐stage renal disease</h6> <p>None of the trials reported data on end‐stage renal disease loss.</p> </section> <section id="CD012204-sec-0153"> <h6 class="title">Non‐serious adverse events</h6> <p>One trial reported data on non‐serious adverse events (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). A total of 1342/1524 (88.1%) participants in the liraglutide arm versus 586/755 (77.6%) participants in the placebo arm experienced a non‐serious adverse event at 172 weeks (RR 1.13, 95% CI 1.09 to 1.18 in favour of placebo; <a href="./references#CD012204-fig-0018" title="">Analysis 4.3</a>). Gastrointestinal disorders were the most common adverse effects in the liraglutide group; 41% of the participants in the liraglutide group reported nausea; 25% diarrhoea and 22% constipation; compared with 17% nausea; 14% diarrhoea and 11% constipation in the placebo group. Gastrointestinal adverse events were also the most common cause of withdrawal (118/1501 (8%) participants in the liraglutide group versus 11747 (2%) participants in the placebo group) (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). </p> </section> <section id="CD012204-sec-0154"> <h6 class="title">Hypoglycaemia</h6> <p>Two trials reported data on the incidence of hypoglycaemic episodes (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). One of the trials reported that no participant experienced mild hypoglycaemia (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). The <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a> trial reported hypoglycaemia as a non‐serious adverse event after 172 weeks in 295/1524 (19.4%) participants in the liraglutide group and in 35/755 (4.6%) participants in the placebo group (RR 4.18, 95% CI 2.97 to 5.86 in favour of placebo; <a href="./references#CD012204-fig-0019" title="">Analysis 4.4</a>). More individuals with liraglutide compared with placebo had biochemical hypoglycaemia adverse events during fasting plasma glucose visits (3.6% versus 0.8%). </p> <p>One of the trials reported that none of the participants experienced severe hypoglycaemia (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). No severe hypoglycaemic events were defined as serious or requiring third party assistance in the other trial (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). </p> </section> <section id="CD012204-sec-0155"> <h6 class="title">Health‐related quality of life</h6> <p>One trial reported HRQoL using the 36‐item Short Form (SF‐36) (see <a href="./appendices#CD012204-sec-0195">Appendix 17</a>) (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Changes in scores were reported from baseline to week 160. Participants on liraglutide 3.0 mg had greater mean improvements in the physical functioning component score (PCS) (MD 0.87 points, 95% CI 0.17 to 1.58; P = 0.02). There was no substantial difference for the mental component score (MCS) between the interventions (MD 0.88, 95% CI ‐0.09 to 1.63; P = 0.08; very low‐quality evidence). In this cohort, a one point lower score on the PCS is approximately associated with an RR for mortality of 1.09 (<a href="./references#CD012204-bbs2-0087" title="BjornerJB , LyngWM , GundgaardJ , MillerKA . Benchmarks for interpretation of score differences on the SF‐36 health survey for patients with diabetes. Value in Health2013;16(6):993‐1000. ">Bjorner 2013</a>). </p> <p>The total number of randomised participants was 1203 in the liraglutide group versus 588 in the placebo group; the number of participants completing the 160 weeks' follow‐up was 586 in the liraglutide group and 244 in the placebo group (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). HRQoL was only evaluated in participants from countries with validated translations of SF‐36 (14/29 countries). The method of imputation for missing data was LOCF. </p> </section> <section id="CD012204-sec-0156"> <h6 class="title">Time to progression to type 2 diabetes mellitus</h6> <p>The mean time from randomisation to the diagnosis of T2DM was 99 (SD 47) weeks for the 26 participants who developed T2DM during the trial in the liraglutide group versus 87 (47) weeks for the 46 participants who developed T2DM during the trial in the placebo group. The time to onset of diabetes over 160 weeks among all participants was 2.7 times longer with liraglutide than with placebo (95% CI 1.9 to 3.9; P &lt; 0.0001), corresponding with an HR of 0.21 (95% CI 0.13 to 0.34) (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). None of the predefined sensitivity analyses (e.g. completer population, excluding potentially unblinded participants) showed any influence on the time of onset of T2DM. No sensitivity analyses were performed according to diagnostic criteria (IFG, IGT, HbA1c), age, gender, ethnicity or BMI. </p> </section> <section id="CD012204-sec-0157"> <h6 class="title">Measures of blood glucose control</h6> <p>Two trials reported data on glycaemic variables that could be used in our review (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). In the <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a> trial, the participants were not supposed to take the trial medication in the morning on the OGTT days. OGTT was performed every sixth month. FPG and HbA1c were measured every third month. The participants were allowed to take the trial medication on the days when FPG was measured (except if OGTT was planned to be measured at the same visit) (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). In the other trial, the medication was given after glycaemic testing (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>). In the <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a> trial, the mean changes in glycaemic variables were reported between baseline and week 56 and week 160. </p> <p>In one trial (published as an abstract only), it was stated that FPG and two‐hour blood glucose concentrations were measured, but data were reported in a format unsuitable for meta‐analyses. Useable data might be available in updates (<a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>). </p> <section id="CD012204-sec-0158"> <p><b>Fasting plasma glucose</b></p> <p>Two trials reported data on fasting plasma glucose concentrations (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). One of the trials reported end of follow‐up concentrations of fasting plasma glucose (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>). The other trial reported change from baseline after 56 and 160 weeks of intervention (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). At 56 weeks, the change in FPG from baseline was ‐0.46 mmol/L in 1495 participants in the liraglutide group and ‐0.006 mmol/L in 746 participants in the placebo group (glucose values were converted from mg/dL to mmol/L by multiplying by 0.0555; numbers were read from a figure in the primary publication). The change in FPG from baseline to week 160 was ‐0.37 (SD 0.68) mmol/L in 1472 participants in the liraglutide group and 0.05 (SD 0.62) mmol/L in 738 participants in the placebo group (estimated MD ‐0.42 mmol/L, 95% CI ‐0.48 to ‐0.36; <a href="./references#CD012204-fig-0020" title="">Analysis 4.5</a>). After 12 weeks of treatment cessation, the effect of liraglutide on fasting plasma glucose was reduced (a change in FPG in the liraglutide group of ‐0.08 (SD 0.66) mmol/L in 783 participants versus a change in FPG in the placebo group of 0.06 (0.67) mmol/L in 326 participants (estimated treatment difference ‐0.13 mmol/L, 95% CI ‐0.21 to ‐0.05). </p> <p>TSA could not be performed as the required information size was exceeded already when analysing one trial. </p> </section> <section id="CD012204-sec-0159"> <p><b>Two‐hour plasma glucose concentrations (oral glucose tolerance test)</b></p> <p>One trial reported data on two‐hour plasma glucose concentrations (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Glucose values two hours after an OGTT could be read from a figure in the primary publication. In week 56, two‐hour plasma glucose concentrations were estimated to be 5.4 mmol/L in the 1495 participants of the liraglutide group versus 7.1 mmol/L in the 746 participants of the placebo group. Data after 160 weeks were presented at the European Association for the Study of Diabetes meeting in 2016; two‐hour glucose concentration was 7.4 (SD 1.8) mmol/L in the 1505 participants of the liraglutide group versus 7.4 (SD 1.7) mmol/L in the 749 participants of the placebo group. In the publication reporting data after 160 weeks of follow‐up, the two‐hour glucose concentration was lowered by ‐1.6 (SD 2.1) mmol/L in the 1472 participants of the liraglutide group versus ‐0.2 (2.2) mmol/L in the 738 participants of the placebo group (MD ‐1.40, 95% CI ‐1.59 to ‐1.21 in favour of liraglutide; <a href="./references#CD012204-fig-0021" title="">Analysis 4.6</a>). By week 172, the effects on two‐hour glucose levels were comparable with placebo levels (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). </p> </section> <section id="CD012204-sec-0160"> <p><b>Glycosylated haemoglobin A1c</b></p> <p>One trial reported data on HbA1c (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). The mean change from baseline in HbA1c was ‐0.32% (SD 0.34%) in the 1495 participants of the liraglutide group and ‐0.07% (SD 0.34%) in the 746 participants of the placebo group (MD ‐0.25%, 95% CI ‐0.28 to ‐0.22 in favour of liraglutide; <a href="./references#CD012204-fig-0022" title="">Analysis 4.7</a>). Estimated treatment difference for liraglutide versus placebo was ‐0.25% (95% CI ‐0.28% to ‐0.23%; P &lt; 0.001). At the EASD meeting 2016, HbA1c at week 160 was reported as 5.8% (SD 0.3%) in the 1505 participants of the liraglutide group and 5.7% (SD 0.3%) in the 749 participants of the placebo group (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). In the publication reporting data after 160 weeks of follow‐up, the HbA1c was lowered with ‐0.35% (SD 0.32%) in the 1472 participants of the liraglutide group versus ‐0.14% (0.34%) in the 738 participants of the placebo group after. After 12 weeks of treatment cessation, the effect of liraglutide on fasting plasma glucose were no longer evident (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). </p> </section> </section> <section id="CD012204-sec-0161"> <h6 class="title">Socioeconomic effects</h6> <p>None of the trials reported data on socioeconomic effects.</p> </section> </section> </section> <section id="CD012204-sec-0162"> <h4 class="title">GLP‐1 analogues as monotherapy versus no intervention</h4> <p>We identified no trials comparing GLP‐1 analogues as monotherapy with no intervention.</p> </section> <section id="CD012204-sec-0163"> <h4 class="title">GLP‐1 analogues as a part of a combination therapy versus any pharmacological glucose‐lowering agent (e.g. acarbose, metformin, sulphonylurea) </h4> <p>We identified no trials comparing GLP‐1 analogues as a part of a combination therapy with any pharmacological glucose‐lowering agent. </p> </section> <section id="CD012204-sec-0164"> <h4 class="title">Subgroup analyses</h4> <p>We did not perform subgroups analyses because there were insufficient trials to estimate effects in various subgroups. </p> </section> <section id="CD012204-sec-0165"> <h4 class="title">Sensitivity analyses</h4> <p>We did not perform sensitivity analyses because there were insufficient trials to explore the influence of our predefined factors on effect sizes. </p> </section> <section id="CD012204-sec-0166"> <h4 class="title">Assessment of reporting bias</h4> <p>We did not draw funnel plots due to limited number of trials (seven).</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012204-sec-0167" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012204-sec-0167"></div> <section id="CD012204-sec-0168"> <h3 class="title" id="CD012204-sec-0168">Summary of main results</h3> <p>This Cochrane Review is the first systematic review investigating the effects of DPP‐4 inhibitors and GLP‐1 analogues compared with other pharmacological glucose‐lowering interventions, placebo, diet and exercise, or no intervention in people at increased risk for developing T2DM. We included seven trials with 2702 participants. We judged all trials to have unclear or high risk of bias in one or more 'Risk of bias' domains. The amount of evidence on patient‐important outcomes was limited. Use of DPP‐4 inhibitors neither revealed an advantage nor a disadvantage for the incidence of T2DM. Use of liraglutide has the potential to delay the onset of T2DM but the evidence base is weak. For incidence of T2DM as well as for all‐cause mortality and cardiovascular mortality, we judged the quality of evidence as very low. </p> </section> <section id="CD012204-sec-0169"> <h3 class="title" id="CD012204-sec-0169">Overall completeness and applicability of evidence</h3> <p>We conducted an extensive search for trials, including publications in all languages, and tried to obtain additional data on all trials. However, no additional data were provided. We looked for additional trials and cross‐checked our data with the data from other meta‐analyses and Cochrane Reviews of relevance (<a href="./references#CD012204-bbs2-0084" title="AndersonDCJr . Pharmacologic prevention or delay of type 2 diabetes mellitus. Annals of Pharmacotherapy2005;39(1):102‐9. [PUBMED: 15562143] ">Anderson 2005</a>; <a href="./references#CD012204-bbs2-0086" title="BhardwajA , AgarwalV , PhungOJ , BakerWL , TongbramV , ColemanCI . Can oral hypoglycemic agents restore normoglycemia in individuals with insulin resistance?. 70th Scientific Sessions of the American Diabetes Association; 2010 25‐29 June; Orlando (FL). 2010. ">Bhardwaj 2010</a>; <a href="./references#CD012204-bbs2-0121" title="HopperI , BillahB , SkibaM , KrumH . Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta‐analysis of randomised controlled clinical trials. European Journal of Cardiovascular Prevention and Rehabilitation2011;18(6):813‐23. [PUBMED: 21878448] ">Hopper 2011</a>; <a href="./references#CD012204-bbs2-0142" title="PhungOJ , BakerWL , TongbramV , BhardwajA , ColemanCI . Oral antidiabetic drugs and regression from prediabetes to normoglycemia: a meta‐analysis. Annals of Pharmacotherapy2012;46(4):469‐76. [PUBMED: 22474136] ">Phung 2012</a>; <a href="./references#CD012204-bbs2-0156" title="Van deLaarFA , LucassenPL , AkkermansRP , Van deLisdonkEH , DeGrauwWJ . Alpha‐glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD005061.pub2] ">Van de Laar 2006</a>). </p> <p>The diagnosis of intermediate hyperglycaemia was mostly established by the criteria from the WHO and ADA. Only one trial did not specify how the diagnosis of intermediate hyperglycaemia was established (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>). The included trials used different types of DPP‐4 inhibitors (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>; <a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>), as well as GLP‐1 analogues (<a href="./references#CD012204-bbs2-0001" title="ArielD , KimSH , AbbasiF , LamendolaCA , LiuA , ReavenGM . Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutrition, Metabolism, and Cardiovascular diseases2014;24(12):1317‐22. [PUBMED: 25280957] KimS , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Liraglutide for overweight, older individuals with prediabetes. Diabetes2013;62(0):A260. KimSH , AbbasiF , LamendolaC , LiuA , ArielD , SchaafP , et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care2013;36(10):3276‐82. [PUBMED: 23835684] KimSH , LiuA , ArielD , AbbasiF , LamendolaC , GroveK , et al. Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study. Diabetologia2014;57(3):455‐62. [PUBMED: 24326527] NCT01784965 . Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. ">Ariel 2014</a>; <a href="./references#CD012204-bbs2-0002" title="KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes. Diabetes2012;61(0):A112. KellyAS , BergenstalRM , Gonzalez‐CampoyJM , KatzH , BankAJ . Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial. Cardiovascular Diabetology2012;11:64. [PUBMED: 22681705] NCT00546728 . The vascular effects of exenatide versus metformin in patients with pre‐diabetes. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. ">Kelly 2012</a>; <a href="./references#CD012204-bbs2-0004" title="McLaughlinT . Exenatide/diet vs diet alone for treatment of prediabetes. Diabetes2011;60(Suppl 1):34‐LB. NCT02084654 . Exenatide and weight loss for diabetes prevention. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. TamJK , McLaughlinTL , LamendolaCA , LernerKD , PeckM , LiuLF . Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation. Endocrine Reviews2013;34(3):SUN‐854. ">McLaughlin 2011</a>; <a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Moreover, one of the included trials used the GLP‐1 analogue in doses approved for weight reduction (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). </p> <p>A potential selection bias exists as more healthy and motivated people may participate in a clinical trial. However, one Cochrane systematic review observed that clinical outcomes in people participating in RCTs are comparable to outcomes in comparable individuals outside RCTs (<a href="./references#CD012204-bbs2-0158" title="VistGE , BryantD , SomervilleL , BirminghemT , OxmanAD . Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.MR000009.pub4] ">Vist 2008</a>). </p> </section> <section id="CD012204-sec-0170"> <h3 class="title" id="CD012204-sec-0170">Quality of the evidence</h3> <p>For all trials, we contacted one or more authors to obtain supplemental information on baseline data, bias domains and outcomes. In addition, authors were asked to confirm risk of bias assessments, extracted outcome data and other issues if unclear in the publication. Two trial investigators (29%) either just confirmed a question or provided additional data that could be implemented for the risk of bias assessment or the meta‐analyses of outcomes (<a href="./references#CD012204-bbs2-0003" title="Martinez‐AbundisE , Gonzalez‐HerediaT , Hernandez‐CoronaDM , Gonzalez‐OrtizM . Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance. Diabetes2015; Vol. 64, issue 0:A635‐6. ">Martinez‐Abundis 2015</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). We excluded eight trials because they did not provide separate data on participants with intermediate hyperglycaemia (<a href="./references#CD012204-bbs2-0017" title="DanieleG , IozzoP , Molina‐CarrionM , LancasterJ , CiociaroD , CersosimoE , et al. Exenatide regulates cerebral glucose metabolism in brain areas associated with glucose homeostasis and reward system. Diabetes2015;64(10):3406‐12. [PUBMED: 26116695] DanieleG , IozzoP , Molina‐WilkinsM , LancasterJ , CiociaroD , TriplittC , et al. Effect of exenatide on postprandial cerebral and liver glucose metabolism: a double‐blind randomised clinical trial. Diabetologia2014;57(1):S37‐8. DanieleG , Molina‐WilkinsM , LancasterJ , CiociaroD , TriplittC , CersosimoE , et al. Exenatide affects the distribution of cerebral postprandial glucose uptake: a double‐blind, randomized clinical trial. Diabetes2014;63:A85. NCT01588418 . Effect of exenatide on brain, adipose tissue, pancreas, and liver function. clinicaltrials.gov/ct2/show/NCT01588418 Date first received: 19 March 2012. ">Daniele 2015</a>; <a href="./references#CD012204-bbs2-0018" title="DushayJ , GaoC , GopalakrishnanGS , CrawleyM , MittenEK , WilkerE , et al. Short‐term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabetes Care2012;35(1):4‐11. [DOI: 10.2337/dc11‐0931] NCT00456885 . The effect of exenatide on weight and hunger in obese, healthy women. clinicaltrials.gov/ct2/show/NCT00456885 Date first received: 4 April 2007. ">Dushay 2012</a>; <a href="./references#CD012204-bbs2-0023" title="IshikawaS , ShimanoM , WataraiM , KoyasuM , UchikawaT , IshiiH , et al. Impact of sitagliptin on carotid intima‐media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus. American Journal of Cardiology2014;114(3):384‐8. [PUBMED: 24929624] ">Ishikawa 2014</a>; <a href="./references#CD012204-bbs2-0035" title="NCT01018602 . PINGUIN (Postpartum Intervention in Women with Gestational Diabetes Using Insulin). clinicaltrials.gov/ct2/show/NCT01018602 Date first received: 20 November 2009. ">NCT01018602</a>; <a href="./references#CD012204-bbs2-0038" title="NCT01122641 . The vascular effects of vildagliptin in insulin resistant individuals. clinicaltrials.gov/ct2/show/NCT01122641 Date first received: 12 May 2010. ">NCT01122641</a>; <a href="./references#CD012204-bbs2-0040" title="NCT01472640 . The effect of liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes mellitus. clinicaltrials.gov/ct2/show/NCT01472640 Date first received: 11 November 2011. ">NCT01472640</a>; <a href="./references#CD012204-bbs2-0030" title="NCT00845182 . Effect of pioglitazone and exenatide on body weight and beta cell function (PIO‐EX). clinicaltrials.gov/ct2/show/study/NCT00845182 Date first received: 17 February 2009. ">NCT00845182</a>; <a href="./references#CD012204-bbs2-0048" title="AramakiM . Alogliptin, but not voglibose, ameliorates dyslipidemia and LDL particle size in patients with impaired glucose tolerance or Type 2 diabetes. Clinical Lipidology2013;8(5):533‐40. TsuchiyaM . Alogliptin ameliorates dyslipidemia and LDL‐size in patients with IGT or type 2 diabetes: comparing alogliptin and voglibose. Diabetes2011;60:A280. TsuchiyaM . Alogliptin decreases liver fat content in patients with IGT or type Q2 DM: comparing alogliptin and voglibose. Diabetes2011;60:A595. TsuchiyaM , MaegawaH . DPP4 inhibition ameliorates intramuscular fat content in patients with IGT or type 2 DM: comparing alogliptin and voglibose. Diabetes2013;62:A297. ">Tsuchiya 2011</a>). We contacted all the investigators of these trials, but due to lack of additional information, these could not be included. Three trials including participants with intermediate hyperglycaemia as a part of the study population might be included in the updates of this review (<a href="./references#CD012204-bbs2-0053" title="AstrupA , CarraroR , FinerN , HarperA , KunesovaM , LeanME , et al. Safety, tolerability and sustained weight loss over 2 years with the once‐daily human GLP‐1 analog, liraglutide. International Journal of Obesity (2005)2012;36(6):843‐54. [PUBMED: 21844879] AstrupA , RossnerS , VanGaalL , RissanenA , NiskanenL , Al HakimM , et al. Effects of liraglutide in the treatment of obesity: a randomised, double‐blind, placebo‐controlled study. Lancet2009;374(9701):1606‐16. [PUBMED: 19853906] EudraCT2006‐004481‐13 . Effect of liraglutide on body weight in obese subjects without diabetes. A 20‐week randomised, double‐blind, placebo‐controlled, six armed parallel group, multi‐centre, multinational trial with an open label orlistat comparator arm with an 84 week extension period. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004481‐13/DK Date first received: 3 October 2006. FinerN , AstrupA , CarraroR , HartvigH , KunesovaM , LeanME , et al. Liraglutide once daily reduces the prevalence of prediabetes and metabolic syndrome in obese non‐diabetic adults over two years. Journal of Diabetes2011;3:30. FinerN , HakimMA , AstrupA , HarperA , LeanM , NiskanenL , et al. Liraglutide, a once‐daily human GLP‐1 analog, reverses indices of prediabetes in obese subjects: a randomized placebo‐controlled 20‐week trial. Diabetes2009;58. FinerN , HakimMA , AstrupA , HarperA , LeanM , Niskanen , L , et al. Liraglutide, a once‐daily human GLP‐1 analogue, reduces the prevalence of prediabetes in obese subjects over 20 weeks: a randomized placebo‐controlled trial. Diabetologia2009;52(0):S11‐2. LeanME , CarraroR , FinerN , HartvigH , LindegaardML , RossnerS , et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non‐diabetic adults. International Journal of Obesity2014;38(5):689‐97. [PUBMED: 23942319] NCT00422058 . The effect of liraglutide on body weight in obese subjects without diabetes. clinicaltrials.gov/ct2/show/NCT00422058 Date first received: 12 January 2007. NN8022‐1807 . The effect of liraglutide on body weight in obese subjects without diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221807.pdf (assessed 3 July 2016). NiskanenL , AstrupA , HakimMA , CarraroR , FinerN , HartvigH , et al. Liraglutide once daily reduces the prevalence of prediabetes and metabolic syndrome in obese non‐diabetic adults: a 2‐year randomized trial. Obesity2010;18:S56. SynopsisNN8022‐1807 . Effect of liraglutide on body weight in obese subjects without diabetes. A 20‐week randomised, double‐blind, placebo‐controlled, six armed parallel group, multi‐centre, multinational trial with an open label orlistat comparator arm with an 84 week extension period. novonordisk‐trials.com/website/pdf/registry/bin_20110928‐123116‐617.pdf (assessed 3 July 2016). ">Astrup 2009</a>; <a href="./references#CD012204-bbs2-0059" title="BlackmanA , FosterGD , ZammitG , RosenbergR , AronneL , WaddenT , et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. International Journal of Obesity2016;40(8):1310‐9. [PUBMED: 27005405] NCT01557166 . Effect of liraglutide in obese subjects with moderate or severe obstructive sleep apnoea: SCALE™ ‐ sleep apnoea. clinicaltrials.gov/ct2/show/NCT01272232 Date first received: 6 January 2011. NN8022‐3970 . Effect of liraglutide in obese subjects with moderate or severe obstructive sleep apnoea: SCALE™ ‐ sleep apnoea. novonordisk‐trials.com/Website/pdf/registry/nn80223970.pdf (accessed 30 September 2016). ">SCALE‐SLEEP</a>; <a href="./references#CD012204-bbs2-0058" title="HollanderP , AronneL , KleinS , NiswenderK , JensenCB , WooV , et al. Diet‐induced weight loss and subsequent addition of liraglutide 3.0 mg reduces impaired fasting glucose in overweight/obese adults in the SCALEtm maintenance 56‐week randomised trial. Journal of Diabetes2013;5:124. KleinS , AronneL , HollanderP , NiswenderK , Bjorn JensenC , LindegaardM , et al. Effect of diet‐induced weight loss and subsequent addition of liraglutide 3.0 MG on impaired fasting glucose in overweight/obese adults in the SCALEtm maintenance 56‐week phase 3 randomised trial. Obesity Facts2012;5:206. KleinS , AronneLJ , HollanderP , NiswenderK , WooV , HalePM , et al. Effect of liraglutide on cardiovascular (CV) risk factors in adults without diabetes after diet‐induced weight loss: the SCALE 56‐week randomized study. Obesity (Silver Spring, Md.)2011; Vol. 19:S177. NCT00781937 . Comparison of liraglutide versus placebo in weight loss maintenance in obese subjects: SCALE ‐ maintenance. clinicaltrials.gov/show/NCT00781937 Date first received: 28 October 2008. WaddenTA , HollanderP , KleinS , NiswenderK , WooV , HalePM , et al. NN8022‐1923 Investigators. Weight maintenance and additional weight loss with liraglutide after low‐calorie‐diet‐induced weight loss: the SCALE maintenance randomized study. International Journal of Obesity2013;37(11):1443‐51. [DOI: 10.1038/ijo.2013.120] ">SCALE 2013</a>). Application to the sponsor has been send to request additional data. We made a concerted effort to obtain additional data from all trial authors. If we were unable to retrieve contact information for the corresponding author, we attempted to contact one of the coauthors. For all trials, we identified contact information for one or more authors. </p> <p>None of the seven included trials in our review was classified as having low risk of bias in all 'Risk of bias' domains. In general, the description of randomisation and allocation in the included studies was insufficient. Three trials had insufficient reporting of one or more outcomes of relevance to our review and were, therefore, classified as having high risk of bias for selective outcome reporting bias. We were able to assess one or more of our predefined outcomes in six of the seven included trials. The largest of the included trials imputed missing data with LOCF (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>), which is not an optimal imputation method (<a href="./references#CD012204-bbs2-0152" title="SiddiquiO , HungHM , O'NeillR . MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. Journal of Biopharmaceutical Statistics2009;19(2):227‐46. ">Siddiqui 2009</a>). Therefore, all outcomes reported from this trial were judged at high risk of incomplete outcome data. </p> <p>For the DPP‐4 inhibitors and the GLP‐1 analogues, we judged the quality of evidence to be low or very low because of very limited data and various risk of bias. </p> <p>Most trials had received free drugs or financial funding from the pharmaceutical industry. It is known that trials receiving funding or provision of free drugs or devices from a pharmaceutical company lead to more favourable results and conclusions compared to trials sponsored by other sources (<a href="./references#CD012204-bbs2-0133" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3] ">Lundh 2017</a>). </p> </section> <section id="CD012204-sec-0171"> <h3 class="title" id="CD012204-sec-0171">Potential biases in the review process</h3> <p>We were unable to draw funnel plots to assess small‐study bias due to lack of data. If more data had been available and more meta‐analyses could have been performed, we would have investigated heterogeneity and the potential reasons for it. </p> <p>We were dealing with a substantial heterogeneous group of trials. Our meta‐analyses, when performed, were limited by the inability to use individual participant data to assess whether distinct clinical characteristics may have influenced the effect estimates of the interventions. We would have explored heterogeneity using sensitivity analyses for our patient‐important outcomes, if possible. However, data were limited, so no subgroup analyses or sensitivity analyses were performed. Many of the included trials were not designed or powered to detect our predefined patient‐important outcomes. </p> <p>Some trials required the participants to take the study drug on the days the glycaemic variables were measured, whereas others did not. This may have influenced the glucose measurements in these trials, as well as the incidence of T2DM (which is based on glycaemic measurements) making it difficult to reliably compare incidence rates. </p> <p>Most of the included trials had a relatively small number of participants and the information sizes in the meta‐analyses were equally small. This increases the risk of unrealistic estimates of the intervention effects due to bias (systematic errors) and chance (random errors) (<a href="./references#CD012204-bbs2-0159" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>; <a href="./references#CD012204-bbs2-0165" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601‐5. ">Wood 2008</a>). We have attempted to clarify systematic errors. We contacted all trial authors for clarification if one of the bias domains was not adequately reported. To reduce the risk of random errors, we conducted TSA on all predefined outcomes, whenever possible. </p> <p>Several trials were published in more than one publication, which for some trials made it difficult to separate the primary publication from companion papers (for details, see <a href="./references#CD012204-bbs1-0001" title="">Included studies</a>). </p> <p>We excluded trials in participants with IGT due to other conditions (e.g. cystic fibrosis or glucocorticoid treatment). </p> <p>We included trials with a minimum duration of 12 weeks to detect clinically relevant differences for the predefined outcomes. We identified four trials with a duration of less than 12 weeks (<a href="./references#CD012204-bbs2-0010" title="Almeda‐ValdesP , Cuevas‐RamosD , Brito‐CordovaG , Gomez‐PerezFJ . Treatment with sitagliptin phosphate in patients with symptomatic reactive hypoglycemia. A randomized, placebo‐controlled, double‐blinded, clinical trial. 94th Annual Meeting and Expo; 2012 23‐26 Jun; Houston (TX)2012:SUN‐209. NCT00847080 . Treatment with sitagliptin for reactive hypoglycemia secondary to dysinsulinism. clinicaltrials.gov/ct2/show/NCT00847080 Date first received: 18 February 2009. ">Almeda‐Valdes 2012</a>; <a href="./references#CD012204-bbs2-0015" title="BockG , Dalla ManC , MichelettoF , BasuR , GieslerPD , LaugenJ , et al. The effect of DPP‐4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clinical Endocrinology2010;73(2):189‐96. [DOI: 10.1111/j.1365‐2265.2009.03764.x] MichelettoF , Dalla ManC , VellaA , CobelliC . Estimation of GLP‐1 induced potentiation of insulin secretion from an oral model. Diabetes2011;60(0):A447. NCT00364377 . Incretins in impaired fasting glucose. clinicaltrials.gov/ct2/show/NCT00364377 Date first received: 14 August 2006. NelsonRH , MilesJM , VellaA . Sitagliptin effects on triglyceride and free fatty acid metabolism. Diabetologia2009;52:S313. ">Bock 2010</a>; <a href="./references#CD012204-bbs2-0024" title="KakuK , KadowakiT , TerauchiY , OkamotoT , SatoA , OkuyamaK , et al. Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2015;17(11):1033‐41. [PUBMED: 26094974] NCT01405911 . Dose response finding study of MK‐0431/ONO‐5435 in Japanese subjects with impaired glucose tolerance (MK‐0431‐105). clinicaltrials.gov/ct2/show/NCT01405911 Date first received: 28 July 2011. ">Kaku 2015</a>; <a href="./references#CD012204-bbs2-0047" title="KoskaJ , SandsM , BurciuC , D'SouzaKM , RaravikarK , LiuJ , et al. Exenatide protects against glucose‐ and lipid‐induced endothelial dysfunction: evidence for direct vasodilation effect of GLP‐1 receptor agonists in humans. Diabetes2015;64(7):2624‐35. [PUBMED: 25720388] KoskaJ , SchwartzEA , MullinMP , SchwenkeDC , ReavenPD . Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent‐onset type 2 diabetes. Diabetes Care2010;33(5):1028‐30. [PUBMED: 20200309] MullinMP , KoskaJ , SchwartzEA , SchwenkeDC , ReavenPD . Acute administration of exenatide improves endothelial function following a high‐fat meal. Diabetes2009;58:P‐640. SchwartzEA , KoskaJ , MullinMP , SchwenkeDC , ReavenPD . Effects of acute exenatide administration on postprandial lipids and lipoproteins in individuals with impaired glucose metabolism. Diabetes2009; Vol. 58:375‐OR. SchwartzEA , KoskaJ , MullinMP , SyoufiI , SchwenkeDC , ReavenPD . Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis2010;212(1):217‐22. [PUBMED: 20557887] ">Schwartz 2010</a>). Unfortunately, the reporting of long‐term data in the included trials was poor. </p> <p>Two review authors carried out data extraction. However, the review authors extracting the data were not blinded as to which trial they were extracting data from. </p> </section> <section id="CD012204-sec-0172"> <h3 class="title" id="CD012204-sec-0172">Agreements and disagreements with other studies or reviews</h3> <p>Several RCTs have assessed the effects of different pharmacological glucose‐lowering interventions for the prevention of T2DM (<a href="./references#CD012204-bbs2-0098" title="DeFronzoRA , TripathyD , SchwenkeDC , BanerjiM , BrayGA , BuchananTA , et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. New England Journal of Medicine2011;364(12):1104‐15. [PUBMED: 21428766] ">DeFronzo 2011</a>; <a href="./references#CD012204-bbs2-0099" title="Diabetes Prevention Program Research Group, KnowlerWC , FowlerSE , HammanRF , ChristophiCA , HoffmanHJ , et al. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9702):1677‐86. [DOI: 10.1016/S0140‐6736(09)61457‐4; PUBMED: 19878986] ">Diabetes Prevention Program 2009</a>; <a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). A pharmacological approach to the prevention or delay of T2DM is appealing to both the clinician and the pharmaceutical industry. However, although a reduction in, or delay of, the incidence of T2DM is important, the major public health impact of prevention trials will be determined by the extent to which prevention or delay of T2DM will translate into a reduction in diabetes‐specific macrovascular and microvascular complications. </p> <p>Given the intertwined relationship between obesity and T2DM, one well‐established approach to reduce the risk of T2DM is weight loss. Weight loss with liraglutide is dose‐dependent up to 3.0 mg once daily. In the SCALE trial, participants lost a mean of 6.5 (SD 7.3) kg of body weight versus 2.0 (SD 7.3) kg in the placebo group after 160 weeks of intervention. Liraglutide reduced the incidence or delayed the onset of T2DM (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Twelve weeks after the end of intervention, a mean weight regain occurred in the liraglutide group, so the total loss of mean weight was 5.6 (SD 9.2) kg in the liraglutide group versus 2.2 (SD 8.4) kg in the placebo group. The people progressing to T2DM during the study period had a median weight gain of 0.3% in the liraglutide group and 1.7% in the placebo group (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). The number of participants progressing from intermediate hyperglycaemia to T2DM was low. The effect on reducing the risk of T2DM with liraglutide seemed to depend on how intermediate hyperglycaemia was measured. It appeared more pronounced in people with IFG, intermediate elevated HbA1c levels, or both. However, the number of participants with different subtypes of intermediate hyperglycaemia was low. The subtype of intermediate hyperglycaemia with the lowest incidence of T2DM in the placebo group was people with IGT only. Furthermore, 12 weeks after the end of intervention, five participants in the liraglutide group compared with one participant in the placebo group developed T2DM. After 160 weeks of the intervention, 970/1472 (66%) participants had regressed from intermediate hyperglycaemia to normoglycaemia compared with 268/738 (36%) in the placebo group. Furthermore, after 12‐week treatment cessation, 740/1472 (50%) participants in the liraglutide group compared with 263/738 (36%) participants in the placebo group had normoglycaemia. Even though the duration of post‐treatment follow‐up was short, the data did not indicate long‐term beneficial effects on the incidence of T2DM. Also, the glycaemic improvements in HbA1c and fasting plasma glucose were no longer evident. Whether liraglutide is more effective in the longer term (e.g. 10 years) or whether other GLP‐1 analogues are more effective than other interventions (e.g. metformin, diet and exercise) recommended by the ADA to prevent the progression to T2DM and its associated complications remains to be confirmed (<a href="./references#CD012204-bbs2-0082" title="American Diabetes Association. Standards of medical care in diabetes ‐ 2015. Diabetes Care2015;38(Suppl 1):S1‐93. [PUBMED: 24357209] ">ADA 2015</a>). </p> <p>Several ongoing trials investigating the effects of a DPP‐4 inhibitors or a GLP‐1 analogues in people at increased risk for the development of T2DM exist. This reflects the interest from the scientific community and the pharmaceutical companies as several of the DPP‐4 inhibitors and GLP‐1 analogues still are patent‐registered. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012204-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012204-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials)." data-id="CD012204-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial (blank cells indicate that the particular outcome was not measured in some trials)." data-id="CD012204-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial (blank cells indicate that the particular outcome was not measured in some trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 1 Non‐serious adverse events." data-id="CD012204-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 1 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 2 Fasting blood glucose." data-id="CD012204-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 2 Fasting blood glucose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 3 2‐hour glucose." data-id="CD012204-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 3 2‐hour glucose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 4 Haemoglobin A1c." data-id="CD012204-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 4 Haemoglobin A1c. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 1 Incidence of type 2 diabetes mellitus." data-id="CD012204-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 1 Incidence of type 2 diabetes mellitus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 2 Serious adverse events." data-id="CD012204-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 2 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 3 Congestive heart failure." data-id="CD012204-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 3 Congestive heart failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 4 Non‐serious adverse events." data-id="CD012204-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 4 Non‐serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 5 Fasting glucose." data-id="CD012204-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 5 Fasting glucose.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 6 2‐hour glucose values." data-id="CD012204-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 6 2‐hour glucose values.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 7 Haemoglobin A1c." data-id="CD012204-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 7 Haemoglobin A1c.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Glucagon‐like peptide (GLP)‐1 analogues versus metformin, Outcome 1 Fasting blood glucose." data-id="CD012204-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Glucagon‐like peptide (GLP)‐1 analogues versus metformin, Outcome 1 Fasting blood glucose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 1 Incidence of type 2 diabetes mellitus." data-id="CD012204-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 1 Incidence of type 2 diabetes mellitus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 2 Serious adverse events." data-id="CD012204-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 2 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 3 Non‐serious adverse events." data-id="CD012204-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 3 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 4 Mild hypoglycaemia." data-id="CD012204-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 4 Mild hypoglycaemia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 5 Fasting blood glucose." data-id="CD012204-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 5 Fasting blood glucose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 6 2‐hour glucose." data-id="CD012204-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 6 2‐hour glucose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/urn:x-wiley:14651858:media:CD012204:CD012204-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_t/tCD012204-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 7 Haemoglobin A1c." data-id="CD012204-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 7 Haemoglobin A1c. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012204-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">DPP‐4 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>DPP‐4 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population</b>: people at risk for development of T2DM </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: DPP‐4 inhibitors </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trial(s))</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>DPP‐4 inhibitors</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial on vildagliptin reported that none of the participants died (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of T2DM</b> </p> <p>Definition: WHO criteria</p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported that 3/90 in the vildagliptin group vs 1/89 in the placebo group developed T2DM (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported that 1/90 in the vildagliptin group vs 2/89 in the placebo group experienced a serious adverse event (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported that none of the participants died (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) Non‐fatal myocardial infarction</b> </p> <p><b>(2) Non‐fatal stroke</b> </p> <p><b>(3) Congestive heart failure</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) ‐</p> <p>(2) ‐</p> <p>(3) 179 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) + (2): not reported</p> <p>(3): 1 trial on vildagliptin reported 1/90 in the vildagliptin group vs 0/89 in the placebo group experienced heart failure (<a href="./references#CD012204-bbs2-0005" title="CLAF237A2357. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). EudraCT2005‐002778‐30 . A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT). www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. NCT00237250 . Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. RosenstockJ , FoleyJE , RendellM , Landin‐OlssonM , HolstJJ , DeaconCF , et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care2008;31(1):30‐5. [PUBMED: 17947341] ">Rosenstock 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Socioeconomic effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>DPP‐4:</b> dipeptidyl‐peptidase‐4; <b>RR:</b> risk ratio; <b>T2DM:</b> type 2 diabetes mellitus; <b>WHO:</b> World Health Organization. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*Assumed risk was derived from the event rates in the comparator groups.</p> <p><sup>a</sup>Downgraded by three levels because of indirectness, imprecision (very sparse data) and risk of publication bias (see <a href="./appendices#CD012204-sec-0193">Appendix 15</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">DPP‐4 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012204-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">GLP‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GLP‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population</b>: people at risk for development of T2DM </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: GLP‐1 analogues </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>GLP‐1 analogues</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (trial(s))</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: up to 172 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2281 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported that 2/1501 in the liraglutide group vs 2/747 in the placebo group died after 160 weeks of intervention. </p> <p>Liraglutide used in doses approved for weight‐reducing purposes (3.0 mg) (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). </p> <p>1 trial using exenatide reported that none of the participants died (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of T2DM</b> </p> <p>Definition/description: 1 trial established the diagnosis of T2DM defined as HbA1c ≥ 6.5%, or fasting plasma glucose ≥ 7.0 mmol/L, or 2‐hour plasma glucose post‐challenge (oral glucose tolerance test) ≥ 11.1 mmol/L (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). Other trial did not report how the diagnosis of T2DM was established. </p> <p>Follow‐up: up to 172 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2243 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 160 weeks, 26/1472 (1.8%) participants in the liraglutide group vs 46/738 (6.2%) participants in the placebo group developed T2DM (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). The incidence of T2DM after the 12‐week off‐treatment extension period (i.e. after 172 weeks) showed that 5 additional participants were diagnosed with T2DM in the liraglutide group, compared with 1 participant in the placebo group. </p> <p>Liraglutide used in doses approved for weight‐reducing purposes (3.0 mg).</p> <p>1 trial reported that 2/17 in the exenatide group vs1/16 in the placebo group developed T2DM (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: up to 172 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2312 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial on liraglutide reported that 227/1501 (15.1%) participants in the liraglutide 3.0 mg group vs 96/747 (12.7%) participants in the placebo group experienced a serious adverse event after 160 weeks (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). </p> <p>1 trial on exenatide reported that none of the participants experienced a serious adverse event (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> <p>Follow‐up: up to 172 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2281 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported that none of the participants died (<a href="./references#CD012204-bbs2-0006" title="NCT00500370A . Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. RosenstockJ , KlaffLJ , SchwartzS , NorthrupJ , HolcombeJH , WilhelmK , et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes. Diabetes Care2010;33(6):1173‐5. [PUBMED: 20332357] TrautmannM , NorthrupJ , CaoD , GlassL , HolcombeJ . Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients. Journal of Diabetes2009;1(0):A196‐7. ">Rosenstock 2010</a>). 1 trial reported that 1/1501 participants in the liraglutide group died from cardiac arrest; no participant in the placebo group died of cardiovascular reasons (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(1) Non‐fatal myocardial infarction</b> </p> <p><b>(2) Non‐fatal stroke</b> </p> <p><b>(3) Congestive heart failure</b> </p> <p>Follow‐up: up to 172 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 2279 (1)</p> <p>(2) See comments</p> <p>(3) 2279 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 1 trial reported 1/1524 participants in the liraglutide 3.0 mg group vs 0/755 participants in the placebo group (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>) </p> <p>(2) Not reported</p> <p>(3) 1 trial reported 1/1524 in the liraglutide 3.0 mg group vs 1/755 participants in the placebo group (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p>SF‐36 scale: total score 0‐100, 8 subscales. Higher values mean better health‐related quality of life. </p> <p>Follow‐up: 160 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1791 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Physical functioning component score had mean difference of 0.87 in favour of liraglutide (<a href="./references#CD012204-bbs2-0007" title="AstrupA , FujiokaK , Violante OrtizR , JensenCB , LillerreSK , O'NeilP . Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial. Obesity Facts2015;8(0):42. BjornerJB , BrettJH , MeinckeHH , KolotkinRL . The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data. Diabetologia2016; Vol. 59:S330. BjornerJB , FujiokaK , LeLayA , BrettJ , KolotkinR . Liraglutide 3.0 mg improves health utilities in weight management compared with placebo. Diabetes2015;64(0):A565‐6. BluherM , HermansenK , GreenwayF , FujiokaK , DonsmarkM , JensenCB , et al. Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks. Diabetologia2015;58(1):S310. EudraCT2008‐001049‐24 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. FujiokaK , WildingJPH , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S368‐9. GaalLV , Pi‐SunyerX , HemmingssonJU , ClaudiusB , SvendsenCB , BaysH . Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Obesity Facts2015;8(0):41‐2. KolotkinRL , FujiokaK , WoldenML , BrettJH , BjornerJB . Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity2016;6(4):233‐42. [PUBMED: 27198973] KolotkinRL , MeinckeHJ , ManningLS , BjornerJB . Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme. Value in Health2015;18(7):A674‐5. [PUBMED: 26533777] KrempfM , AstrupA , FujiokaK , GreenwayF , HalpernA , LauDC , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial. Obesity Facts2015;8(0):210. KrempfM , AstrupA , leRouxC , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S368. LauDC , DaviesM , Pi‐SunyerFX , WildingJ , ManningLS , JensenCB , et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial. Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA)2015:OR07‐2. LauDC , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial. Obesity Facts2015;8(0):185. LauDC , GreenwayF , FujiokaK , AstrupA , HalpernA , KrempfM , et al. Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial. Canadian Journal of Diabetes2015;39(0):S48. LauDC , KrempfM , AstrupA , leRouxCW , FujiokaK , GreenwayF , et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial. Canadian Journal of Diabetes2015;39(0):S48‐9. LauDCW , WildingJPH , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S358. LeRouxC , LauDCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial. Diabetologia2014;57(1):S338. LeRouxC , LauDCW , FujiokaK , CatersonID , CancinoAP , JensenCB , et al. The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme. Diabetologia2015;58(1):S311. LeRouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] LiutkusJF , FujiokaK , AstrupA , GreenwayF , HalpernA , KrempfM , et al. Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial. Canadian Journal of Diabetes2015;39(0):S36. MadsbadS , LiebermanG , SkjothTV , LilleoreSK , DeFronzoRA . Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial. Diabetologia2016; Vol. 59, issue 0:540‐1. NCT01272219 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. NN8022‐1839 . Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , HalpernA , KrempfM , et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine2015;373(1):11‐22. [DOI: 10.1056/NEJMoa1411892] Pi‐SunyerX , FujiokaK , leRouxC , AstrupA , GreenwayF , HalpernA , et al. Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial. Diabetologia2014;57(1):S37. ProiettoJ , leRouxCW , Pi‐SunyerX , AstrupA , FujiokaK , GreenwayF , et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial. Obesity Research and Clinical Practice2014;8(0):117. WildingJ , AstrupA , FujiokaK , GreenwayF , KrempfM , LauD , et al. In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32(0):71. WildingJ , LauD , AstrupA , FujiokaK , GreenwayF , KrempfM , et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial. Diabetic Medicine2015;32:70. WildingJP , OvergaardRV , JacobsenLV , JensenCB , leRouxCW . Exposure‐response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity &amp; Metabolism2016;18(5):491‐9. WildingJPH , BluherM , HermansenK , GreenwayF , FujiokaK , ClaudiusB , et al. Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo. Diabetes2015;64:A568. WittertG , leRouxCW , AstrupA , FujiokaK , GreenwayF , HalpernA , et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial. Obesity Research and Clinical Practice2014;8:118. ">SCALE</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Socioeconomic effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>GLP‐1</b> : glucagon‐like peptide‐1; <b>HbA1c:</b> glycosylated haemoglobin A1c; <b>RR:</b> risk ratio; <b>SF‐36:</b> 36‐item Short Form health survey; <b>T2DM:</b> type 2 diabetes mellitus. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by three levels because of indirectness, imprecision (sparse data) and risk of attrition and publication bias (see <a href="./appendices#CD012204-sec-0194">Appendix 16</a>).<br/> <sup>b</sup>Downgraded by two levels because of imprecision (sparse data) and risk of attrition and publication bias (see <a href="./appendices#CD012204-sec-0194">Appendix 16</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">GLP‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012204-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of trial populations</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial (design)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention and comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description of power and sample size calculation and handling of missing data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Screened/eligible<br/> (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised<br/> (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ITT<br/> (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysed<br/> (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Finishing trial<br/> (n)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised finishing trial<br/> (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up<br/> (extended follow‐up)<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Ariel 2014</b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: liraglutide 1.8 mg, once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Targeted sample size of 30 subjects in each group provided 90% power to detect a 20% difference (2.2 mmol/L) in SSPG concentration. With 24 subjects per group, there was 82% power to detect a 20% difference. A difference of 20% was chosen because this is the degree of difference in SSPG concentration seen with modest weight loss of 7%." </p> <p>"Only subjects who had end‐of‐study testing were included in the analyses."</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>14 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo, once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.8</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Kelly 2012</b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: exenatide 10 μg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 1000 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Martinez‐Abundis 2015</b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: linagliptin 5 mg + placebo in the evening</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>90 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: metformin 500 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>McLaughlin 2011</b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: exenatide 10 μg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>30 weeks (1 year)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Rosenstock 2008</b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: vildagliptin 50 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>956</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.4</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Rosenstock 2010</b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: exenatide 10 μg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Includes participants that received at least 1 dose of study drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>322<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>24 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>SCALE</b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I: liraglutide 3.0 mg, once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"The power for the primary endpoint weight change is calculated based on a two sided t‐test with a significance level of 5%. The power with regard to the co‐primary dichotomous endpoints proportion of subjects with a weight loss of at least 5% or more than 10%, respectively, is calculated based on a two‐sided chi‐square test." </p> <p>"The large number of randomised subjects also provides sufficient power for the fourth primary endpoint new onset of diabetes among subjects with pre‐diabetes. The endpoint new onset of diabetes will be analysed using methods for analysis of interval censored failure time data. A conservative estimate of the power may be calculated as if the endpoint diabetes yes/no among completers during the 160 weeks is analysed by use of a two‐sided Chisquare test with a significance level of 5%. </p> <p>It is assumed that the annual conversion rate of subjects with pre‐diabetes to diabetes equals 7% among placebo treated subjects, whereas it is 60% lower, 2.1%, among liraglutide treated subjects. After 160 weeks of treatment with liraglutide/placebo, the percentage of subjects with diabetes is therefore equal to 1‐(1‐0.07)3 = 20% among liraglutide placebo treated subjects and 1‐(1‐0.021)<sup>3</sup> = 6% among liraglutide treated subjects. It is assumed that the drop‐out during the 160 weeks may be as large as 65% in both groups. The power for conversion rates for placebo of 5, 7 and 9% and conversion rates 60 and 70% lower in the liraglutide group may be seen in Table 18‐1." </p> <p>From the numbers in Table 18‐1 following numbers are specified:</p> <p>"Based on these figures it is apparent that a sample size of 2400 liraglutide treated subjects and 1200 liraglutide placebo treated subjects will provide sufficient power also for the fourth primary endpoint onset of diabetes" </p> <p>"Missing values were imputed with the use of the last‐observation‐carried‐forward method for measurements made after baseline." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>4992<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Period week 0‐56: 1528</p> <p>Period week 0‐172: 1505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1472<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1472<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Period week 0‐56: 1110</p> <p>Period week 0‐172: 783<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Period week 0‐56: 72.6</p> <p>Period week 0‐172: 52.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>160 weeks (172 weeks)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Period week 0‐56: 757</p> <p>Period week 0‐172: 749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>738<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>738<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Period week 0‐56: 505</p> <p>Period week 0‐172: 327<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Period week 0‐56: 66.7</p> <p>Period week 0‐172: 43.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b><i>Grand total</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All interventions<sup>h</sup> </i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>1718</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>924</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All c</i> <i>omparators<sup>h</sup> </i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>946</i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>471</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All interventions and c</i> <i>omparators<sup>i</sup> </i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>2702</i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>1428<sup>j</sup> </i> </b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>‐ denotes not reported.</p> <p><sup>a</sup>Follow‐up under randomised conditions until end of trial or if not available, duration of intervention; extended follow‐up refers to follow‐up of participants once the original study was terminated as specified in the power calculation.<br/> <sup>b</sup>Total number of screened.<br/> <sup>c</sup>Article stated that 38 participants out of the total randomised population had impaired fasting glucose or impaired glucose tolerance, or both.<br/> <sup>d</sup>Number retrieved from abstract.<br/> <sup>e</sup>One of the abstracts reports that 68 participants were randomised and another abstract reports 66 participants.<br/> <sup>f</sup>The SCALE had different number of participants included in the analyses depending on outcome. A full analyses set is reported in the table and was defined as: "All randomised subjects exposed to at least one dose of the trial product and with at least one post baseline assessment of any efficacy endpoint will be included. Subjects in the FAS will be analysed according to randomised treatment." Beside safety analysis set was defined as: "All randomised subjects who have been exposed to at least one dose of trial product. Subjects in the safety analysis set will be analysed "as treated" ". The number of participants started in the trial according to clinicaltrial.gov varied from the period of week 0 to week 56 and from week 0 to 172 due to misclassification of screened participants.<br/> <sup>g</sup>In the publication reporting long‐term data, it was stated that 791 (53%) participants in the liraglutide group and 337 (15%) participants in the placebo group completed the trial (<a href="./references#CD012204-bbs2-0131" title="Lle RouxCW , AstrupA , FujiokaK , GreenwayF , LauDC , VanGaalL , et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet2017;389(10077):1399‐409. [PUBMED: 28237263] ">Le Roux 2017</a>).<br/> <sup>h</sup>Not all trials described the number of participants randomised to each intervention/comparator group.<br/> <sup>i</sup>One trial did not report the number of randomised participants per intervention group. Therefore, numbers do not add up accurately.<br/> <sup>j</sup>Not all trials reported the number of participants finishing the trial. </p> <p>C: comparator; I: intervention; ITT: intention to treat; n: number of participants; N/A: not applicable; RCT: randomised controlled trial; SCALE: Satiety and Clinical Adiposity ‐ Liraglutide Evidence in Nondiabetic and Diabetic Individuals; SSPG: steady‐state plasma glucose. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of trial populations</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012204-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 2‐hour glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Haemoglobin A1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012204-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">DDP‐4 inhibitors versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of type 2 diabetes mellitus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Congestive heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Fasting glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 2‐hour glucose values <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Haemoglobin A1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">DDP‐4 inhibitors versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012204-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Glucagon‐like peptide (GLP)‐1 analogues versus metformin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Glucagon‐like peptide (GLP)‐1 analogues versus metformin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012204-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Glucagon‐like peptide (GLP)‐1 analogues versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of type 2 diabetes mellitus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mild hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 2‐hour glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Haemoglobin A1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Glucagon‐like peptide (GLP)‐1 analogues versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012204.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012204-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012204-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD012204-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012204-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012204\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012204\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012204\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012204\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012204.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012204.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012204.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012204.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012204.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728261730"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012204.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728261734"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012204.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec0253e9af46e',t:'MTc0MDcyODI2Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 